

CITATION REPORT

List of articles citing

Diagnostic criteria for Parkinson disease

DOI: 10.1001/archneur.56.1.33
Archives of Neurology, 1999, 56, 33-9.

Source: <https://exaly.com/paper-pdf/30670609/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2286	Neurodegenerative disease: a different view of diagnosis. 1999 , 5, 514-7		17
2285	The Lewy body variant of Alzheimer's disease: clinical, pathophysiological and conceptual issues. 1999 , 249 Suppl 3, 64-7		29
2284	No pathogenic mutations in the persyn gene in Parkinson's disease. 1999 , 259, 65-6		13
2283	No pathogenic mutations in the beta-synuclein gene in Parkinson's disease. 1999 , 269, 107-9		25
2282	Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. 2000 , 59, 830-41		121
2281	Contribution of neuroimaging to the differential diagnosis of dementias and other late life psychiatric disorders. 2000 , 10, 55-68		1
2280	Degeneration of the centr [^] 'median [^] parafascicular complex in Parkinson's disease. 2000 , 47, 345-352		149
2279	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. 2000 , 47, 718-728		103
2278	Linkage exclusion in French families with probable Parkinson's disease. 2000 , 15, 1075-83		32
2277	Treatment of persistent hemiballism with botulinum toxin type A. 2000 , 15, 1281-2		6
2276	No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. 2000 , 15, 1265-7		28
2275	Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson's disease in a Chinese population. 2000 , 15, 1267-9		9
2274	Modafinil treatment of pramipexole-associated somnolence. 2000 , 15, 1269-71		47
2273	Neuroacanthocytosis presenting as parkinsonism. 2000 , 15, 1271-3		18
2272	Dopa-resistant parkinsonism, oculomotor disturbances, chorea, mirror movements, dyspraxia, and dementia: the expanding clinical spectrum of hypoparathyroidism. A case report. 2000 , 15, 1273-6		12
2271	Nicotine-sensitive writer's cramp. 2000 , 15, 1276-9		12
2270	Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?. 2000 , 15, 1279-81		11

2269	McLeod syndrome and neuroacanthocytosis with a novel mutation in the XK gene. 2000 , 15, 1282-4	24
2268	Chorea in new variant Creutzfeldt-Jacob disease. 2000 , 15, 1284-5	21
2267	Primary anticholinergic-responsive Pisa syndrome. 2000 , 15, 1285-7	34
2266	Radiation-induced 'Meige syndrome'. 2000 , 15, 1287-8	
2265	Pseudoathetosis in a patient with cervical myelitis: neurophysiologic and functional MRI studies. 2000 , 15, 1288-93	12
2264	Hyperekplexia in the first year of life. 2000 , 15, 1293-6	24
2263	Persistence of rhythmic movement disorder beyond childhood: a videotape demonstration. 2000 , 15, 1296-8	25
2262	Friedreich ataxia associated with dystonic head tremor provoked by prolonged exercise. 2000 , 15, 1298-9	3
2261	Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. 2000 , 107, 303-19	108
2260	Movement Disorder Surgery: Patient Selection and Evaluation of Surgical Results. 2000 , 15, 78-90	2
2259	Progressive dementia and gait disorder in a 78 year old woman. 2000 , 68, 526-31	3
2258	Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?. 2000 , 54, 1195-8	109
2257	Tiefe Hirnstimulation bei M. Parkinson, Tremor und Dystonie: Patientenselektion. 2000 , 27, S16-S22	2
2256	The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. <i>Archives of Neurology</i> , 2000 , 57, 369-72	173
2255	The Older Driver with Parkinson's Disease. 2000 , 34, 39-49	22
2254	Molecular Etiology of Parkinson Disease: Recent Progress. 2000 , 6, 234-240	3
2253	Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. 2000 , 123 (Pt 7), 1410-21	181
2252	Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. 2000 , 157, 1439-45	228

2251	Proton magnetic resonance spectroscopy of patients with parkinsonism. 2000 , 52, 589-95	68
2250	Neuropsychiatric aspects of Parkinson's disease. 2000 , 41, 15-23	78
2249	Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. 2000 , 16, 365-79	126
2248	Defining diastolic heart failure: a call for standardized diagnostic criteria. 2000 , 101, 2118-21	576
2247	Amyloid precursor protein gene isoforms in Alzheimer's disease and other neurodegenerative disorders. 2000 , 173, 81-92	14
2246	Regularity of force tremor in Parkinson's disease. 2001 , 112, 1594-603	86
2245	Genetic analysis of synphilin-1 in familial Parkinson's disease. 2001 , 8, 317-23	17
2244	Alcohol dehydrogenase polymorphism and Parkinson's disease. 2001 , 305, 70-2	18
2243	Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease. 2001 , 308, 21-4	22
2242	Dystonia and parkinsonism. 2001 , 8, 109-21	90
2241	The role of neuroimaging in dementia. 2001 , 17, 255-79	31
2240	Parkinson's Disease: Drug Therapy Considerations for Rehabilitation. 2001 , 17, 52-60	1
2239	Updated guidelines for the management of Parkinson's disease. 2001 , 62, 456-70	19
2238	Primary brain lymphoma presenting as Parkinson's disease. 2001 , 43, 36-40	23
2237	Cortical Lewy body pathology in the diagnosis of dementia. 2001 , 102, 355-63	221
2236	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. 2001 , 16, 999-1006	57
2235	Nocturnal body core temperature falls in Parkinson's disease but not in Multiple-System Atrophy. 2001 , 16, 226-32	65
2234	Parkinson's disease with late Pick's dementia. 2001 , 16, 311-9	12

2233	Lewy bodies and parkinsonism in families with parkin mutations. 2001 , 50, 293-300	425
2232	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr β -Synuclein mutation. 2001 , 49, 313-319	316
2231	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. 2001 , 16, 184-91	122
2230	Barriers to treatment: the unique challenges for physicians providing dementia care. 2001 , 14, 188-98	20
2229	Lesion of thalamic centromedian--parafascicular complex after chronic deep brain stimulation. 2001 , 56, 1576-9	44
2228	Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. 2001 , 56, 1757-9	90
2227	Pathophysiology of slow vertical saccades in progressive supranuclear palsy. 2001 , 57, 2070-7	86
2226	alpha-Synuclein gene haplotypes are associated with Parkinson's disease. 2001 , 10, 1847-51	270
2225	Accurate determination of ataxin-2 polyglutamine expansion in patients with intermediate-range repeats. 2002 , 6, 217-20	15
2224	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. 2002 , 125, 391-403	511
2223	Where does parkinson disease pathology begin in the brain?. 2002 , 61, 413-26	508
2222	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. 2002 , 125, 2431-45	324
2221	Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. 2002 , 58, 90-7	49
2220	The differential diagnosis of Parkinson's disease. 2002 , 12, 40-51	
2219	Functional association of the parkin gene promoter with idiopathic Parkinson's disease. 2002 , 11, 2787-92	81
2218	Parkinson's disease. 2002 , 477-489	1
2217	Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. 2002 , 72, 708-12	232
2216	Restless legs syndrome in Parkinson's disease. 2002 , 196, 33-6	121

2215	Lewy body-free nigral degeneration--a case report. 2002 , 198, 97-100	3
2214	Management of Parkinson's Disease. 2002 , 10, 643-659	1
2213	Cognitive slowing in Parkinson's disease resolves after practice. 2002 , 73, 524-8	16
2212	The Metabolic Substrates of Bradykinesia and Tremor in Uncomplicated Parkinson's Disease. 2002 , 17, 688-699	35
2211	An inflammatory review of Parkinson's disease. 2002 , 68, 325-40	267
2210	Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. 2002 , 23, 245-54	99
2209	Idiopathic Parkinson's disease(s) may follow subclinical episodes of perivenous demyelination. 2002 , 59, 762-9	4
2208	Parkinson's genetics: molecular insights for the new millennium. 2002 , 23, 503-14	17
2207	Transcranial magnetic stimulation and Parkinson's disease. 2002 , 38, 309-27	159
2206	The tau H1 haplotype is associated with Parkinson's disease in the Norwegian population. 2002 , 322, 83-6	61
2205	Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. 2002 , 58, 881-4	100
2204	Comparison of Healthcare Utilization and Direct Costs in Three Degenerative Dementias. 2002 , 10, 328-336	12
2203	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. 2002 , 125, 789-800	115
2202	Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. 2002 , 955, 138-52	64
2201	Complex relationship between Parkin mutations and Parkinson disease. 2002 , 114, 584-91	154
2200	Evolution of the response to levodopa during the first 4 years of therapy. 2002 , 51, 686-93	92
2199	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. 2002 , 52, 205-10	270
2198	Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients. 2002 , 16, 13-20	23

2197	Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. 2002 , 17, 795-8	63
2196	Genetics of parkinsonism. 2002 , 17, 645-56	87
2195	ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. 2002 , 17, 767-71	44
2194	Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. 2002 , 17, 670-5	42
2193	Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study. 2002 , 17, 812-6	30
2192	Clinical correlates of the pathology underlying parkinsonism: a population perspective. 2002 , 17, 910-6	62
2191	Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness. 2002 , 17, 934-41	41
2190	Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2. 2002 , 17, 1046-51	60
2189	Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. 2002 , 17, 1166-73	94
2188	Repetitive magnetic stimulation of cortical motor areas in Parkinson's disease: implications for the pathophysiology of cortical function. 2002 , 17, 467-73	62
2187	Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. 2002 , 17, 133-7	83
2186	The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease. 2002 , 109, 77-89	7
2185	Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese. 2002 , 109, 1403-14	12
2184	Co-occurrence of Parkinson's disease with progressive supranuclear palsy. 2002 , 103, 526-30	25
2183	Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). 2002 , 249 Suppl 3, III/1-5	383
2182	Distinguishing progressive supranuclear palsy from other forms of Parkinson's disease: evaluation of new signs. 2002 , 956, 484-6	13
2181	Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. 2002 , 29, 1623-9	40
2180	Impaired production of plasma interleukin-6 in patients with Parkinson's disease. 2002 , 133, 81-3	23

2179	[N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. 2003 , 30, 127-31	37
2178	Differential diagnosis of parkinsonian syndromes: dynamics of time courses are essential. 2003 , 250 Suppl 1, 111-4	13
2177	Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. 2003 , 149, 187-94	330
2176	Magnetization transfer changes of grey and white matter in Parkinson's disease. 2003 , 45, 224-30	37
2175	Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. 2003 , 106, 191-201	139
2174	Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. 2003 , 106, 243-50	34
2173	New insights into Parkinson's disease. 2003 , 250 Suppl 3, III15-24	32
2172	Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. 2003 , 24, 174-5	29
2171	Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. 2003 , 110, 517-36	995
2170	Juvenile parkinsonism. 2003 , 10, 62-7	9
2169	Genes and parkinsonism. 2003 , 2, 221-8	85
2168	Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. 2003 , 18, 467-86	835
2167	Abnormal sensorimotor integration is related to disease severity in Parkinson's disease: a TMS study. 2003 , 18, 1316-24	19
2166	Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. 2003 , 18, 1123-31	25
2165	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. 2003 , 108, 368-73	61
2164	Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. <i>European Journal of Neurology</i> , 2003 , 10, 391-8	6 439
2163	Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. 2003 , 212, 47-53	324
2162	Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism. 2003 , 215, 51-5	29

2161	Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia. 2003 , 216, 105-8	32
2160	Paired transcranial magnetic stimulation for the early diagnosis of corticobasal degeneration. 2003 , 114, 272-8	29
2159	The diagnosis of Parkinson's disease. 2003 , 24, s157-s164	1
2158	Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. 2003 , 183, 418-29	39
2157	Are ubiquitination pathways central to Parkinson's disease?. 2003 , 114, 1-8	200
2156	Staging of brain pathology related to sporadic Parkinson's disease. 2003 , 24, 197-211	6699
2155	The youngest reported case of corticobasal degeneration. 2003 , 10, 47-50	8
2154	Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease. 2003 , 9 Suppl 2, S65-71	32
2153	Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. 2003 , 74, 56-60	56
2152	Recognition and treatment of depression in Parkinson's disease. 2003 , 16, 178-83	149
2151	Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. 2003 , 278, 24095-102	99
2150	HLA typing and Parkinson's disease. 2003 , 50, 64-8	33
2149	Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. <i>Archives of Neurology</i> , 2003 , 60, 545-9	149
2148	Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. 2003 , 74, 956-8	20
2147	Schulter-Arm-Schmerz als Fr̂hsymptom der Parkinson-Krankheit. 2003 , 79, 358-361	1
2146	Morbo di Parkinson: Correlazione fra i reperti RM, la SPECT di perfusione e la SPECT con 123I-FP-CIT e lo stadio clinico della malattia. 2003 , 16, 62-63	
2145	Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease. 2003 , 20, 375-81	61
2144	Neuroimaging del trasportatore della dopamina con SPET-DaTSCAN nella malattia di Parkinson. 2003 , 16, 64-65	

2143	Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. 2003 , 13, 365-9	57
2142	[123I]β-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. 2003 , 42, 31-38	37
2141	. 2004 ,	2
2140	Avaliação da doença de Parkinson pela ressonância magnética. 2004 , 37, 83-90	1
2139	DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. 2004 , 41, e22	59
2138	Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. 2004 , 62, 201-7	234
2137	Epidemiology of Parkinson's disease. 2004 , 14, 211	9
2136	Assessing the executive function deficits of patients with Parkinson's disease: utility of the Tower of London-Drexel. 2004 , 11, 27-39	37
2135	(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. <i>Archives of Neurology</i> , 2004 , 61, 1224-9	127
2134	Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. 2004 , 63, 329-37	49
2133	Substantia Nigra and Locus Coeruleus. 2004 , 449-463	19
2132	Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. 2004 , 18, 932-4	105
2131	Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. 2004 , 62, 1999-2004	49
2130	Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. <i>Archives of Neurology</i> , 2004 , 61, 865-8	117
2129	Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. 2004 , 24, 72-8	44
2128	Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. 2004 , 52, 784-8	289
2127	R-R interval variation in Parkinson's disease and multiple system atrophy. 2004 , 109, 276-9	15
2126	The antibodies against Bordetella pertussis in sera of patients with Parkinson's disease and other non-neurological diseases. 2004 , 110, 113-7	6

2125	Effect of intention and visual fixation disengagement on prosaccades in Parkinson's disease patients. 2004 , 42, 624-32	18
2124	PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. 2004 , 3, 652-62	52
2123	Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. 2004 , 31, 243-68	23
2122	Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. 2004 , 251, 340-5	47
2121	Lewy body-related alpha-synucleinopathy in the aged human brain. 2004 , 111, 1219-35	217
2120	Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. 2004 , 31, 1119-27	43
2119	Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms. 2004 , 61, 1729-50	41
2118	Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. 2004 , 31, 155-61	55
2117	Identification of families with cortical Lewy body disease. 2004 , 128B, 118-22	13
2116	The dopamine transporter: importance in Parkinson's disease. 2004 , 55, 766-73	97
2115	PINK1 mutations are associated with sporadic early-onset parkinsonism. 2004 , 56, 336-41	397
2114	Executive processes in Parkinson's disease: FDG-PET and network analysis. 2004 , 22, 236-45	86
2113	Quality of life in Polish patients with long-lasting Parkinson's disease. 2004 , 19, 667-72	43
2112	Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations. 2004 , 19, 677-81	13
2111	Muscle relaxation is impaired in dystonia: a reaction time study. 2004 , 19, 681-7	26
2110	Cerebellar metabolic symmetry in essential tremor studied with 1H magnetic resonance spectroscopic imaging: implications for disease pathology. 2004 , 19, 672-7	34
2109	Lack of mutations in DJ-1 in a cohort of Taiwanese ethnic Chinese with early-onset parkinsonism. 2004 , 19, 1065-9	26
2108	Development of Parkinson's disease in patients with blepharospasm. 2004 , 19, 1069-1072	19

2107	Effects of dopaminergic treatment on bladder function in Parkinson's disease. 2004 , 23, 689-96	83
2106	Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. 2004 , 291-6	42
2105	Cognitive rehabilitation in Parkinson's disease. 2004 , 387-91	82
2104	The neuropsychiatry of Parkinson's disease and related disorders. 2004 , 27, 801-25	73
2103	Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. 2004 , 351, 1972-7	456
2102	Cabergoline : a review of its use in the treatment of Parkinson's disease. 2004 , 64, 2125-41	23
2101	Management of Parkinson Disease. 2004 , 12, 39-54	3
2100	Cognitive issues in Parkinson's disease. 2004 , 22, S91-S106	7
2099	Deep brain stimulation and its effect on sleep in Parkinson's disease. 2004 , 5, 211-4	26
2098	Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. 2004 , 17, 219-36	131
2097	Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. 2004 , 355, 193-6	31
2096	Assessment of Nurr1 nucleotide variations in familial Parkinson's disease. 2004 , 366, 135-8	19
2095	Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease. 2004 , 367, 97-100	23
2094	Mitochondrial polymorphisms in Parkinson's Disease. 2004 , 370, 171-4	32
2093	Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. 2004 , 117, 412-9	37
2092	Linkage disequilibrium and association of MAPT H1 in Parkinson disease. 2004 , 75, 669-77	130
2091	Parkinson's disease. 2004 , 363, 1783-93	874
2090	Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. 2004 , 27, 153-6	159

2089	Effects of respiratory muscle weakness on daily living function, quality of life, activity levels, and exercise capacity in mild to moderate Parkinson's disease. 2004 , 83, 601-7		39
2088	The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. 2004 , 15, 1715-8		62
2087	Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. 2004 , 31, 7-21		20
2086	Validation of a polysomnographic score for REM sleep behavior disorder. 2005 , 28, 993-7		106
2085	Medical History and Physical Examination in Parkinsonian Syndromes. 2005 , 155-162		
2084	Evaluation of epidemiologic and animal data associating pesticides with Parkinson's disease. 2005 , 47, 1059-87		59
2083	A cohort study of Parkinson's disease and other neurodegenerative disorders in Danish welders. 2005 , 47, 466-72		44
2082	Neurofilament M gene in a French-Canadian population with Parkinson's disease. 2005 , 32, 68-70		9
2081	Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. <i>European Journal of Neurology</i> , 2005 , 12, 199-207	6	110
2080	Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. <i>European Journal of Neurology</i> , 2005 , 12, 842-50	6	70
2079	Dual tasking, gait rhythmicity, and Parkinson's disease: which aspects of gait are attention demanding?. 2005 , 22, 1248-56		534
2078	Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. 2005 , 25, 188-94		25
2077	Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). 2005 , 5, 135-41		90
2076	G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. 2005 , 111, 351-2		24
2075	Function of sigma1 receptors in Parkinson's disease. 2005 , 112, 103-7		120
2074	99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. 2005 , 112, 380-5		28
2073	The effects of levodopa on word intelligibility in Parkinson's disease. 2005 , 38, 187-96		51
2072	Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. 2005 , 20, 418-22		37

2071	Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. 2005 , 137B, 5-16	175
2070	Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. 2005 , 57, 176-9	534
2069	Familial Parkinson's disease: clinical and genetic analysis of four Basque families. 2005 , 57, 365-72	48
2068	Is freezing of gait in Parkinson's disease related to asymmetric motor function?. 2005 , 57, 656-63	238
2067	Clinical features of LRRK2-associated Parkinson's disease in central Norway. 2005 , 57, 762-5	150
2066	Torsin A haplotype predisposes to idiopathic dystonia. 2005 , 57, 765-7	70
2065	Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. 2005 , 57, 933-4	81
2064	Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. 2005 , 58, 773-6	280
2063	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. 2005 , 58, 829-39	172
2062	Salivary production in Parkinson's disease. 2005 , 20, 204-7	135
2061	Treadmill walking as an external pacemaker to improve gait rhythm and stability in Parkinson's disease. 2005 , 20, 1109-14	247
2060	A systematic review of prevalence studies of dementia in Parkinson's disease. 2005 , 20, 1255-63	636
2059	Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: the utility of factorial discriminant analysis. 2005 , 20, 1431-8	12
2058	Unified Parkinson's disease rating scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable?. 2005 , 20, 1577-84	153
2057	Imaging in cell-based therapy for neurodegenerative diseases. 2005 , 32 Suppl 2, S417-34	12
2056	Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. 2005 , 109, 141-50	92
2055	Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. 2005 , 252, 1310-5	193
2054	Lrrk2 pathogenic substitutions in Parkinson's disease. 2005 , 6, 171-7	207

2053	REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study. 2005 , 25, 316-21	146
2052	Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. 2005 , 32, 307-31	21
2051	Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently. 2005 , 2, 23	155
2050	Laryngeal Function in Individuals With Parkinson's Disease. 2005 , 15, 9-15	1
2049	Parkinson's Disease. 2005 , 31-50	
2048	Respiratory muscle strength training: Treatment and response duration in a patient with early idiopathic Parkinson's disease. 2005 , 20, 323-333	50
2047	Functional Neurosurgery for Movement Disorders. 2005 , 607-616	
2046	Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism. 2005 , 1, 159-65	29
2045	Detection of a brachial artery pseudoaneurysm using ultrasonography and EMG. 2005 , 65, 649	10
2044	Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. 2005 , 65, 651-2	44
2043	Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. 2005 , 76, 1636-9	195
2042	A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample. <i>Archives of Neurology</i> , 2005 , 62, 74-8	41
2041	Cognitive status correlates with neuropathologic stage in Parkinson disease. 2005 , 64, 1404-10	434
2040	Hypointense leptomeningeal vessels at T2*-weighted MRI in acute ischemic stroke. 2005 , 65, 652-3	32
2039	Carotid dissection causing occipital lobe infarction. 2005 , 65, 1408	4
2038	Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. 2005 , 14, 3549-56	68
2037	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. 2005 , 128, 2272-80	92
2036	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. 2005 , 128, 2665-74	252

2035	Searching for a relationship between manganese and welding and Parkinson's disease. 2005 , 64, 2021-8	135
2034	Atypical Parkinsonian Disorders. 2005 ,	10
2033	Clinical Diagnosis of Vascular Parkinsonism and Nondegenerative Atypical Parkinsonian Disorders. 2005 , 393-408	3
2032	Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. 2005 , 65, 1402-8	118
2031	Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease. 2005 , 65, 650-1	7
2030	Neurosurgery. 2005 ,	9
2029	Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. <i>Archives of Neurology</i> , 2005 , 62, 82-7	75
2028	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. 2005 , 128, 1259-66	125
2027	Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. 2005 , 128, 2654-64	159
2026	Clinical practice. Diagnosis and initial management of Parkinson's disease. 2005 , 353, 1021-7	227
2025	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. 2005 , 76, 672-80	453
2024	Camptocormia: pathogenesis, classification, and response to therapy. 2005 , 65, 355-9	335
2023	Cognitive profile of patients with newly diagnosed Parkinson disease. 2005 , 65, 1239-45	759
2022	Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. 2005 , 382, 297-9	13
2021	Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism. 2005 , 162, 222-32	46
2020	Marmoset monkey models of Parkinson's disease: which model, when and why?. 2005 , 68, 140-9	81
2019	S100B and NSE serum levels in patients with Parkinson's disease. 2005 , 11, 39-43	49
2018	Micrographia on free writing versus copying tasks in idiopathic Parkinson's disease. 2005 , 11, 57-63	32

2017	Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. 2005 , 11, 349-52	26
2016	Nosology of Parkinson's disease: looking for the way out of a quagmire. 2005 , 47, 479-82	80
2015	Tear film tests in Parkinson's disease patients. 2005 , 112, 1795	57
2014	Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. 2005 , 86, 626-32	178
2013	Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan. 2005 , 232, 91-4	4
2012	Dopamine and Glutamate in Psychiatric Disorders. 2005 ,	5
2011	Utility of 6-Hydroxydopamine Lesioned Rats in the Preclinical Screening of Novel Treatments for Parkinson Disease. 2005 , 193-208	12
2010	Increased intracranial volume in Parkinson's disease. 2005 , 239, 45-52	36
2009	Genomewide association, Parkinson disease, and PARK10. 2006 , 78, 1084-8; author reply 1092-4	50
2008	I.5 Early diagnosis in PD: ultrasonography. 2006 , 12, 1-2	
2007	I.6 Anhedonia and depression in Parkinson's Disease. 2006 , 12, 2	
2006	I.7 Pain in Parkinson's Disease. 2006 , 12, 2	2
2005	Parkinson's disease: background, diagnosis, and initial management. 2006 , 22, 735-51, v	16
2004	Prevalence of haemochromatosis gene mutations in Parkinson's disease. 2007 , 78, 315-7	33
2003	Virtual action planning in Parkinson's disease: a control study. 2006 , 9, 342-7	57
2002	Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa. 2006 , 240, 31-6	54
2001	Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. 2006 , 243, 57-60	18
2000	Are dementia and depression in Parkinson's disease related?. 2006 , 248, 138-42	36

1999	Genetic analysis of LRRK2 mutations in patients with Parkinson disease. 2006 , 251, 102-6	53
1998	Is it Parkinson's disease, and if not, what is it?. 2006 , 6, 154-165	6
1997	Perioperative risk assessment in the surgical care of geriatric patients. 2006 , 18, 19-34, v-vi	3
1996	Evaluation of extracranial blood flow in Parkinson disease. 2006 , 391, 131-5	1
1995	Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. 2006 , 404, 56-60	47
1994	Correlation of tau gene polymorphism with age at onset of Parkinson's disease. 2006 , 405, 202-6	8
1993	Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. 2006 , 410, 80-4	46
1992	Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. 2006 , 406, 235-9	28
1991	The diagnosis of manganese-induced parkinsonism. 2006 , 27, 340-6	183
1990	Amphetamine exposure is elevated in Parkinson's disease. 2006 , 27, 1003-6	61
1989	Parkinson's disease in diphenyl-exposed workers--a causal association?. 2006 , 12, 29-34	9
1988	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. 2006 , 12, 309-13	2
1987	Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. 2006 , 12, 427-31	30
1986	Evaluation of sympathetic skin response in Parkinson's disease. 2006 , 12, 486-91	22
1985	Enriched environment improves motor function in intact and unilateral dopamine-depleted rats. 2006 , 140, 1127-38	75
1984	[Neuroimaging of the dopamine transporter in Parkinson's disease: first study using [^{99m} Tc]-TRODAT-1 and SPECT in Brazil]. 2006 , 64, 628-34	20
1983	Parkinson's disease and dopamine transporter neuroimaging: a critical review. 2006 , 124, 168-75	41
1982	Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. 2006 , 45, 135-40	31

1981 Parkinson's disease and deep brain stimulation. **2006**, 2, 473-487

1980 Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. **2006**, 65, 116-23 74

1979 The ratio of square wave jerk rates to blink rates distinguishes progressive supranuclear palsy from Parkinson disease. **2006**, 26, 257-9 25

1978 Clinical heterogeneity of the LRRK2 G2019S mutation. *Archives of Neurology*, **2006**, 63, 1242-6 26

1977 Malignant melanoma and other types of cancer preceding Parkinson disease. **2006**, 17, 582-7 126

1976 Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. *Archives of Neurology*, **2006**, 63, 273-7 36

1975 Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. **2006**, 65, 66-77 82

1974 A novel P755L mutation in LRRK2 gene associated with Parkinson's disease. **2006**, 17, 1859-62 15

1973 Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. **2006**, 18, 377-83 24

1972 Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. **2006**, 27, 945-51 39

1971 Monitoring activity in individuals with Parkinson disease: a validity study. **2006**, 30, 12-21 26

1970 The neurology of menopause. **2006**, 12, 149-59 19

1969 LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. *Archives of Neurology*, **2006**, 63, 377-82 102

1968 Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. **2006**, 9, 293-348 324

1967 Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson's disease. **2006**, 24, 1815-20 197

1966 Parkinsonism genes: culprits and clues. **2006**, 99, 1062-72 92

1965 LRRK2 mutations are a common cause of Parkinson's disease in Spain. *European Journal of Neurology*, **2006**, 13, 391-4 6 46

1964 Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. **2006**, 26, 1198-212 201

1963	Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. 2006 , 296, 661-70	403
1962	Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson's disease: one year follow-up of a randomised observer-blind multi centre trial. 2006 , 148, 1247-55; discussion 1255	34
1961	Orthostatic hypotension as an early finding in Parkinson's disease. 2006 , 16, 46-54	144
1960	IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. 2006 , 33, 1073-83	27
1959	Impact of subthalamic nucleus stimulation on the initiation of gait in Parkinson's disease. 2006 , 172, 519-32	66
1958	Preclinical diagnosis of Parkinson's disease: are we there yet?. 2006 , 6, 295-301	41
1957	The diagnosis of Parkinson's disease. 2006 , 5, 75-86	476
1956	The mystery of motor asymmetry in Parkinson's disease. 2006 , 5, 796-802	245
1955	Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. 2006 , 23, 36-43	54
1954	Prevalence of bladder dysfunction in Parkinson's disease. 2006 , 25, 116-22	99
1953	Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease. 2006 , 27, 588-97	140
1952	Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. 2006 , 21, 270-3	39
1951	Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. 2006 , 21, 380-4	110
1950	Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. 2006 , 21, 1261-4	35
1949	Does subthalamic nucleus deep brain stimulation really improve quality of life in Parkinson's disease?. 2006 , 21, 1465-8	26
1948	Striatal dopa and glucose metabolism in PD patients with freezing of gait. 2006 , 21, 1326-32	84
1947	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. 2006 , 21, 1663-6	28
1946	Surface electromyography shows increased mirroring in Parkinson's disease patients without overt mirror movements. 2006 , 21, 1461-5	27

1945	Hyperhidrosis in Parkinson's disease. 2006 , 21, 1744-8	42
1944	Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. 2006 , 21, 1856-63	166
1943	Increase in body weight after pramipexole treatment in Parkinson's disease. 2006 , 21, 1972-4	29
1942	Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. 2006 , 21, 1954-9	68
1941	Identification of a risk haplotype of the alpha-synuclein gene in Japanese with sporadic Parkinson's disease. 2006 , 21, 2157-64	2
1940	Biochemical and pathological characterization of Lrrk2. 2006 , 59, 315-22	205
1939	Clinical features and gene analysis in Korean patients with early-onset Parkinson disease. <i>Archives of Neurology</i> , 2006 , 63, 1170-4	16
1938	Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation. 2006 , 9, 767-8	10
1937	Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. 2006 , 66, 415-7	79
1936	Differences in neuropathologic characteristics across the Lewy body dementia spectrum. 2006 , 67, 1931-4	255
1935	Evaluation of physical therapy in parkinsonian patients with freezing of gait: a pilot study. 2006 , 20, 31-5	36
1934	A specific clinical pattern of camptocormia in Parkinson's disease. 2006 , 77, 1229-34	94
1933	Familial occurrence of dementia and parkinsonism: a systematic review. 2006 , 22, 288-95	19
1932	Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 2006 , 66, 968-75	216
1931	Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. 2006 , 56, 127-32	62
1930	Pain and motor complications in Parkinson's disease. 2006 , 77, 822-5	153
1929	A common cognitive profile in elderly fallers and in patients with Parkinson's disease: the prominence of impaired executive function and attention. 2006 , 32, 411-29	141
1928	PINK1 mutation heterozygosity and the risk of Parkinson's disease. 2007 , 78, 82-4	32

1927	Primary Cerebral Lymphoma presenting with Parkinsonism. 2007 , 52, 55-55	1
1926	Parkinsonism. 2007 , 79-103	
1925	Parkinson's disease: genetics and beyond. 2007 , 5, 99-113	20
1924	Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. 2007 , 4, 403-5	58
1923	Carotid atherosclerosis is associated with brain atrophy in Japanese elders. 2007 , 53, 1-6	19
1922	Differentiating Parkinson's disease from other parkinsonian disorders. 2007 , 27, 356-62	13
1921	Limb-kinetic apraxia in Parkinson disease. 2007 , 68, 150-1	57
1920	Motor procedural learning in Parkinson's disease. 2007 , 130, 2887-97	113
1919	Parkinsonism: a review-of-systems approach to diagnosis. 2007 , 27, 113-22	12
1918	Gene-expression profiling in Parkinson's disease: discovery of valid biomarkers, molecular targets and biochemical pathways. 2007 , 2, 29-38	7
1917	The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease. 2007 , 69, 2155-61	30
1916	Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. 2007 , 7, 374-82	61
1915	A Randomized Trial Comparing Unilateral Pallidotomy with Bilateral Subthalamic Nucleus Stimulation in PD: Perspectives for Future Implication in Clinical Practice. 2007 , 2, 13-26	
1914	Pearls in patient selection for deep brain stimulation. 2007 , 13, 253-60	79
1913	Phenylthiocarbamide (PTC) perception in Parkinson disease. 2007 , 20, 145-8	15
1912	Imaging in dementia with Lewy bodies: a review. 2007 , 28, 511-9	26
1911	Exploring the relationship between essential tremor and Parkinson's disease. 2007 , 13, 67-76	145
1910	Incidence of Parkinson's disease in Singapore. 2007 , 13, 40-3	21

1909	Problems with deep brain stimulation devices referred to private practice for follow up. 2007 , 13, 520-3	2
1908	Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. 2007 , 13, 89-92	148
1907	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. 2007 , 13, 528-31	57
1906	Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease. 2007 , 13, 386-8	5
1905	Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. 2007 , 28, 1682-8	16
1904	Cortical inhibition in Parkinson's disease: new insights from early, untreated patients. 2007 , 150, 64-71	25
1903	The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. 2007 , 109, 495-500	54
1902	The association between impaired turning and normal straight walking in Parkinson's disease. 2007 , 26, 172-8	144
1901	Serum biomarkers for Alzheimer's disease: proteomic discovery. 2007 , 61, 383-9	42
1900	The control of equilibrium in Parkinson's disease patients: delayed adaptation of balancing strategy to shifts in sensory set during a dynamic task. 2007 , 74, 258-70	45
1899	A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat. 2007 , 81, 441-8	2
1898	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. 2007 , 414, 170-3	9
1897	Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. 2007 , 416, 299-301	20
1896	Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. 2007 , 419, 104-7	9
1895	Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. 2007 , 422, 193-7	17
1894	The error negativity in nonmedicated and medicated patients with Parkinson's disease. 2007 , 118, 1223-9	46
1893	An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. 2007 , 118, 2189-94	68
1892	3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. 2007 , 37, 440-50	27

1891	TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. 2007 , 171, 227-40	376
1890	Test-retest reliability of 24 hours of activity monitoring in individuals with Parkinson's disease in home and community. 2007 , 21, 327-40	29
1889	Parkinson's Disease. 2007 ,	1
1888	Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. 2007 , 49, 120-6	103
1887	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. 2007 , 91-104	54
1886	Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners. 2007 , 21, 783-91	43
1885	Autonomic dysfunction in Parkinson's disease. 2007 , 83, 343-63	5
1884	Motor symptoms in Parkinson's disease. 2007 , 83, 329-42	18
1883	Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. 2008 , 167, 553-60	116
1882	Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. 2007 , 106, 621-5	155
1881	Validation of PDQ-8 as an independent instrument in English and Chinese. 2007 , 255, 77-80	28
1880	The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. 2007 , 260, 199-203	41
1879	Lewy Body Disorders. 2007 , 267-343	3
1878	Lack of mutations in spinocerebellar ataxia type 2 and 3 genes in a Taiwanese (ethnic Chinese) cohort of familial and early-onset parkinsonism. 2007 , 144B, 434-8	8
1877	Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease. 2007 , 144B, 458-62	27
1876	Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. 2007 , 28, 98	51
1875	Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15). 2007 , 22, 1025-30	15
1874	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. 2007 , 22, 389-92	8

1873	Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. 2007 , 22, 334-40		116
1872	Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients. 2007 , 22, 324-7		35
1871	Carbidopa/levodopa-responsive myoclonus. 2007 , 22, 392-5		
1870	ELAVL4, PARK10, and the Celts. 2007 , 22, 585-7		19
1869	Identifying incident cases of parkinsonism among veterans using a tertiary medical center. 2007 , 22, 915-23		4
1868	Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. 2007 , 22, 550-5		65
1867	The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study. 2007 , 22, 880-3		38
1866	Treatment with levodopa and risk for malignant melanoma. 2007 , 22, 1252-7		48
1865	Analysis of olfactory function and the depth of olfactory sulcus in patients with Parkinson's disease. 2007 , 22, 1563-6		28
1864	Role of DAT-SPECT in the diagnostic work up of parkinsonism. 2007 , 22, 1229-38		180
1863	MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. 2007 , 85, 1288-94		57
1862	Parkinson's disease: a dual-hit hypothesis. 2007 , 33, 599-614		561
1861	Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. <i>European Journal of Neurology</i> , 2007 , 14, 7-11	6	47
1860	Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing. <i>European Journal of Neurology</i> , 2007 , 14, 1405-8	6	58
1859	Functional imaging of working memory in Parkinson's disease: compensations and deficits. 2007 , 17, 277-85		14
1858	Global Mobility Task: index for evaluating motor impairment and motor rehabilitation programs in Parkinson's disease patients. 2007 , 116, 182-9		5
1857	Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. 2007 , 1184, 284-94		278
1856	ICU management of patients with Parkinson's disease or Parkinsonism. 2007 , 18, 227-236		7

1855	Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. 2007 , 128, 378-82	51
1854	How common are the "common" neurologic disorders?. 2007 , 68, 326-37	1048
1853	Gait asymmetry in patients with Parkinson's disease and elderly fallers: when does the bilateral coordination of gait require attention?. 2007 , 177, 336-46	248
1852	A new measure for quantifying the bilateral coordination of human gait: effects of aging and Parkinson's disease. 2007 , 181, 561-70	219
1851	Quantification of Parkinson's disease-related network expression with ECD SPECT. 2007 , 34, 496-501	65
1850	The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. 2007 , 34, 1240-53	86
1849	A direct ROI quantification method for inherent PVE correction: accuracy assessment in striatal SPECT measurements. 2007 , 34, 1480-9	15
1848	Cardiac sympathetic neuronal imaging using PET. 2007 , 34 Suppl 1, S74-85	37
1847	Mitochondrial DNA polymorphisms and the risk of Parkinson's disease in Taiwan. 2007 , 114, 1017-21	11
1846	Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. 2007 , 114, 1161-5	40
1845	Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. 2007 , 113, 421-9	257
1844	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. 2007 , 114, 221-9	307
1843	Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. 2007 , 254, 84-90	103
1842	Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. 2007 , 254, 501-7	59
1841	Diagnostic accuracy of the clapping test in Parkinsonian disorders. 2007 , 254, 1366-9	12
1840	Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease. 2007 , 52, 201-204	9
1839	Brain volumetrics to investigate aging and the principal forms of degenerative cognitive decline: a brief review. 2008 , 26, 1065-70	24
1838	Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. 2008 , 18, 103-19	142

1837	Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. 2008 , 35, 1334-42	29
1836	[Atypical Parkinson syndromes]. 2008 , 79, 1203-20; quiz 1221-2	1
1835	LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. 2008 , 15, 661-7	40
1834	The PRIAMO study: background, methods and recruitment. 2008 , 29, 61-5	24
1833	Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. 2008 , 29, 391-5	17
1832	Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. 2008 , 115, 1001-9	175
1831	Clinical heterogeneity in newly diagnosed Parkinson's disease. 2008 , 255, 716-22	64
1830	Levodopa reduces risk factors for vascular disease in parkinsonian patients. 2008 , 255, 1266-7	3
1829	Epidemiology of Parkinson's disease. 2008 , 255 Suppl 5, 18-32	257
1828	Genetic association study of synphilin-1 in idiopathic Parkinson's disease. 2008 , 9, 19	11
1827	Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. 2008 , 86, 1895-901	25
1826	Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: analysis of [11C] raclopride PET study. 2008 , 23, 207-11	44
1825	Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. 2008 , 23, 405-10	70
1824	Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. 2008 , 23, 850-7	177
1823	Applause sign in Parkinsonian disorders and Huntington's disease. 2008 , 23, 2307-11	41
1822	Suicidal and death ideation in Parkinson's disease. 2008 , 23, 1573-9	93
1821	Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. 2008 , 23, 1860-6	115
1820	The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. 2008 , 23, 2328-34	103

1819	Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. 2008 , 147B, 495-9		12
1818	Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. 2008 , 64, 88-92		176
1817	Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. 2008 , 70, 1456-60		109
1816	Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease. 2008 , 56, 765-7		17
1815	Lifestyle changes after oral glucose tolerance test improve glucose intolerance in community-dwelling elderly people after 1 year. 2008 , 56, 767-9		8
1814	A genome-wide scan in an Amish pedigree with parkinsonism. 2008 , 72, 621-9		10
1813	Medications used to treat Parkinson's disease and the risk of gambling. <i>European Journal of Neurology</i> , 2008 , 15, 350-4	6	25
1812	Factors affecting health-related quality of life amongst Asian patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2008 , 15, 737-42	6	39
1811	Bilateral coordination of walking and freezing of gait in Parkinson's disease. 2008 , 27, 1999-2006		150
1810	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. 2008 , 8, 1		32
1809	The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. 2008 , 7, 417-24		195
1808	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. 2008 , 31, 41-5		50
1807	Spreading activation of lexical-semantic networks in Parkinson's disease. 2008 , 46, 1908-14		14
1806	Whose Syndrome? Stories of Medical Eponyms. 2008 , 87-102		
1805	Decreased NURR1 gene expression in patients with Parkinson's disease. 2008 , 273, 29-33		99
1804	Environmental exposures and adverse pregnancy outcomes: a review of the science. 2008 , 15, 631-50		235
1803	Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. 2008 , 64, 850-5		143
1802	Changes in processing of proprioceptive information in Parkinson's disease and multiple system atrophy. 2008 , 119, 1139-46		12

1801	Neuroanatomy and Pathology of Sporadic Parkinson's Disease. 2008,	2
1800	Vascular parkinsonism. 2008, 5, 237-255	25
1799	Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. 2008, 8, 219-28	93
1798	Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. 2008, 430, 18-22	20
1797	HSPA5 promoter polymorphisms and risk of Parkinson's disease in Taiwan. 2008, 435, 219-22	7
1796	Polychlorinated biphenyl-induced oxidative stress in organotypic co-cultures: experimental dopamine depletion prevents reductions in GABA. 2008, 29, 301-8	21
1795	Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. 2008, 29, 379-96	53
1794	Complete ascertainment of Parkinson disease in the Swedish Twin Registry. 2008, 29, 1765-73	22
1793	Visual field analysis in patients with Parkinson's disease. 2008, 14, 193-8	33
1792	An analysis of genetic studies of Parkinson's disease in Africa. 2008, 14, 177-82	11
1791	Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families. 2008, 14, 286-90	69
1790	Clinical features at first visit and rapid disease progression in Parkinson's disease. 2008, 14, 431-5	17
1789	Handedness as a predictor of side of onset of Parkinson's disease. 2008, 14, 633-5	51
1788	Grey matter atrophy in early versus late dementia in Parkinson's disease. 2008, 14, 620-5	16
1787	Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. 2008, 14, 544-7	8
1786	Genetic variation of Omi/HtrA2 and Parkinson's disease. 2008, 14, 539-43	53
1785	Parkinson's disease: clinical features and diagnosis. 2008, 79, 368-76	2854
1784	Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. 2008, 19, 370-1	23

1783	Neural substrates of cognitive skill learning in Parkinson's disease. 2008 , 68, 134-43	32
1782	Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. 2008 , 38, 274-86	16
1781	Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. 2008 , 4, S67-76	61
1780	Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. 2008 , 131, 1903-11	275
1779	Neuropsychology of dementia with Lewy bodies. 2008 , 88, 549-66	5
1778	Altered diffusion in the frontal lobe in Parkinson disease. 2008 , 29, 501-5	152
1777	Mutations in LRRK2 as a cause of Parkinson's disease. 2008 , 16, 99-105	41
1776	Determinants of disability and quality of life in mild to moderate Parkinson disease. 2008 , 70, 2241-7	251
1775	Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. 2008 , 71, 1727-32	83
1774	Incidental Lewy body disease and preclinical Parkinson disease. <i>Archives of Neurology</i> , 2008 , 65, 1074-80	138
1773	Animal Models of Parkinson's Disease to Aid Drug Discovery and Development. 2008 , 159-205	1
1772	Thought Speed, Mood, and the Experience of Mental Motion. 2008 , 3, 461-85	46
1771	Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. <i>Archives of Neurology</i> , 2008 , 65, 1191-4	186
1770	Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. <i>Archives of Neurology</i> , 2008 , 65, 1348-52	238
1769	CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. 2008 , 129, 526-9	222
1768	Single photon-emission computed tomography imaging in early Parkinson's disease. 2008 , 8, 1853-64	4
1767	Postmortem analysis following 71 months of deep brain stimulation of the subthalamic nucleus for Parkinson disease. 2008 , 109, 325-9	45
1766	Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. 2008 , 22, 729-37	55

1765	Cortical Lewy body disease: dementia with Lewy bodies and Parkinson's disease with dementia. 2008 , 293-320		
1764	Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. 2008 , 337, a2494		77
1763	Executive cognitive tests for the evaluation of patients with Parkinson's disease. 2008 , 2, 206-210		7
1762	The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. 2008 , 66, 152-6		45
1761	Visuospatial cognitive tests for the evaluation of patients with Parkinson's disease. 2008 , 2, 201-205		6
1760	Assistive technology in everyday living – A user survey of people with Parkinson's disease. 2009 , 20, 271-282		3
1759	Non-motor off symptoms in Parkinson's disease. 2009 , 24, 311-4		22
1758	Neuroimaging in Parkinsonism: a study with magnetic resonance and spectroscopy as tools in the differential diagnosis. 2009 , 67, 1-6		7
1757	A cross-study transcriptional analysis of Parkinson's disease. 2009 , 4, e4955		70
1756	Usefulness of Diffusion-Weighted MRI for Differentiation between Parkinson's Disease and Parkinson Variant of Multiple System Atrophy. <i>Journal of Movement Disorders</i> , 2009 , 2, 64-8	2.9	18
1755	Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. 2009 , 27, 404-17		61
1754	Visuospatial dysfunction may be a key in the differentiation between Alzheimer's disease and subcortical cognitive impairment in moderate to severe stages. 2009 , 28, 288-94		12
1753	Occupation and risk of parkinsonism: a multicenter case-control study. <i>Archives of Neurology</i> , 2009 , 66, 1106-13		160
1752	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. 2009 , 73, 1738-45		687
1751	Elevated serum pesticide levels and risk of Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 870-5		85
1750	A prospective study of alterations in balance among patients with Parkinson's Disease. Protocol of the postural evaluation. 2009 , 61, 171-6		57
1749	Assessing cognition in Parkinson disease: use of the cognitive linguistic quick test. 2009 , 22, 228-34		12
1748	Autoimmune disease and risk for Parkinson disease: a population-based case-control study. 2009 , 73, 1462-8		83

1747	Course in Parkinson disease subtypes: A 39-year clinicopathologic study. 2009 , 73, 206-12	193
1746	White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. 2009 , 30, 1222-6	184
1745	Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. 2009 , 33, 429-35	87
1744	Parkinson Disease and the Nurse Practitioner: Diagnostic and Management Challenges. 2009 , 5, 195-206	5
1743	'Gamma' band oscillatory response to chromatic stimuli in volunteers and patients with idiopathic Parkinson's disease. 2009 , 49, 726-34	4
1742	Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. 2009 , 1265, 158-70	95
1741	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. 2009 , 8, 1150-7	567
1740	Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. 2009 , 52, 663-70	45
1739	PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications. 2009 , 150B, 124-9	19
1738	Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9 g > a single nucleotide polymorphism and risk of Taiwanese PD. 2010 , 153B, 229-34	6
1737	Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. 2008 , 64 Suppl 2, S139-47	43
1736	Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. 2008 , 64 Suppl 2, S111-21	23
1735	A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's disease. 2009 , 33, 657-67	24
1734	Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. 2009 , 87, 2578-90	32
1733	A unique case of cortical myoclonus sensitive to visual stimuli in the peripersonal space. 2009 , 24, 422-5	
1732	Myoclonus of peripheral origin: two case reports. 2009 , 24, 274-7	28
1731	Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. 2009 , 24, 104-8	22
1730	Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. 2009 , 24, 32-9	38

1729	Prevalence of unilateral tremor in autosomal dominant essential tremor. 2009 , 24, 108-11	28
1728	Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease. 2009 , 24, 111-5	19
1727	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. 2009 , 24, 833-8	52
1726	Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson's Disease Questionnaire (PDQ-8). 2009 , 24, 183-7	27
1725	Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. 2009 , 24, 277-82	98
1724	Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. 2009 , 24, 115-8	16
1723	Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. 2009 , 24, 119-22	19
1722	Increased oxidative stress in patients with amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii peninsula, Japan. 2009 , 24, 123-6	9
1721	Intention tremor in essential tremor: Prevalence and association with disease duration. 2009 , 24, 626-7	86
1720	Increase in the tactile catchment area of a sensory trick for alleviating blepharospasm following pallidal DBS. 2009 , 24, 624-6	3
1719	Responsiveness to levodopa in epsilon-sarcoglycan deletions. 2009 , 24, 425-8	34
1718	Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. 2009 , 24, 126-9	67
1717	Allied health care in Parkinson's disease: referral, consultation, and professional expertise. 2009 , 24, 282-6	50
1716	Microsubthalamotomy effect at day 3: screening for determinants. 2009 , 24, 286-9	23
1715	Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. 2009 , 24, 414-21	42
1714	Pseudohypoparathyroidism manifesting with paroxysmal dyskinesias and seizures. 2009 , 24, 623-4	16
1713	Cognitive decline in early Parkinson's disease. 2009 , 24, 605-8	44
1712	Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. 2009 , 24, 129-33	48

1711	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. 2009 , 24, 290-2	22
1710	Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. 2009 , 24, 133-7	16
1709	Hiccups associated with levodopa in Parkinson's disease. 2009 , 24, 621-22	25
1708	Atypical dystonic shoulder movements following neuralgic amyotrophy. 2009 , 24, 293-6	12
1707	Genetic association study of the P-type ATPase ATP13A2 in late-onset Parkinson's disease. 2009 , 24, 429-33	12
1706	Reverse sensory geste in cervical dystonia. 2009 , 24, 297-300	6
1705	Zonisamide for essential tremor: an evaluator-blinded study. 2009 , 24, 437-40	34
1704	Validity of the Cornell scale for depression in dementia in Parkinson's disease with and without cognitive impairment. 2009 , 24, 433-7	14
1703	Recurrent hemichorea following a single infarction in the contralateral subthalamic nucleus. 2009 , 24, 617-8	14
1702	Walking along circular trajectories in Parkinson's disease. 2009 , 24, 598-604	28
1701	Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease. 2009 , 24, 449-52	17
1700	Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. 2009 , 24, 618-9	16
1699	Effects of inhibitory rTMS on bladder function in Parkinson's disease patients. 2009 , 24, 445-8	32
1698	A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. 2009 , 24, 441-5	59
1697	FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. 2009 , 24, 455-9	38
1696	Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient. 2009 , 24, 627-8	25
1695	Traditional Chinese medicine on four patients with Huntington's disease. 2009 , 24, 453-5	17
1694	Tramadol hydrochloride use and acute deterioration in Parkinson's disease tremor. 2009 , 24, 622-3	5

1693	Reported mutations in GIGYF2 are not a common cause of Parkinson's disease. 2009 , 24, 619-20	24
1692	Gene expression changes in blood as a putative biomarker for Huntington's disease. 2009 , 24, 2277-81	23
1691	Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. 2009 , 24, 1139-43	145
1690	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. 2009 , 24, 1641-9	919
1689	MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. 2009 , 24, 1650-5	51
1688	Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. 2009 , 24, 1998-2001	50
1687	Tremor in 48,XXYY syndrome. 2009 , 24, 2001-7	19
1686	Complementary and alternative medicine use in Gilles de la Tourette syndrome. 2009 , 24, 2015-9	43
1685	Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: genetic, clinical, and positron emission tomography findings. 2009 , 24, 2007-11	32
1684	GCH1 in early-onset Parkinson's disease. 2009 , 24, 2070-5	14
1683	Clinical and genetic characteristics of Mexican Huntington's disease patients. 2009 , 24, 2012-5	26
1682	Brain atrophy and white matter hyperintensities in early Parkinson's disease(a). 2009 , 24, 2233-41	43
1681	Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. 2009 , 24, 2242-8	48
1680	Positive family history of essential tremor influences the motor phenotype of Parkinson's disease. 2009 , 24, 2285-8	14
1679	Isolated head tremor: part of the clinical spectrum of essential tremor? Data from population-based and clinic-based case samples. 2009 , 24, 2281-5	31
1678	Apathy may herald cognitive decline and dementia in Parkinson's disease. 2009 , 24, 2391-7	148
1677	Voiding dysfunction in patients with Parkinson's disease: impact of neurological impairment and clinical parameters. 2009 , 28, 510-5	52
1676	SCA8 repeat expansion: large CTA/CTG repeat alleles in neurological disorders and functional implications. 2009 , 125, 437-44	9

1675	LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. 2009 , 10, 157-9	62
1674	Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. 2009 , 117, 169-74	151
1673	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. 2009 , 117, 613-34	433
1672	Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. 2009 , 256, 563-7	70
1671	Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease. 2009 , 25, 321-30	20
1670	Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. 2009 , 16, 63	115
1669	Fine-mapping and candidate gene investigation within the PARK10 locus. 2009 , 17, 336-43	24
1668	Augmenting the Cartesian medical discourse with an understanding of the person's lifeworld, lived body, life story and social identity. 2009 , 10, 241-52	15
1667	Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. 2009 , 57, 304-8	238
1666	GRN 3'UTR+78 C>T is not associated with risk for Parkinson's disease. <i>European Journal of Neurology</i> , 2009 , 16, 909-11	6 6
1665	Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. 2009 , 80, 851-7	165
1664	Motor Control: Pyramidal, Extrapyramidal, and Limbic Motor Control. 2009 ,	
1663	[Classification of parkinsonian syndromes via factorial discriminant analysis of brain SPECT data]. 2009 , 165, 440-8	3
1662	Intralaminar nuclei of the thalamus in Lewy body diseases. 2009 , 78, 97-104	41
1661	Molecular mechanisms of alpha-synuclein neurodegeneration. 2009 , 1792, 616-24	156
1660	Both pre- and post-lesion experiential therapy is beneficial in 6-hydroxydopamine dopamine-depleted female rats. 2009 , 158, 373-86	12
1659	Dual-isotope single-photon emission computed tomography for dopamine and serotonin transporters in normal and Parkinsonian monkey brains. 2009 , 36, 605-11	10
1658	Parkinson's disease and the heterozygous state for glucocerebrosidase mutations among Brazilians. 2009 , 15, 76-8	13

1657	Lack of evidence for association of a parkin promoter polymorphism with early-onset Parkinson's disease in a Chinese population. 2009 , 15, 149-52	3
1656	Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. 2009 , 15, 156-9	48
1655	Clinimetric analyses of the Modified Parkinson Activity Scale. 2009 , 15, 263-9	25
1654	Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. 2009 , 15, 277-80	16
1653	Acute stepwise challenge test with levodopa in treated patients with parkinsonism. 2009 , 15, 354-8	7
1652	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. 2009 , 15, 466-7	28
1651	Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. 2009 , 15, 374-8	39
1650	Analysis of PArkin Co-Regulated Gene in a Taiwanese-ethnic Chinese cohort with early-onset Parkinson's disease. 2009 , 15, 417-21	7
1649	Involuntary emotional expression disorder (IEED) in Parkinson's disease. 2009 , 15, 511-5	16
1648	Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 2009 , 15, 576-81	39
1647	A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. 2009 , 15, 627-32	77
1646	DYT1 mutations in early onset primary torsion dystonia and Parkinson disease patients in Chinese populations. 2009 , 450, 117-21	6
1645	Phactr2 and Parkinson's disease. 2009 , 453, 9-11	12
1644	Changes in walking activity and endurance following rehabilitation for people with Parkinson disease. 2009 , 90, 43-50	49
1643	Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. 2009 , 11, 439-48	106
1642	Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. 2009 , 72, 1121-6	488
1641	Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. 2009 , 60, 41-5	52
1640	Disparate cardio-cerebral vascular modulation during standing in multiple system atrophy and Parkinson disease. 2009 , 276, 84-7	6

1639	Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. 2009 , 287, 200-4	70
1638	Cognitive decline in Parkinson's disease: a prospective longitudinal study. 2009 , 15, 426-37	114
1637	Functionalised copper-64 complexes as precursors of potential PET imaging agents for neurodegenerative disorders. 2009 , 33, 1845	6
1636	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. 2009 , 47, 2083-9	54
1635	Markers of Alzheimer's disease in a population attending a memory clinic. 2009 , 5, 307-17	49
1634	Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. 2009 , 175, 54-65	73
1633	Thalamic changes in Parkinson's disease. 2009 , 15 Suppl 3, S152-5	97
1632	Parkinson disease and comorbid cerebrovascular disease. 2009 , 5, 533-41	40
1631	Vestibular rehabilitation with computerised dynamic posturography in patients with Parkinson's disease: improving balance impairment. 2009 , 31, 1907-16	41
1630	Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. 2009 , 17, 986-95	19
1629	Anaesthesia and Parkinson's disease: how to manage with new therapies?. 2009 , 22, 419-424	33
1628	Othello syndrome in Parkinson disease patients without dementia. 2009 , 15, 34-6	31
1627	Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. 2009 , 23, 365-70	85
1626	The auditory system involvement in Parkinson disease: electrophysiological and neuropsychological correlations. 2009 , 26, 430-7	24
1625	Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. 2009 , 68, 785-96	28
1624	Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. 2009 , 68, 1073-83	132
1623	Transcranial sonography in Parkinson's disease. 2009 , 5, 43-49	9
1622	Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. 2009 , 68, 994-1005	65

1621	Hypertension and cerebral diffusion tensor imaging in small vessel disease. 2010 , 41, 2801-6	60
1620	Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases. 2010 , 69, 442-8	52
1619	Maladie de Parkinson idiopathique : aspects cliniques, diagnostiques et thérapeutiques. 2010 , 7, 1-30	
1618	Patient selection. 4-19	
1617	Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's disease. 2010 , 7, 319-29	13
1616	Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. 2010 , 37, 556-64	48
1615	Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. 2010 , 119, 689-702	594
1614	The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. 2010 , 120, 131-43	400
1613	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. 2010 , 257, 5-14	115
1612	Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline. 2010 , 257, 79-84	46
1611	Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. 2010 , 257, 217-23	73
1610	Cognitive status of patients with Parkinson's disease and pathological gambling. 2010 , 257, 247-52	42
1609	Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. 2010 , 257, 139-41	14
1608	REM sleep behaviour disorder and visuoperceptive dysfunction: a disorder of the ventral visual stream?. 2010 , 257, 383-91	54
1607	T1rho and T2rho MRI in the evaluation of Parkinson's disease. 2010 , 257, 964-8	53
1606	Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. 2010 , 257, 1073-82	174
1605	LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. 2010 , 11, 401-8	106
1604	The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features. 2010 , 31, 47-52	15

1603	Myocardial MIBG scintigraphy: a useful clinical tool? : A retrospective study in 50 parkinsonian patients. 2010 , 31, 403-6	13
1602	Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. 2010 , 117, 369-75	39
1601	Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. 2010 , 117, 1093-8	32
1600	Responsiveness of the EQ-5D and 8-item Parkinson's Disease Questionnaire (PDQ-8) in a 4-year follow-up study. 2010 , 19, 565-9	22
1599	Imaging for early differential diagnosis of parkinsonism. 2010 , 9, 130-1	9
1598	EARLY antiplatelet treatment after ischaemic stroke. 2010 , 9, 131-3	1
1597	Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. 2010 , 37, 510-8	726
1596	Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. 2010 , 37, 723-30	43
1595	Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. 2010 , 10, 108	102
1594	Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients. 2010 , 10, 70	37
1593	Microstructural changes in patients with progressive supranuclear palsy: a diffusion tensor imaging study. 2010 , 32, 69-75	49
1592	Reckless generosity in Parkinson's disease. 2010 , 25, 221-3	14
1591	Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. 2010 , 25, 672-8	63
1590	Parkinson's at risk syndrome: can Parkinson's disease be predicted?. 2010 , 25 Suppl 1, S89-93	53
1589	Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease. 2010 , 25, 623-8	28
1588	Gray matter correlations of cognition in incident Parkinson's disease. 2010 , 25, 629-33	52
1587	Rehabilitation in Parkinson's disease: assessing the outcome using objective metabolic measurements. 2010 , 25, 609-14	12
1586	Carisbamate in essential tremor: brief report of a proof of concept study. 2010 , 25, 634-8	15

1585	Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. 2010 , 25, 710-6	106
1584	Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. 2010 , 25, 70-5	58
1583	Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [¹¹ C-123]FP-CIT SPECT study. 2010 , 25, 35-43	68
1582	Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. 2010 , 25, 638-42	30
1581	The relationship between uric acid levels and Huntington's disease progression. 2010 , 25, 224-8	64
1580	Parkinsonism in patients with a history of amphetamine exposure. 2010 , 25, 228-31	29
1579	Functional correlates of lower cognitive test scores in essential tremor. 2010 , 25, 481-5	27
1578	External validation of abbreviated versions of the activities-specific balance confidence scale in Parkinson's disease. 2010 , 25, 485-9	24
1577	Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. 2010 , 25, 489-93	73
1576	Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. 2010 , 25, 232-8	39
1575	Artistic profession: a potential risk factor for dopamine dysregulation syndrome in Parkinson's disease?. 2010 , 25, 493-6	27
1574	B cell depletion therapy for new-onset opsoclonus-myoclonus. 2010 , 25, 238-42	48
1573	Incidental Lewy body disease: clinical comparison to a control cohort. 2010 , 25, 642-6	89
1572	Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. 2010 , 25, 496-9	68
1571	Catatonia during deep brain stimulator implantation complicated by intracranial hemorrhage. 2010 , 25, 1097-8	3
1570	Sleep apnea associated with floppy epiglottis in adult-onset Alexander disease: a case report. 2010 , 25, 1098-100	7
1569	Chorea in adults following pulmonary endarterectomy. 2010 , 25, 1101-4	13
1568	Cerebellar involvement in progressive supranuclear palsy. 2010 , 25, 1104-5	12

1567	Shoulder pain in Parkinson's disease: a case-control study. 2010 , 25, 1105-6	25
1566	Propriospinal myoclonus due to cord compression in the absence of myelopathy. 2010 , 25, 1100-1	9
1565	Is it a tic?--Twenty seconds to make a diagnosis. 2010 , 25, 1106-8	34
1564	Rapid screening of ATP13A2 variant with high-resolution melting analysis. 2010 , 25, 2434-7	7
1563	The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. 2010 , 25, 969-78	131
1562	Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson's disease. 2010 , 25, 1847-52	18
1561	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. 2010 , 25, 2156-63	86
1560	Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience. 2010 , 25, 2438-44	28
1559	Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. 2010 , 25, 1723-32	34
1558	Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study. 2010 , 25, 2355-60	14
1557	Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). 2010 , 25, 2340-5	33
1556	Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. 2010 , 25, 2387-94	32
1555	Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. 2010 , 25, 2550-4	39
1554	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. 2010 , 25, 2444-9	60
1553	Parkinson's disease and pathological gambling: results from a functional MRI study. 2010 , 25, 2449-53	52
1552	Adult cases of congenital muscular torticollis successfully treated with botulinum toxin. 2010 , 25, 2453-6	17
1551	Fatigue in Parkinson's disease: prevalence and associated factors. 2010 , 25, 2456-60	33
1550	Parkinson's disease dementia can be easily detected in routine clinical practice. 2010 , 25, 2769-76	33

1549	Detection of imminent collisions by drivers with Alzheimer's disease and Parkinson's disease: a preliminary study. 2010 , 42, 852-8		21
1548	Analysis of the GIGYF2 gene in familial and sporadic Parkinson disease in the Spanish population. <i>European Journal of Neurology</i> , 2010 , 17, 321-5	6	7
1547	Association of the MAPT locus with Parkinson's disease. <i>European Journal of Neurology</i> , 2010 , 17, 483-6	6	41
1546	The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. <i>European Journal of Neurology</i> , 2010 , 17, 487-92	6	68
1545	Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. <i>European Journal of Neurology</i> , 2010 , 17, 626-30	6	62
1544	Differential diagnosis of dystonia. <i>European Journal of Neurology</i> , 2010 , 17 Suppl 1, 1-8	6	15
1543	Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. <i>European Journal of Neurology</i> , 2010 , 17, 1428-36	6	84
1542	Changes in the serum bone metabolism markers of elderly alcoholics during abstinence. 2010 , 58, 984-6		2
1541	Parkinson's disease in older adults: a new scenario for this old actor?. 2010 , 58, 982-4		3
1540	Anal sphincter EMG in the diagnosis of parkinsonian syndromes. 2010 , 121, 198-203		22
1539	Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. 2010 , 122, 350-9		41
1538	Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. 2010 , 122, 418-24		43
1537	Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset. 2010 , 18, 336-41		38
1536	The progression of pathology in Parkinson's disease. 2010 , 1184, 188-95		169
1535	Neural network algorithm for the early detection of Parkinson's disease from blood plasma by FTIR micro-spectroscopy. 2010 , 53, 181-188		35
1534	Synucleinopathies. 2010 , 203-207		5
1533	Brief practical clinical diagnostic criteria for the neurodegenerative diseases in the elderly. 2010 , 1, 6		1
1532	Microtubule depolymerization potentiates alpha-synuclein oligomerization. 2010 , 1, 5		49

1531	Parkinson's disease: general features, effects of levodopa treatment and future directions. 2010 , 4, 146	8
1530	Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis. 2010 , 5, e11252	65
1529	Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). 2010 , 6, 483-90	13
1528	Mild cognitive impairment is associated with mild parkinsonian signs in a door-to-door study. 2010 , 22, 1005-13	15
1527	Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. 2010 , 23, 27-34	51
1526	Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. 2010 , 75, 448-55	176
1525	Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. 2010 , 75, 1062-9	522
1524	Serum vitamin D and the risk of Parkinson disease. <i>Archives of Neurology</i> , 2010 , 67, 808-11	196
1523	Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. 2010 , 51, 588-95	36
1522	Persistent organochlorine pesticides in serum and risk of Parkinson disease. 2010 , 74, 1055-61	118
1521	CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. 2010 , 81, 1080-6	151
1520	DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity. 2010 , 19, 1425-37	27
1519	DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. 2010 , 107, 9747-52	211
1518	Does cueing training improve physical activity in patients with Parkinson's disease?. 2010 , 24, 469-77	52
1517	Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. 2010 , 42, 823-32	71
1516	A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. 2010 , 24, 587-98	97
1515	Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. 2010 , 10, 1035-50	10
1514	Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. 2010 , 74, 1416-23	115

1513	Manganese and Parkinson's disease: a critical review and new findings. 2010 , 118, 1071-80	243
1512	EEG evidence of posterior cortical disconnection in PD and related dementias. 2010 , 120, 88-98	29
1511	Transgenic mouse models of Parkinson's disease and Huntington's disease. 2010 , 9, 455-70	9
1510	Availability of brain serotonin transporters in patients with restless legs syndrome. 2010 , 74, 513-8	35
1509	Gait in elderly with cerebral small vessel disease. 2010 , 41, 1652-8	92
1508	Study of the prevalence of Parkinson's disease using dopamine transporter imaging. 2010 , 32, 845-51	5
1507	A mining technique using n-grams and motion transcripts for body sensor network data repository. 2010 ,	1
1506	Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici. 2010 , 10, 1-29	
1505	The epidemiology of dementia associated with Parkinson disease. 2010 , 289, 18-22	276
1504	Early diagnosis of Parkinson's disease. 2010 , 90, 81-92	21
1503	Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. 2010 , 477, 57-60	16
1502	Mitochondrial translation initiation factor 3 polymorphism and Parkinson's disease. 2010 , 486, 228-30	17
1501	Arm swing magnitude and asymmetry during gait in the early stages of Parkinson's disease. 2010 , 31, 256-60	127
1500	Horizontal and vertical attentional orienting in Parkinson's disease. 2010 , 74, 179-85	12
1499	SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. 2010 , 411, 375-80	23
1498	Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson's disease among Taiwanese. 2010 , 411, 955-8	22
1497	Falls and gait disorders in geriatric neurology. 2010 , 112, 265-74	84
1496	Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. 2010 , 16, 237-42	108

1495	Genealogical studies in LRRK2-associated Parkinson's disease in central Norway. 2010 , 16, 527-30	13
1494	Isolated delusional syndrome in Parkinson's Disease. 2010 , 16, 550-2	21
1493	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. 2010 , 6, 274-9	23
1492	Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study. 2010 , 49, 772-81	71
1491	Emerging parkinsonian phenotypes. 2010 , 166, 834-40	3
1490	Data Aggregation in Body Sensor Networks: A Power Optimization Technique for Collaborative Signal Processing. 2010 ,	9
1489	The image recognition of brain-stem ultrasound images with using a neural network based on PCA. 2011 ,	5
1488	Development of a highly efficient 2-D system with a serially coupled long column and its application in identification of rat brain integral membrane proteins with ionic liquids-assisted solubilization and digestion. 2011 , 10, 732-8	17
1487	Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease. 2011 , 18, 235-41	31
1486	Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. 2011 , 63, 1056-60	3
1485	Parkinson disease: diagnostic utility of diffusion kurtosis imaging. 2011 , 261, 210-7	178
1484	Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment. 2011 , 8, 109-16	6
1483	Moving forward: advances in the treatment of movement disorders with deep brain stimulation. 2011 , 5, 69	23
1482	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. 2011 , 310, 64-9	57
1481	Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. 2011 , 144, 132-42	162
1480	Evaluation of cerebral vasomotor reactivity in Parkinson's disease: is there any association with orthostatic hypotension?. 2011 , 113, 368-72	11
1479	Dreaming and cognition in patients with frontotemporal dysfunction. 2011 , 20, 1027-35	6
1478	Levodopa effect on electromyographic activation patterns of tibialis anterior muscle during walking in Parkinson's disease. 2011 , 33, 436-41	22

1477	Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson's disease. 2011 , 165, 195-200	51
1476	Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. 2011 , 42, 131-41	51
1475	Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression. 2011 , 59, 280-9	20
1474	βSynuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. 2011 , 32, 622-9	27
1473	γHexachlorocyclohexane levels in serum and risk of Parkinson's disease. 2011 , 32, 640-5	42
1472	Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson's disease. 2011 , 18, 922-5	12
1471	Multi-joint movements with reversal in Parkinson's disease: Kinematics and electromyography. 2011 , 21, 376-83	8
1470	Neuroprotective and nootropic drug noopept rescues βSynuclein amyloid cytotoxicity. 2011 , 414, 699-712	14
1469	Synchronous pattern distinguishes resting tremor associated with essential tremor from rest tremor of Parkinson's disease. 2011 , 17, 30-3	39
1468	Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease. 2011 , 17, 46-9	21
1467	Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease. 2011 , 17, 84-8	28
1466	Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. 2011 , 17, 172-6	119
1465	Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods. 2011 , 17, 464-9	6
1464	Significance of cerebellar Purkinje cell loss to pathogenesis of essential tremor. 2011 , 17, 410-2	12
1463	Association analysis of PARP1 polymorphisms with Parkinson's disease. 2011 , 17, 701-4	5
1462	Functional brain changes in early Parkinson's disease during motor response and motor inhibition. 2011 , 32, 115-24	39
1461	Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. 2011 , 32, 1839-48	63
1460	Heritability of Parkinson disease in Swedish twins: a longitudinal study. 2011 , 32, 1923.e1-8	61

1459	Ataxin-2 repeat-length variation and neurodegeneration. 2011 , 20, 3207-12	128
1458	Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. 2011 , 25, 2898-910	91
1457	Monoamine Transporter Pathologies. 2011 , 169-193	
1456	Parkinson's Disease and Other Movement Disorders. 2011 , 567-646	6
1455	Torpeza en el miembro superior derecho en un varón de mediana edad. 2011 , 10, 4989.e1-4989.e4	
1454	Elevated levels of β -synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. 2011 , 7, 215-22	126
1453	Manganese and Parkinson's disease: a critical review and new findings. 2011 , 16, 4549-66	24
1452	Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large Israeli population. 2011 , 1, 35-47	27
1451	The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. 2011 , 2011, 716859	50
1450	Diagnosis and Differential Diagnosis of Parkinson's Disease. 2011 ,	1
1449	Dementia in Parkinson's Disease: A Clinical Review. 2011 , 2, 35-47	3
1448	Striatal Distribution of Dopamine Transporters and Dopamine D2 Receptors at Different Stages of Parkinson's Disease. A CFT and RAC PET Study. 2011 , 24, 235-41	7
1447	Event-based prospective memory in newly diagnosed, drug-naïve Parkinson's disease patients. 2011 , 17, 1158-62	12
1446	Alternate but do not swim: a test for executive motor dysfunction in Parkinson disease. 2011 , 17, 702-8	3
1445	Verbal memory in drug-naïve, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. 2011 , 25, 114-24	71
1444	Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with ^{123}I -FP-CIT SPECT. 2011 , 28, 881-6	20
1443	Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. 2011 , 37, 791-802	29
1442	Economic burden of Parkinson's disease in Singapore. <i>European Journal of Neurology</i> , 2011 , 18, 519-26	6 18

1441	Death-associated protein kinase 1 variation and Parkinson's disease. <i>European Journal of Neurology</i> , 2011 , 18, 1090-3	6	4
1440	SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. <i>European Journal of Neurology</i> , 2011 , 18, 876-81	6	31
1439	A genome-wide linkage screen in the Amish with Parkinson disease points to chromosome 6. 2011 , 75, 351-8		7
1438	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. 2011 , 10, 898-908		237
1437	A new measure of movement symmetry in early Parkinson's disease patients using symbolic processing of inertial sensor data. 2011 , 58, 2127-35		59
1436	Feature selection for accelerometer-based posture analysis in Parkinson's disease. 2011 , 15, 481-90		79
1435	The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy. 2011 , 11, 157		35
1434	Genetic variations of Omi/HTRA2 in Chinese patients with Parkinson's disease. 2011 , 1385, 293-7		17
1433	Preservation of function in Parkinson's disease: what's learning got to do with it?. 2011 , 1423, 96-113		22
1432	VPS35 mutations in Parkinson disease. 2011 , 89, 162-7		618
1431	Translation initiator EIF4G1 mutations in familial Parkinson disease. 2011 , 89, 398-406		213
1430	Epidemiology and etiology of Parkinson's disease: a review of the evidence. 2011 , 26 Suppl 1, S1-58		707
1429	Postmortem interval effect on RNA and gene expression in human brain tissue. 2011 , 12, 311-8		94
1428	Cognitive differences between patients with left-sided and right-sided Parkinson's disease. A review. 2011 , 21, 405-24		67
1427	Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. 2011 , 130, 817-27		48
1426	Neuropathology underlying clinical variability in patients with synucleinopathies. 2011 , 122, 187-204		292
1425	Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson's disease. 2011 , 258, 50-5		42
1424	Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. 2011 , 258, 627-33		92

1423	Management of punding in Parkinson's disease: an open-label prospective study. 2011 , 258, 656-60	43
1422	Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms. 2011 , 258, 740-5	52
1421	Physical inactivity in Parkinson's disease. 2011 , 258, 2214-21	194
1420	Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases. 2011 , 118, 809-19	23
1419	Striatal β -amyloid in dementia with Lewy bodies but not Parkinson's disease. 2011 , 118, 713-9	68
1418	Dream features in the early stages of Parkinson's disease. 2011 , 118, 1613-9	27
1417	[Static posturography in selected Parkinson syndromes: quantitative analysis of postural control]. 2011 , 82, 1584-9	1
1416	Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. 2011 , 38, 2209-18	26
1415	Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson's disease suffering from motor response fluctuations. 2011 , 208, 169-79	85
1414	Postural instability and fall risk in Parkinson's disease: impaired dual tasking, pacing, and bilateral coordination of gait during the "ON" medication state. 2011 , 210, 529-38	98
1413	Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration. 2011 , 44, 13-27	23
1412	Causes and consequences of cerebral small vessel disease. The RUN DMC study: a prospective cohort study. Study rationale and protocol. 2011 , 11, 29	117
1411	Characterization of kinases involved in the phosphorylation of aggregated β -synuclein. 2011 , 89, 231-47	54
1410	Clinical correlates of similar pathologies in parkinsonian syndromes. 2011 , 26, 499-506	15
1409	Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. 2011 , 26, 65-72	69
1408	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. 2011 , 26, 297-301	43
1407	The most cited works in Parkinson's disease. 2011 , 26, 380-90	43
1406	Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. 2011 , 26, 449-56	61

1405	Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. 2011 , 26, 527-33	63
1404	Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. 2011 , 26, 889-92	115
1403	Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. 2011 , 26, 1875-80	31
1402	FMR1 gray-zone alleles: association with Parkinson's disease in women?. 2011 , 26, 1900-6	37
1401	Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. 2011 , 26, 2026-31	44
1400	Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. 2011 , 26, 2051-7	57
1399	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. 2011 , 26, 1814-24	527
1398	Genetic variants of Synuclein are not associated with essential tremor. 2011 , 26, 2552-6	12
1397	Temporal stability of the Unified Dyskinesia Rating Scale. 2011 , 26, 2556-9	15
1396	Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test. 2011 , 26, 2559-63	22
1395	Reproductive factors and Parkinson's disease: a multicenter case-control study. 2011 , 26, 2563-6	26
1394	Camptocormia in Japanese patients with Parkinson's disease: a multicenter study. 2011 , 26, 2567-71	35
1393	ATP13A2 variability in Taiwanese Parkinson's disease. 2011 , 156B, 720-9	17
1392	Autonomic and cognitive functions in Parkinson's disease (PD). 2011 , 52, 84-8	15
1391	Diffusion tensor imaging and gait in elderly persons with cerebral small vessel disease. 2011 , 42, 373-9	42
1390	Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. 2011 , 42, 3382-6	94
1389	Lower vascular tone and larger plasma volume in Parkinson's disease with orthostatic hypotension. 2011 , 111, 443-8	9
1388	Imbalanced estrogen metabolism in the brain: possible relevance to the etiology of Parkinson's disease. 2011 , 16, 434-44	10

1387	MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. 2011 , 77, 1042-7	57
1386	Eine vergleichende biomechanische Ganganalyse zwischen dem Idiopathischen Parkinson-Syndrom und dem Normaldruckhydrozephalus. 2011 , 38, 292-297	
1385	Brief cognitive assessment in the early stages of Parkinson disease. 2011 , 24, 169-73	20
1384	Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. 2011 , 134, 2116-24	109
1383	Ideational apraxia in Parkinson disease. 2011 , 24, 122-7	5
1382	Loss of white matter integrity is associated with gait disorders in cerebral small vessel disease. 2011 , 134, 73-83	188
1381	Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. 2011 , 168, 1066-74	192
1380	Rotenone, paraquat, and Parkinson's disease. 2011 , 119, 866-72	804
1379	Effects of virtual reality-augmented balance training on sensory organization and attentional demand for postural control in people with Parkinson disease: a randomized controlled trial. 2011 , 91, 862-74	125
1378	Reduced uptake of [¹⁸ F]FDOPA PET in asymptomatic welders with occupational manganese exposure. 2011 , 76, 1296-301	70
1377	Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. 2011 , 2011, 232473	100
1376	Clock drawing in the Montreal Cognitive Assessment: recommendations for dementia assessment. 2011 , 31, 179-87	49
1375	Risk of falling in Parkinson's disease at the Hoehn-Yahr stage III. 2011 , 66, 298-304	18
1374	Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. <i>Archives of Neurology</i> , 2011 , 68, 925-31	33
1373	Parkinsonism. 2011 , 66-92	4
1372	Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. 2011 , 32, 677-81	100
1371	Delayed Parkinson's disease diagnosis among African-Americans: the role of reporting of disability. 2011 , 36, 150-4	21
1370	Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. 2011 , 134, 50-8	96

1369	E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. 2011 , 286, 35104-18	93
1368	Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. 2011 , 52, 1210-7	267
1367	Diagnostic challenges in parkinsonism. 2011 , 11, 1099-101	2
1366	The Little Black Book of Neuropsychology. 2011 ,	49
1365	The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders. 2011 , 2011, 439397	6
1364	Depressive Symptoms and Amygdala Volume in Elderly with Cerebral Small Vessel Disease: The RUN DMC Study. 2011 , 2011, 647869	8
1363	Altered activation patterns within the olfactory network in Parkinson's disease. 2011 , 21, 1246-53	35
1362	Increased risk of leg motor restlessness but not RLS in early Parkinson disease. 2011 , 77, 1941-6	85
1361	Pragmatic communication is impaired in Parkinson disease. 2011 , 121, 254-6	30
1360	Quantitative analysis of language production in Parkinson's disease using a cued sentence generation task. 2012 , 26, 863-81	14
1359	DJ-1 promotes the proteasomal degradation of Fis1: implications of DJ-1 in neuronal protection. 2012 , 447, 261-9	31
1358	Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. 2012 , 2012, 259349	48
1357	Culture and characterization of rat mesencephalic dopaminergic neurons. 2012 , 846, 91-101	3
1356	Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale. 2012 , 2, 215-23	14
1355	Neuro-ophthalmology of movement disorders. 2012 , 23, 491-6	16
1354	Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET. 2012 , 265, 240-7	27
1353	Diffusion kurtosis and diffusion-tensor MR imaging in Parkinson disease. 2012 , 265, 645-6; author reply 646-7	22
1352	WOMAC-pf as a measure of physical function in patients with Parkinson's disease and late-onset sequels of poliomyelitis: unidimensionality and item behaviour. 2012 , 34, 1423-30	4

1351	External cueing improves motor imagery quality in patients with Parkinson disease. 2012 , 26, 27-35	48
1350	Evaluation of Neurofeedback Training in the Treatment of Parkinson's Disease: A Pilot Study. 2012 , 16, 4-11	5
1349	Hypertension is related to the microstructure of the corpus callosum: the RUN DMC study. 2012 , 32, 623-31	26
1348	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. 2012 , 83, 76-82	64
1347	Coherence analysis for movement disorder motion captured by six degree-of-freedom inertial sensing. 2012 , 6,	
1346	[123I]FP-CIT SPECT in atypical degenerative parkinsonism. 2012 , 4, 411-421	2
1345	Clinico-pathological correlations of the most common neurodegenerative dementias. 2012 , 3, 68	23
1344	Using mobile phones for activity recognition in Parkinson's patients. 2012 , 3, 158	65
1343	Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinson's disease. 2012 , 2012, 235765	49
1342	WITHDRAWN: Mechanisms Underlying Inhibitory and Facilitatory Transcranial Magnetic Stimulation Abnormalities in a Large Sample of Patients with Parkinson's Disease. 2012 ,	
1341	Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers. 2012 , 38, 186-93	45
1340	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. 2012 , 34, 669-76	47
1339	Subthalamic nucleus stimulation reverses spinal motoneuron activity in parkinsonian patients. 2012 , 135, 139-47	15
1338	Cardiovascular responses during a submaximal exercise test in patients with Parkinson's disease. 2012 , 2, 241-7	19
1337	Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. 2012 , 30, 295-301	15
1336	Lowered serum amyloid- β 1-42 autoantibodies in individuals with lifetime depression. 2012 , 32, 95-100	7
1335	Altered pharyngeal muscles in Parkinson disease. 2012 , 71, 520-30	92
1334	Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. 2012 , 18, 380-7	80

1333	Reliability and diagnostic characteristics of clinical tests of upper limb motor function. 2012 , 19, 1246-51	9
1332	Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. 2012 , 18 Suppl 1, S90-2	51
1331	Gait patterns in Parkinsonian patients with or without mild cognitive impairment. 2012 , 27, 1536-43	52
1330	Genetic modification of the association of paraquat and Parkinson's disease. 2012 , 27, 1652-8	63
1329	Transcranial sonography on Parkinson's disease and essential tremor in a Chinese population. 2012 , 33, 1005-9	16
1328	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. 2012 , 33, 1319-27	21
1327	Mutations du g [^] Ēe EIF4G 1 (Eukaryotic translation initiation factor 4-gamma) et maladie de Parkinson. 2012 , 168, S9-S10	
1326	Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. 2012 , 20, 142-8	47
1325	Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease. 2012 , 33, 226-33	14
1324	Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. 2012 , 33, 206.e29-39	62
1323	Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. 2012 , 33, 2113-24	51
1322	Diffusion tensor imaging and mild parkinsonian signs in cerebral small vessel disease. 2012 , 33, 2106-12	11
1321	What predicts cognitive decline in de novo Parkinson's disease?. 2012 , 33, 1127.e11-20	28
1320	Asymmetry in parkinsonism, spreading pathogens and the nose. 2012 , 18, 1-9	13
1319	Doctor, is it Parkinson's disease?. 2012 , 18, 113-4	1
1318	Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3. 2012 , 18, 185-90	16
1317	Heart rate variability in patients with idiopathic Parkinson's disease with and without obstructive sleep apnea syndrome. 2012 , 18, 525-31	19
1316	Cortical involvement in a gait-related imagery task: comparison between Parkinson's disease and normal aging. 2012 , 18, 537-42	42

1315	Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease. 2012 , 18, 567-71	27
1314	The relationship between cerebral vascular disease and parkinsonism: The VADO study. 2012 , 18, 775-80	49
1313	The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients. 2012 , 18, 788-93	27
1312	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. 2012 , 18, 871-5	20
1311	Comparison of patient rated treatment response with measured improvement in Parkinson's disease. 2012 , 83, 1001-5	17
1310	Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. <i>Archives of Neurology</i> , 2012 , 69, 394-7	21
1309	Spinal cord lesions in sporadic Parkinson's disease. 2012 , 124, 643-64	113
1308	Cerebral white matter lesions and lacunar infarcts contribute to the presence of mild parkinsonian signs. 2012 , 43, 2574-9	39
1307	A training program to improve gait while dual tasking in patients with Parkinson's disease: a pilot study. 2012 , 93, 176-81	94
1306	Studies of protein aggregation in A53T β -synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. 2012 , 507, 137-42	5
1305	Lower serum UA levels in Parkinson's disease patients in the Chinese population. 2012 , 514, 152-5	11
1304	Painful abdominal contractions in patients with Parkinson disease. 2012 , 19, 624-7	7
1303	Diffusion tensor imaging and cognition in cerebral small vessel disease: the RUN DMC study. 2012 , 1822, 401-7	62
1302	Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy. 2012 , 226, 519-28	23
1301	The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis. 2012 , 231, 60-74	149
1300	Occupational exposure to pesticides and Parkinson's disease: a systematic review and meta-analysis of cohort studies. 2012 , 46, 30-43	116
1299	Both coordination and symmetry of arm swing are reduced in Parkinson's disease. 2012 , 35, 373-7	68
1298	Effects of explicit prioritization on dual task walking in patients with Parkinson's disease. 2012 , 35, 641-6	51

1297	Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. 2012 , 259, 1727-31	99
1296	Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease. 2012 , 12, 54	54
1295	Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. 2012 , 39, 1767-77	72
1294	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. <i>Archives of Neurology</i> , 2012 , 69, 1445-52	327
1293	Cortical thickness is associated with gait disturbances in cerebral small vessel disease. 2012 , 59, 1478-84	62
1292	Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. 2012 , 314, 41-7	40
1291	Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. 2012 , 323, 33-9	88
1290	Downregulation of Pael-R expression in a Parkinson's disease cell model reduces apoptosis. 2012 , 19, 1433-6	3
1289	Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. 2012 , 12, 640-3	20
1288	Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. 2012 , 119, 2161-7	93
1287	Tai chi and postural stability in patients with Parkinson's disease. 2012 , 366, 511-9	530
1286	Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up. 2012 , 26, 144-50	65
1285	Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. 2012 , 39, 1937-48	39
1284	Essential tremor is not a neurodegenerative disease. 2012 , 2, 259-268	39
1283	Induced Pluripotent Stem Cells in Brain Diseases. 2012 ,	
1282	Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. 2012 , 7, 13	57
1281	Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. 2012 , 7, e32383	74
1280	Role of basal ganglia circuits in resisting interference by distracters: a swLORETA study. 2012 , 7, e34239	15

1279	Evaluation of the role of SNCA variants in survival without neurological disease. 2012 , 7, e42877	7
1278	Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. 2012 , 7, e47387	131
1277	Alpha-synuclein levels in blood plasma from LRRK2 mutation carriers. 2012 , 7, e52312	30
1276	SIRT2 as a Therapeutic Target for Age-Related Disorders. 2012 , 3, 82	90
1275	High prevalence of mild cognitive impairment and Alzheimer's disease in arabic villages in northern Israel: impact of gender and education. 2012 , 29, 431-9	40
1274	Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. 2012 , 2012, 391438	25
1273	Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. 2012 , 2012, 910454	9
1272	Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study. 2012 , 2012, 214714	37
1271	Psychosis assessment in early-stage Parkinson's disease: comparing Parkinson's psychosis questionnaire with the brief psychiatric rating scale in a portuguese sample. 2012 , 2012, 469126	2
1270	Increasing the Detection Limit of the Parkinson Disorder through a Specific Surface Chemistry Applied onto Inner Surface of the Titration Well. 2012 , 3, 298-312	1
1269	Parkinsonism. 83-102	
1268	Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. 2012 , 31, 439-45	55
1267	Idiopathic Parkinson's Disease, Vascular Risk Factors and Cognition: A Critical Review. 2012 ,	1
1266	Prospects for Cell Replacement Therapies for Neurodegenerative Diseases. 2012 , 43-54	
1265	Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. 2012 , 90, 2306-16	34
1264	Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. 2012 , 27, 617-26	339
1263	Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. 2012 , 27, 750-3	23
1262	Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. 2012 , 27, 858-63	85

1261	Bladder dysfunction in advanced Parkinson's disease. 2012 , 31, 1279-83	46
1260	Optogenetic investigation of neural circuits underlying brain disease in animal models. 2012 , 13, 251-66	540
1259	Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. 2012 , 12, 687-96	87
1258	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. 2012 , 124, 23-35	138
1257	Solvent exposures and Parkinson disease risk in twins. 2012 , 71, 776-84	97
1256	Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?. 2012 , 21, 710-7	73
1255	[A biomechanical analysis of cyclical hand motor function: a pilot study in different Parkinsonian syndromes]. 2012 , 83, 766-71	
1254	PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway. 2012 , 47, 582-94	20
1253	Contribution of routine brain MRI to the differential diagnosis of parkinsonism: a 3-year prospective follow-up study. 2012 , 259, 929-35	22
1252	Energy cost of spontaneous walking in Parkinson's disease patients. 2012 , 33, 779-84	15
1251	Regional cortical thickness and cognitive functions in non-demented Parkinson's disease patients: a pilot study. <i>European Journal of Neurology</i> , 2012 , 19, 172-5	6 24
1250	Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. 2012 , 12, 102-7	67
1249	Parkinson's disease (PD) in the elderly: an example of geriatric syndrome (GS)?. 2012 , 54, 242-6	21
1248	[(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. 2012 , 126, 12-6	36
1247	Vasomotor reactivity as a predictor for syncope in patients with orthostatism. 2012 , 126, 32-6	6
1246	Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model. 2012 , 45, 645-55	13
1245	Reproducibility of brain dopamine transporter binding with Tc-99m TRODAT-1 SPECT in healthy young men. 2012 , 201, 222-5	5
1244	A Mining Technique Using $\$N\$$ n-Grams and Motion Transcripts for Body Sensor Network Data Repository. 2012 , 100, 107-121	4

1243	Fatigue in early Parkinson's disease. Minor inconvenience or major distress?. <i>European Journal of Neurology</i> , 2012 , 19, 963-8	6	48
1242	Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. <i>European Journal of Neurology</i> , 2012 , 19, 1213-8	6	33
1241	ATXN8 -62 G/A promoter polymorphism and risk of Taiwanese Parkinson's disease. <i>European Journal of Neurology</i> , 2012 , 19, 1462-9	6	3
1240	Subjective sleep problems in patients with early Parkinson's disease. <i>European Journal of Neurology</i> , 2012 , 19, 1575-81	6	12
1239	Diffusion tensor imaging of the hippocampus and verbal memory performance: the RUN DMC study. 2012 , 33, 542-51		36
1238	Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. 2012 , 27, 8-30		285
1237	25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. 2012 , 27, 264-71		54
1236	Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. 2012 , 27, 559-61		69
1235	Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. 2012 , 27, 421-7		55
1234	Head injury, Synuclein Rep1, and Parkinson's disease. 2012 , 71, 40-8		66
1233	Predictive value of dopamine transporter SPECT imaging with [¹²³ I]PE2I in patients with subtle parkinsonian symptoms. 2012 , 39, 242-50		22
1232	Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders. 2012 , 262, 131-8		13
1231	Psychiatric symptoms screening in the early stages of Parkinson's disease. 2012 , 259, 124-31		21
1230	Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. 2012 , 259, 251-60		26
1229	Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern?. <i>European Journal of Neurology</i> , 2013 , 20, 198-201	6	76
1228	Frequencies of falls and associated features at different stages of Parkinson's disease. <i>European Journal of Neurology</i> , 2013 , 20, 160-6	6	29
1227	Impact of sub-thalamic nucleus deep brain stimulation on dual tasking gait in Parkinson's disease. 2013 , 10, 38		9
1226	TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. 2013 , 8, 19		255

1225	The contribution of postural control and bilateral coordination to the impact of dual tasking on gait. 2013 , 226, 81-93	54
1224	Parkinson's disease and pesticide exposure--a new assessment. 2013 , 43, 515-34	57
1223	REM sleep behavior disorder and motor dysfunction in Parkinson's disease--a longitudinal study. 2013 , 19, 1084-7	48
1222	A systematic review of biomarkers for disease progression in Parkinson's disease. 2013 , 13, 35	27
1221	Novel mechanisms underlying inhibitory and facilitatory transcranial magnetic stimulation abnormalities in Parkinson's disease. 2013 , 44, 221-8	24
1220	Pisa syndrome in Parkinson's disease: an electrophysiological and imaging study. 2013 , 260, 2138-48	52
1219	Bone mineral density and vitamin D status in Parkinson's disease patients. 2013 , 260, 754-60	53
1218	Parkinson disease loci in the mid-western Amish. 2013 , 132, 1213-21	11
1217	Neuropsychological features of patients with Parkinson's disease and impulse control disorders. 2013 , 34, 1207-13	48
1216	The role of small intestinal bacterial overgrowth in Parkinson's disease. 2013 , 28, 1241-9	194
1215	Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. 2013 , 34, 1751-8	10
1214	Evaluation of the cerebrospinal fluid amyloid- β 1-42/amyloid- β 1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. 2013 , 36, 99-110	37
1213	A prognostic view on the application of individualized genomics in Parkinson's disease. 2013 , 1, 52-57	11
1212	Feasibility of adapting a classroom balance training program to a video game platform for people with Parkinson's disease. 2013 , 19, 298-304	7
1211	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. 2013 , 120, 613-8	60
1210	Relationship Between Serum Level of Selenium and Metabolites Using 1HNMR-Based Metabonomics in Parkinson's Disease. 2013 , 44, 721-734	5
1209	Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". 2013 , 34, 2015-22	21
1208	Influence of physiotherapy on severity of motor symptoms and quality of life in patients with Parkinson disease. 2013 , 47, 256-62	23

1207	The development of CNS-active LRRK2 inhibitors using property-directed optimisation. 2013 , 23, 3690-6	21
1206	Increased incidence of Parkinsonism among Chinese with β -glucosidase mutation in central Taiwan. 2013 , 3, 92-94	25
1205	Effectiveness of an intensive rehabilitation treatment on different Parkinson's disease subtypes. 2013 , 33, 299-303	10
1204	Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. 2013 , 19, 1027-32	139
1203	Daytime sleepiness is associated with falls in Parkinson's disease. 2013 , 3, 387-91	9
1202	The glial marker YKL-40 is decreased in synucleinopathies. 2013 , 28, 1882-5	35
1201	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. 2013 , 521, 4339-55	41
1200	U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. 2013 , 110, 16562-7	200
1199	Epidemiology and Clinical Diagnosis of Parkinson Disease. 2013 , 8, 447-58	5
1198	Dopamine Transporter SPECT Imaging in Parkinson Disease and Dementia. 2013 , 8, 459-67	3
1197	The effect of forced-exercise therapy for Parkinson's disease on motor cortex functional connectivity. 2013 , 3, 190-8	46
1196	Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 2013 , 19, 1130-5	14
1195	Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms. 2013 , 19, 1004-8	47
1194	Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. 2013 , 128, 73-82	46
1193	Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control. 2013 , 34, 935-40	35
1192	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. 2013 , 14, 161-6	30
1191	The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study. 2013 , 18, 60	10
1190	Sleepwalking, REM sleep behaviour disorder and overlap parasomnia in patients with Parkinson's disease. 2013 , 70, 297-303	38

1189	Gait initiation impairments in both Essential Tremor and Parkinson's disease. 2013 , 38, 956-61		23
1188	The relationship between balance control and vitamin D in Parkinson's disease-a pilot study. 2013 , 28, 1133-7		36
1187	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. 2013 , 81, 1681-9		46
1186	Age-related appearance of dendritic inclusions in catecholaminergic brainstem neurons. 2013 , 34, 286-97		15
1185	Verbal learning in Alzheimer's disease and mild cognitive impairment: fine-grained acquisition and short-delay consolidation performance and neural correlates. 2013 , 34, 361-73		15
1184	The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. 2013 , 70, 121-36		124
1183	Asymmetry and freezing of gait in parkinsonian patients. 2013 , 260, 71-6		43
1182	Vibrotactile neurofeedback balance training in patients with Parkinson's disease: reducing the number of falls. 2013 , 37, 195-200		101
1181	Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases. 2013 , 15, 169-79		10
1180	Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. 2013 , 127, 290-4		25
1179	Phenotypic variability in three families with valosin-containing protein mutation. <i>European Journal of Neurology</i> , 2013 , 20, 251-8	6	49
1178	Estimating the lifetime economic burden of Parkinson's disease in Singapore. <i>European Journal of Neurology</i> , 2013 , 20, 368-74	6	10
1177	Levodopa increases speed of alternating movements in Parkinson's disease patients. 2013 , 120, 309-13		2
1176	Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. 2013 , 34, 1712.e9-13		36
1175	Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. 2013 , 19, 329-34		42
1174	Using experts feedback in clinical case resolution and arbitration as accuracy diagnosis methodology. 2013 , 43, 975-86		9
1173	Predictors of road crossing safety in pedestrians with Parkinson's disease. 2013 , 51, 202-7		9
1172	STX6 rs1411478 is not associated with increased risk of Parkinson's disease. 2013 , 19, 563-5		14

1171	An evidence-based osteopathic approach to Parkinson disease. 2013 , 5, 96-101	26
1170	Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort. 2013 , 19, 251-5	35
1169	Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease. 2013 , 550, 64-8	71
1168	Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson's disease. 2013 , 19, 247-50	19
1167	Rest energy expenditure in Parkinson's disease: role of disease progression and dopaminergic therapy. 2013 , 19, 238-41	30
1166	Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. 2013 , 33, 183-9	166
1165	Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. 2013 , 80, 627-33	63
1164	LRRK2 interactions with α -Synuclein in Parkinson's disease brains and in cell models. 2013 , 91, 513-22	58
1163	Different diagnostic criteria for Parkinson disease: what are the pitfalls?. 2013 , 120, 619-25	16
1162	TARDBP mutations in Parkinson's disease. 2013 , 19, 312-5	31
1161	Parkinson's disease in the nuclear age of neuroinflammation. 2013 , 19, 187-96	88
1160	Cerebrospinal fluid A β levels correlate with structural brain changes in Parkinson's disease. 2013 , 28, 302-10	23
1159	Gait dysfunction in Parkinson's disease and normal pressure hydrocephalus: a comparative study. 2013 , 120, 1201-7	26
1158	Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. 2013 , 70, 580-6	222
1157	Progressive Neurologic Disease and Dysphagia (Including Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Post-Polio Syndrome). 2013 , 395-409	1
1156	Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. 2013 , 8, 43-56	130
1155	Handbook of Parkinson's Disease. 2013 ,	11
1154	Cerebral white matter hyperintensity in Parkinson's disease: a major risk factor for mild cognitive impairment. 2013 , 19, 680-3	56

1153	Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease. 2013 , 7, 225-40	21
1152	Epidemiological, clinical, and molecular study of a cohort of Italian Parkinson disease patients: association with glutathione-S-transferase and DNA repair gene polymorphisms. 2013 , 33, 673-80	14
1151	Treatment in early Parkinson's disease: the Norwegian ParkWest study. 2013 , 128, 107-13	4
1150	An approach for solving multi-level diagnosis in high sensitivity medical diagnosis systems through the application of semantic technologies. 2013 , 43, 51-62	15
1149	In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. 2013 , 19, 47-52	145
1148	Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial. 2013 , 346, f576	90
1147	Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson's disease. 2013 , 28, 154-64	46
1146	Physical activity is related to the structural integrity of cerebral white matter. 2013 , 81, 971-6	62
1145	Differential diagnosis of normal pressure hydrocephalus by MRI mean diffusivity histogram analysis. 2013 , 34, 1168-74	26
1144	How Parkinsonian toxins dysregulate the autophagy machinery. 2013 , 14, 22163-89	52
1143	The experiences of Taiwanese older individuals at different stages of Parkinson disease. 2013 , 45, 370-7	10
1142	Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. 2013 , 84, 774-83	148
1141	Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial. 2013 , 11, 285-90	14
1140	Evolution of mild cognitive impairment in Parkinson disease. 2013 , 81, 346-52	137
1139	Semi-automatic Ultrasound Medical Image Recognition for Diseases Classification in Neurology. 2013 , 125-133	3
1138	Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study. 2013 , 19, 695-708	59
1137	Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. 2013 , 84, 23-8	62
1136	Effect of dopaminergic medication on postural sway in advanced Parkinson's disease. 2013 , 4, 202	11

1135	Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. 2013 , 8, 19-28	10
1134	JNP special issue on Parkinson's disease and cognition. 2013 , 7, 149-52	
1133	Keep moving to retain the healthy self: the meaning of physical exercise in individuals with Parkinson's disease. 2013 , 35, 2237-44	23
1132	Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study. <i>European Journal of Neurology</i> , 2013 , 20, 1398-404	6 48
1131	Daytime course of sleepiness in de novo Parkinson's disease patients. 2013 , 22, 197-200	9
1130	Diagnostic shifts in ALS? From clinical specter to imaging spectra. 2013 , 80, 606-7	1
1129	Molecular biomarkers of neurodegeneration. 2013 , 13, 845-61	23
1128	Cerebrospinal fluid amyloid- β and phenotypic heterogeneity in de novo Parkinson's disease. 2013 , 84, 537-43	48
1127	Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. 2013 , 36, 1885-92	71
1126	REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics. 2013 , 36, 1147-52	155
1125	Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease. 2013 , 5, 55	19
1124	Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. 2013 , 72, 119-29	83
1123	Submandibular gland biopsy for the diagnosis of Parkinson disease. 2013 , 72, 130-6	89
1122	Parkinson disease affects peripheral sensory nerves in the pharynx. 2013 , 72, 614-23	88
1121	A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality. 2013 , 109, 329-37	50
1120	Corneal sensitivity, blink rate, and corneal nerve density in progressive supranuclear palsy and Parkinson disease. 2013 , 32, 631-5	48
1119	PET imaging of serotonin transporters with 4-[¹⁸ F]-ADAM in a Parkinsonian rat model. 2013 , 22, 1295-305	16
1118	Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. 2013 , 12, 189-98	39

1117	Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. 2013 , 9, 1821-6	8
1116	Predictors of cognitive decline in the early stages of Parkinson's disease: a brief cognitive assessment longitudinal study. 2013 , 2013, 912037	7
1115	The role of innate and adaptive immunity in Parkinson's disease. 2013 , 3, 493-514	181
1114	Low CSF levels of both β synuclein and the β synuclein cleaving enzyme neurosin in patients with synucleinopathy. 2013 , 8, e53250	102
1113	The Efficacy of Exercise Programs for Parkinson's Disease: Tai Chi versus Combined Exercise. 2013 , 9, 237-43	37
1112	Short- and long-term efficacy of intensive rehabilitation treatment on balance and gait in parkinsonian patients: a preliminary study with a 1-year followup. 2013 , 2013, 583278	23
1111	An update on the management of young-onset Parkinson's disease. 2013 , 2, 53-62	1
1110	What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?. 2014 , 23, 352-64	15
1109	Parkinson's Disease; Epidemiology. 2014 , 833-839	1
1108	Humor as a reward mechanism: event-related potentials in the healthy and diseased brain. 2014 , 9, e85978	17
1107	Orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. 2014 , 2014, 475854	20
1106	Thioredoxin system regulation in the central nervous system: experimental models and clinical evidence. 2014 , 2014, 590808	47
1105	FBXO7 Y52C polymorphism as a potential protective factor in Parkinson's disease. 2014 , 9, e101392	8
1104	Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls. 2014 , 6, 169	6
1103	Alpha and beta EEG power reflects L-dopa acute administration in parkinsonian patients. 2014 , 6, 302	40
1102	Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson's disease using anatomic likelihood estimation. 2014 , 8, 63	27
1101	Subthalamic nucleus stimulation does not influence basal glucose metabolism or insulin sensitivity in patients with Parkinson's disease. 2014 , 8, 95	4
1100	Rehabilitation Procedures Aimed at Decreasing Motor Symptoms in Parkinson's Disease. 2014 , s5,	1

1099	Correlation of sleep disturbance and cognitive impairment in patients with Parkinson's disease. <i>Journal of Movement Disorders</i> , 2014 , 7, 13-8	2.9	9
1098	Proposed Motor Scoring System in a Porcine Model of Parkinson's Disease induced by Chronic Subcutaneous Injection of MPTP. 2014 , 23, 258-65		8
1097	Frequency of the LRRK2 G2019S mutation in late-onset sporadic patients with Parkinson's disease. 2014 , 72, 356-9		7
1096	<i>Helicobacter pylori</i> and neurological diseases: Married by the laws of inflammation. 2014 , 5, 400-4		51
1095	Clinical Correlates of RBD in Early Parkinson Disease. 2014 , 04,		
1094	Possible Relation Between Trace Element Status and Clinical Outcomes in Parkinson Syndrome. 2014 ,		
1093	Performance of a motor task learned on levodopa deteriorates when subsequently practiced off. 2014 , 29, 54-60		15
1092	Cerebrospinal fluid β -synuclein in the differential diagnosis of parkinsonian syndromes. 2014 , 9, 525-532		7
1091	Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and Atypical Parkinsonian syndromes using DaTSCAN' \square SPECT. 2014 , 28, 851-9		22
1090	Identification of a set of endogenous reference genes for miRNA expression studies in Parkinson's disease blood samples. 2014 , 7, 715		30
1089	Alpha-synuclein biology in Lewy body diseases. 2014 , 6, 73		203
1088	Effects of mechanical stimulation of the feet on gait and cardiovascular autonomic control in Parkinson's disease. 2014 , 116, 495-503		23
1087	Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease. 2014 , 35, 789-94		36
1086	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. 2014 , 4, e003976		31
1085	Three-dimensional brain magnetic resonance imaging segmentation via knowledge-driven decision theory. 2014 , 1, 034001		1
1084	Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis. 2014 , 35, 2257-64		51
1083	Parkinson's Disease and the Claustrum. 2014 , 277-297		1
1082	Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. 2014 , 83, 1396-402		91

1081	Global investigation and meta-analysis of the C9orf72 (G4C2) _n repeat in Parkinson disease. 2014 , 83, 1906-13		49
1080	Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. 2014 , 29, 750-5		18
1079	Effect of aging on magnetic resonance measures differentiating progressive supranuclear palsy from Parkinson's disease. 2014 , 29, 488-95		25
1078	M. paratuberculosis and Parkinson's disease--is this a trigger. 2014 , 83, 709-12		19
1077	Magnetic resonance support vector machine discriminates between Parkinson disease and progressive supranuclear palsy. 2014 , 29, 266-9		45
1076	Motor impairment, depression, dementia: which forms the impression of disease severity in Parkinson's disease?. 2014 , 20, 1365-70		5
1075	From micrographia to Parkinson's disease dysgraphia. 2014 , 29, 1467-75		59
1074	The role of SNCA and MAPT in Parkinson disease and LRRK2 parkinsonism in the Tunisian Arab-Berber population. <i>European Journal of Neurology</i> , 2014 , 21, e91-2	6	6
1073	Suprathreshold odor intensity perception in early-stage Parkinson's disease. 2014 , 29, 1208-12		11
1072	Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. 2014 , 71, 758-66		77
1071	Cognitive deficits in mild Parkinson's disease are associated with distinct areas of grey matter atrophy. 2014 , 85, 576-80		47
1070	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. 2014 , 83, 826-33		59
1069	Retina measurements for diagnosis of Parkinson disease. 2014 , 34, 971-80		29
1068	Disexecutive functions and depression in patients with Parkinson disease: the impact on rehabilitation outcome. 2014 , 93, 764-73		4
1067	Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. 2014 , 37, 91-5		13
1066	Altered activation in visual cortex: unusual functional magnetic resonance imaging finding in early Parkinson's disease. 2014 , 42, 503-15		3
1065	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. 2014 , 29, 1809-15		62
1064	Cognitive Behavior Therapy Ameliorates Non-Motor Symptoms in Parkinson's Disease. 2014 , 912-914, 1995-2005		

1063	Excessive Sensitivity to Uncertain Visual Input in L-DOPA-Induced Dyskinesias in Parkinson's Disease: Further Implications for Cerebellar Involvement. 2014 , 5, 8	6
1062	Role of Trichloroethylene in Parkinson's Disease. 2014 , 91-129	
1061	Lessons for ICD-11 coming after DSM-5. 2014 , 48, 90-1	9
1060	Correlative (99m)tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease. 2014 , 13, 178-83	9
1059	PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. 2014 , 14, 79	34
1058	Subthreshold depression and subjective cognitive complaints in Parkinson's disease. <i>European Journal of Neurology</i> , 2014 , 21, 541-4	6 29
1057	The difference in putamen volume between MSA and PD: evidence from a meta-analysis. 2014 , 20, 873-7	25
1056	Diagnostic accuracy of parkinsonism syndromes by general neurologists. 2014 , 20, 840-4	98
1055	Cerebellar dentate nucleus in progressive supranuclear palsy. 2014 , 118, 32-6	6
1054	La définition de la maladie de Parkinson est-elle clinique ? 2014 , 5, 152-158	
1053	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. 2014 , 121, 71-8	3
1052	HTRA2 variations in Taiwanese Parkinson's disease. 2014 , 121, 491-8	5
1051	Evidence for modest familial co-aggregation between dementia and parkinsonism. 2014 , 29, 49-56	6
1050	Taste performance in Parkinson's disease. 2014 , 121, 119-22	38
1049	Postural rehabilitation and Kinesio taping for axial postural disorders in Parkinson's disease. 2014 , 95, 1067-75	59
1048	Environmental toxins and Parkinson's disease. 2014 , 54, 141-64	249
1047	Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. 2014 , 157, 470-478.e2	101
1046	Advances in the Genetics of Parkinson's Disease: A Guide for the Clinician. 2014 , 1, 3-13	10

1045	Alzheimer's and Parkinson's diseases: an environmental proteomic point of view. 2014 , 104, 24-36	7
1044	A(2A) adenosine receptors and Parkinson's disease severity. 2014 , 129, 276-81	17
1043	Dietary fat intake, pesticide use, and Parkinson's disease. 2014 , 20, 82-7	81
1042	Reduced expression of the chaperone-mediated autophagy carrier hsc70 protein in lymphomonocytes of patients with Parkinson's disease. 2014 , 1546, 46-52	56
1041	Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. 2014 , 35, 266.e5-14	26
1040	Serum 25-hydroxyvitamin D predicts severity in Parkinson's disease patients. 2014 , 35, 67-71	13
1039	Mobility, mood and site of care impact health related quality of life in Parkinson's disease. 2014 , 20, 274-9	8
1038	βSynucleinopathy phenotypes. 2014 , 20 Suppl 1, S62-7	206
1037	Intensive rehabilitation increases BDNF serum levels in parkinsonian patients: a randomized study. 2014 , 28, 163-8	94
1036	Early DEtection of wEaring off in Parkinson disease: the DEEP study. 2014 , 20, 204-11	90
1035	Association between fatigue and other motor and non-motor symptoms in Parkinson's disease patients. 2014 , 261, 382-91	27
1034	Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study. 2014 , 215, 448-52	71
1033	Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease. 2014 , 26, 57-63	15
1032	Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. 2014 , 62, 172-8	57
1031	Lifetime exposure to estrogens and Parkinson's disease in California teachers. 2014 , 20, 1149-56	32
1030	Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease. 2014 , 20, 1177-80	36
1029	Mining Techniques for Body Sensor Network Data Repository. 2014 , 383-407	1
1028	CSF Aβ42 predicts early-onset dementia in Parkinson disease. 2014 , 82, 1784-90	108

1027	Beta oscillatory neurons in the motor thalamus of movement disorder and pain patients. 2014 , 261, 782-90	34
1026	Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. 2014 , 20, 1203-8	65
1025	In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. 2014 , 55, 73-9	36
1024	Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. 2014 , 20, 1009-14	31
1023	Magnetic resonance support vector machine discriminates essential tremor with rest tremor from tremor-dominant Parkinson disease. 2014 , 29, 1216-9	27
1022	Skin nerve synuclein deposits: a biomarker for idiopathic Parkinson disease. 2014 , 82, 1362-9	201
1021	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. 2014 , 82, 858-64	96
1020	G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. 2014 , 324, 1-9	38
1019	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. 2014 , 261, 2112-8	28
1018	Flt3 ligand does not differentiate between Parkinsonian disorders. 2014 , 29, 1319-22	9
1017	Structural and functional imaging in parkinsonian syndromes. 2014 , 34, 1273-92	56
1016	Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. 2014 , 83, 406-12	281
1015	Accuracy of Parkinson disease diagnosis unchanged in 2 decades. 2014 , 83, 386-7	21
1014	Peptidoglycan recognition protein genes and risk of Parkinson's disease. 2014 , 29, 1171-80	37
1013	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. 2014 , 29, 454-62	290
1012	Changes in the thalamus in atypical parkinsonism detected using shape analysis and diffusion tensor imaging. 2014 , 35, 897-903	15
1011	The effects of subthalamic nucleus stimulation on semantic and syntactic performance in spontaneous language production in people with Parkinson's disease. 2014 , 32, 31-41	10
1010	Inflammation in Parkinson's Disease. 2014 ,	3

1009	Phenotypic variability of PINK1 expression: 12 Years' clinical follow-up of two Italian families. 2014 , 29, 1561-6	33
1008	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. 2014 , 10, 477-484.e1	118
1007	Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients. 2014 , 41, 322-9	16
1006	Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. 2014 , 222, 230-7	151
1005	Is posturography able to identify fallers in patients with Parkinson's disease?. 2014 , 40, 53-7	30
1004	The relevance of imaging for the diagnosis of Parkinson's disease. 2014 , 4, 25-27	1
1003	Phosphorylated β -synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. 2014 , 571, 34-8	85
1002	Dementia – The real problem for patients with Parkinson's disease. 2014 , 4, 9-13	6
1001	Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain bundle axotomy. 2014 , 265, 148-54	1
1000	Comparing the effects of hydrotherapy and land-based therapy on balance in patients with Parkinson's disease: a randomized controlled pilot study. 2014 , 28, 1210-7	60
999	Differential protein profile of PC12 cells exposed to proteasomal inhibitor lactacystin. 2014 , 575, 25-30	13
998	Handedness and dominant side of symptoms in Parkinson's disease. 2014 , 142, 141-4	8
997	Freezing of gait in Parkinson's disease: the paradoxical interplay between gait and cognition. 2014 , 20, 824-9	20
996	Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease. 2014 , 219, 381-94	56
995	Impaired visual perception in rapid eye movement sleep behavior disorder. 2014 , 28, 388-393	14
994	Behavioral inhibition errors in Parkinson's disease tested using an antisaccade and antitapping task. 2014 , 4, 599-608	5
993	Increased risk of Parkinson disease in patients with carbon monoxide intoxication: a population-based cohort study. 2015 , 94, e869	20
992	Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease. 2015 , 133, 886-97	13

991	Effects of a Nordic Walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease. 2015 , 37, 245-54	69
990	Differential effects of goal cues on everyday action errors in Alzheimer's disease versus Parkinson's disease dementia. 2015 , 29, 592-602	18
989	Dopaminergic modulation of arm swing during gait among Parkinson's disease patients. 2015 , 5, 141-50	22
988	Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. 2015 , 30, 859-62	25
987	Impact of Parkinson's disease risk loci on age at onset. 2015 , 30, 847-50	31
986	Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease. 2015 , 30, 1874-84	30
985	Patient selection. 5-30	
984	Rapid eye movement sleep behavior disorder: a window on the emotional world of Parkinson disease. 2015 , 38, 287-94	9
983	Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease. 2015 , 30, 1361-70	195
982	The EIF4G1 gene and Parkinson's disease. 2015 , 132, 73-8	21
981	The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. 2015 , 25, 121-35	159
980	White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. 2015 , 25, 754-60	22
979	Fungal Tyrosinases: Why Mushrooms Turn Brown. 2015 ,	6
978	The Latent Dementia Phenotype is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. 2016 , 49, 547-60	17
977	Parkinson's Disease - Just another Infectious Disease. 2015 , 06,	
976	Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?. 2015 , 5, 1467-79	31
975	Fornix as an imaging marker for episodic memory deficits in healthy aging and in various neurological disorders. 2014 , 6, 343	59
974	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. 2015 , 6, 216	31

973	The Parkinsonian Gait Spatiotemporal Parameters Quantified by a Single Inertial Sensor before and after Automated Mechanical Peripheral Stimulation Treatment. 2015 , 2015, 390512	30
972	Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis. 2015 , 46, 17-34	49
971	Optimization of imaging parameters for SPECT scans of [99mTc]TRODAT-1 using Taguchi analysis. 2015 , 10, e0113817	7
970	Impaired Early Attentional Processes in Parkinson's Disease: A High-Resolution Event-Related Potentials Study. 2015 , 10, e0131654	5
969	Olfactory asymmetric dysfunction in early Parkinson patients affected by unilateral disorder. 2015 , 6, 1020	12
968	Relationship between Postural Deformities and Frontal Function in Parkinson's Disease. 2015 , 2015, 462143	3
967	Medical Record Review to Differentiate between Idiopathic Parkinson's Disease and Parkinsonism: A Danish Record Linkage Study with 10 Years of Follow-Up. 2015 , 2015, 781479	5
966	Crossover versus Stabilometric Platform for the Treatment of Balance Dysfunction in Parkinson's Disease: A Randomized Study. 2015 , 2015, 878472	16
965	Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy. 2015 , 2015, 264896	3
964	Altered Brain Activation in Early Drug-Naive Parkinson's Disease during Heat Pain Stimuli: An fMRI Study. 2015 , 2015, 273019	13
963	Changes of retina are not involved in the genesis of visual hallucinations in Parkinson's disease. 2015 , 2015, 709191	5
962	Pisa Syndrome in Parkinson's Disease: Electromyographic Aspects and Implications for Rehabilitation. 2015 , 2015, 437190	8
961	Early Freezing of Gait: Atypical versus Typical Parkinson Disorders. 2015 , 2015, 951645	3
960	Dysphagia in Parkinson's Disease. 2015 ,	
959	Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer's Disease Patients. 2015 , 9, 134	12
958	Homotaurine in Parkinson's disease. 2015 , 36, 1581-7	16
957	Effects of various factors on sleep disorders and quality of life in Parkinson's disease. 2015 , 115, 615-21	5
956	Virtual Reality-Based Training to Improve Obstacle-Crossing Performance and Dynamic Balance in Patients With Parkinson's Disease. 2015 , 29, 658-67	89

955	Mitochondrial DNA mutations in neurodegeneration. 2015 , 1847, 1401-11	84
954	A stereophotogrammetric-based method to assess spatio-temporal gait parameters on healthy and Parkinsonian subjects. 2015 , 2015, 5501-4	1
953	Identification of Daily Activity Impairments in the Diagnosis of Parkinson Disease Dementia. 2015 , 28, 220-8	7
952	Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. 2015 , 35, 354-89	211
951	MDS clinical diagnostic criteria for Parkinson's disease. 2015 , 30, 1591-601	2371
950	Parkinson's disease research in a prospective cohort in China. 2015 , 21, 1200-4	19
949	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. 2015 , 262, 2653-61	30
948	Unraveling predictors affecting compliance to MRI in Parkinson's disease. 2015 , 21, 964-7	1
947	The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes. 2015 , 21, 929-37	19
946	Gait in drug naïve patients with de novo Parkinson's disease--altered but symmetric. 2015 , 37, 712-6	17
945	PR Prolongation and Cardiac 123I-MIBG Uptake Reduction in Parkinson's Disease. 2015 , 74, 107-11	6
944	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease. 2015 , 25, 69-76	28
943	Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. 2015 , 36, 571-82	61
942	Nonmotor symptoms in essential tremor: Comparison with Parkinson's disease and normal control. 2015 , 349, 168-73	29
941	PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. 2015 , 84, 972-80	38
940	CSF biomarkers and clinical progression of Parkinson disease. 2015 , 84, 57-63	126
939	Wearing-off detection in clinical practice: the wearing off real practice key (WORK-PD) study in Parkinson's disease. 2015 , 21, 95-100	10
938	Susceptibility-weighted imaging improves the diagnostic accuracy of 3T brain MRI in the work-up of parkinsonism. 2015 , 36, 454-60	32

937	Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders. 2015 , 88, 66-72	74
936	Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. 2015 , 36, 935-43	5
935	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. 2015 , 31, 140-9	149
934	Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease. 2015 , 9, 619-38	22
933	Non-motor symptoms in Chinese Parkinson's disease patients with and without LRRK2 G2385R and R1628P variants. 2015 , 122, 661-7	16
932	Working on asymmetry in Parkinson's disease: randomized, controlled pilot study. 2015 , 36, 1337-43	17
931	Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study. 2016 , 87, 86-92	18
930	Binary and Multi-class Parkinsonian Disorders Classification Using Support Vector Machines. 2015 , 379-386	
929	Cerebral Peduncle Angle: An Objective Criterion for Assessing Progressive Supranuclear Palsy Richardson Syndrome. 2015 , 205, 386-91	8
928	Continuous non-invasive monitoring to detect covert autonomic dysfunction in Parkinson's disease. 2015 , 21, 723-8	11
927	Inter-limb coupling during diadochokinesis in Parkinson's and Huntington's disease. 2015 , 97, 60-8	9
926	Longitudinal brain volumetric changes and their predictive effects on cognition among cognitively asymptomatic patients with Parkinson's disease. 2015 , 21, 483-8	17
925	Lack of association between the ATP13A2 A746T variant and Parkinson's disease susceptibility in Han Chinese: a meta-analysis. 2016 , 126, 593-9	2
924	Therapeutic potential of PACAP for neurodegenerative diseases. 2015 , 20, 265-78	24
923	Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease Patients. 2015 , 30, 404-17	26
922	Paired neurophysiological and clinical study of the brainstem at different stages of Parkinson's Disease. 2015 , 126, 1871-8	38
921	Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stage. 2015 , 21, 477-82	39
920	When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. 2015 , 85, 404-12	182

919	Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease?. 2015 , 6, 34	13
918	Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. 2015 , 21, 1096-100	28
917	Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease. 2015 , 21, 948-53	10
916	Subthalamic nucleus stimulation and spontaneous language production in Parkinson's disease: A double laterality problem. 2015 , 147, 76-84	8
915	Imaging as Means to Study Cerebrovascular Pathophysiology. 2015 , 1113-1121	
914	Role of 5-hydroxymethylcytosine in neurodegeneration. 2015 , 570, 17-24	51
913	Skin biopsy and I-123 MIBG scintigraphy findings in idiopathic Parkinson's disease and parkinsonism: a comparative study. 2015 , 30, 986-9	17
912	Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. 2015 , 56, 234-42	33
911	White matter integrity and depressive symptoms in cerebral small vessel disease: The RUN DMC study. 2015 , 23, 525-35	34
910	Protocolo diagn ^o stico y terap ^u utico de los s ^o ndromes parkinsonianos. 2015 , 11, 4487-4489	
909	Single-photon emission computed tomography in the differential diagnosis of dementia with Lewy Bodies. 2015 , 24, 1-7	1
908	Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. 2015 , 84, 645-53	82
907	Parkinson's disease. 2015 , 386, 896-912	2652
906	Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. 2015 , 352, 84-7	37
905	Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism. 2015 , 57, 655-69	30
904	Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease. 2015 , 42, 1062-70	14
903	Salsolinol Damaged Neuroblastoma SH-SY5Y Cells Induce Proliferation of Human Monocyte THP-1 Cells Through the mTOR Pathway in a Co-culture System. 2015 , 40, 932-41	2
902	Multidisciplinary intensive rehabilitation treatment improves sleep quality in Parkinson's disease. 2015 , 2, 11	27

901	Does the Pisa syndrome affect postural control, balance, and gait in patients with Parkinson's disease? An observational cross-sectional study. 2015 , 21, 736-41	36
900	Does integrative medicine enhance balance in aging adults? Proof of concept for the benefit of electroacupuncture therapy in Parkinson's disease. 2015 , 61, 3-14	35
899	Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study. 2015 , 181, 808-16	23
898	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. 2015 , 11, 1407-1416	126
897	Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease. 2015 , 31, 245-56	6
896	Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31. 2015 , 36, 1897-902	21
895	Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?. 2015 , 36, 3300-3305	47
894	Predicting Freezing of Gait in Parkinson's Disease with a Smartphone: Comparison Between Two Algorithms. 2015 , 61-69	1
893	Resting-state functional connectivity of dentate nucleus is associated with tremor in Parkinson's disease. 2015 , 262, 2247-56	14
892	Pisa syndrome in Parkinson disease: An observational multicenter Italian study. 2015 , 85, 1769-79	55
891	TCEANC2 rs10788972 and rs12046178 variants in the PARK10 region in Chinese Han patients with sporadic Parkinson's disease. 2015 , 36, 3335.e1-3335.e2	11
890	Increased CSF biomarkers of angiogenesis in Parkinson disease. 2015 , 85, 1834-42	75
889	Challenges in Concussion Detection Using Vocal Acoustic Biomarkers. 2015 , 3, 1143-1160	8
888	Clinical characteristics of leg restlessness in Parkinson's disease compared with idiopathic Restless Legs Syndrome. 2015 , 357, 109-14	17
887	Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations. 2015 , 21, 1232-7	2
886	Biomarker sources for Parkinson's disease: Time to shed tears?. 2015 , 5, 63-69	15
885	Head injury and risk for Parkinson disease: results from a Danish case-control study. 2015 , 84, 1098-103	24
884	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population. 2015 , 262, 2498-503	23

883	Biomechanische Ganganalyse von neurodegenerativen Parkinson-Syndromen. 2015 , 46, 146-152	
882	The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. 2015 , 21, 1067-71	38
881	Altering Effort Costs in Parkinson's Disease with Noninvasive Cortical Stimulation. 2015 , 35, 12287-302	22
880	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. 2015 , 85, 1283-92	20
879	Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease. 2015 , 58, 9179-95	32
878	Voxelwise meta-analysis of gray matter anomalies in Parkinson variant of multiple system atrophy and Parkinson's disease using anatomic likelihood estimation. 2015 , 587, 79-86	37
877	Taste function in early stage treated and untreated Parkinson's disease. 2015 , 262, 547-57	31
876	Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson's disease. 2015 , 21, 205-10	23
875	Genotype-Phenotype Correlations in Parkinson Disease. 2015 , 259-285	1
874	Burden of Neurological Disease. 2015 , 748-764	
873	Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer's disease brains and human microglia. 2015 , 302, 121-37	32
872	Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. 2015 , 36, 1165-79	36
871	Single vial freeze-dried TRODAT-1 kit: preparation and demonstration of clinical efficacy of [(99m)Tc]TRODAT-1 in Indian scenario. 2015 , 96, 57-62	1
870	Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. 2015 , 75, 144-50	60
869	EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. 2015 , 52, 37-41	15
868	Silencing of Hsp70 intensifies 6-OHDA-induced apoptosis and Hsp90 upregulation in PC12 cells. 2015 , 55, 174-183	11
867	G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients. 2015 , 52, 386-98	15
866	Point pressure sensitivity in early stage Parkinson's disease. 2015 , 138, 21-7	2

865	Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up. 2015 , 29, 123-31	103
864	Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. 2015 , 11, 394-403.e1	63
863	Does Postural Rigidity Decrease during REM Sleep without Atonia in Parkinson Disease?. 2016 , 12, 839-47	3
862	Consequences of Gut Dysbiosis on the Human Brain. 2016 ,	1
861	Mechanisms for Neuronal Cell Death in Parkinson's Disease: Pathological Cross Talks Between Epigenetics and Various Signalling Pathways. 2016 ,	
860	Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson's Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study. 2016 , 81, 363-9	28
859	Integration of Osteopathic Manual Treatments in the Management of Foot Dystonia in Parkinson's Disease: A Case Series. 2016 , 03,	
858	Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording. 2016 , 2016, 3724148	13
857	Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor. 2016 , 2016, 9182946	1
856	Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease. 2016 , 2016, 1941034	12
855	Neuro-Ophthalmologic Evaluation as a Biomarker for Diagnosis and Progression in Parkinson Disease. 2016 ,	
854	β-synuclein genetic variability: A biomarker for dementia in Parkinson disease. 2016 , 79, 991-9	64
853	Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. 2016 , 123, 1435-1442	39
852	Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series. 2016 , 15, 623-31	15
851	Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains. 2016 , 36, 333-45	14
850	Pre-stroke dementia does not affect the post-acute care functional outcome of old patients with ischemic stroke. 2016 , 16, 928-33	10
849	Skin nerve misfolded β-synuclein in pure autonomic failure and Parkinson disease. 2016 , 79, 306-16	90
848	Treatment Preferences at the End-of-Life in Parkinson's Disease Patients. 2016 , 3, 483-489	6

847	Alterations of putaminal shape in de novo Parkinson's disease. 2016 , 31, 676-83		8
846	Pathological β synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. 2016 , 79, 940-9		194
845	Cerebral white matter lesions - associations with A β isoforms and amyloid PET. <i>Scientific Reports</i> , 2016 , 6, 20709	4.9	41
844	Positive Effects of Specific Exercise and Novel Turning-based Treadmill Training on Turning Performance in Individuals with Parkinson's disease: A Randomized Controlled Trial. <i>Scientific Reports</i> , 2016 , 6, 33242	4.9	14
843	Nigral dopaminergic PAK4 prevents neurodegeneration in rat models of Parkinson's disease. 2016 , 8, 367ra170		17
842	Diagnostic utility of CSF β synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. 2016 , 6, e011113		8
841	Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. 2016 , 6, 99-108		4
840	The influence of subthalamic nucleus stimulation on pragmatic language production in Parkinson's disease. 2016 , 116, 163-70		5
839	Conjugal parkinsonism is coincidental. 2016 , 33, 149-150		2
838	Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. <i>Scientific Reports</i> , 2016 , 6, 33738	4.9	58
837	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. 2016 , 6, 153-63		39
836	Roles of Cognitive Status and Intelligibility in Everyday Communication in People with Parkinson's Disease: A Systematic Review. 2016 , 6, 453-62		12
835	Chronic pain in Parkinson's disease: Frequency, characteristics, independent factors, and relationship with health-related quality of life. 2016 ,		20
834	Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. 2016 , 29, 727-734		42
833	Influence of Parkinsonism on Hitler's Decision-Making. 2016 , 86, 4		
832	In Reply to the Letter to the Editor, "Influence of Parkinsonism on Hitler's Decision-Making". 2016 , 86, 5		1
831	Split-belt locomotion in Parkinson's disease links asymmetry, dyscoordination and sequence effect. 2016 , 48, 6-12		22
830	Early-onset vs. Late-onset Parkinson's disease: A Clinical-pathological Study. 2016 , 43, 113-9		33

829	Is there a role for Mycobacterium avium subspecies paratuberculosis in Parkinson's disease?. 2016 , 293, 86-90	16
828	DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. 2016 , 139, 1680-7	63
827	White Coat Tales. 2016 ,	4
826	Paradoxical kinesia in Parkinson's disease revisited: Anticipation of temporal constraints is critical. 2016 , 86, 38-44	8
825	Determination of dopamine using a glassy carbon electrode modified with a graphene and carbon nanotube hybrid decorated with molybdenum disulfide flowers. 2016 , 183, 2267-2275	83
824	Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study. 2016 , 87, 1599-1606	32
823	Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis. 2016 , 41, 3161-3170	15
822	A smartphone-based architecture to detect and quantify freezing of gait in Parkinson's disease. 2016 , 50, 28-33	63
821	Conjugal parkinsonism - Clinical, pathology and genetic study. No evidence of person-to-person transmission. 2016 , 31, 87-90	11
820	The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson's disease. 2016 , 633, 279-289	10
819	Hypnic jerks are an underestimated sleep motor phenomenon in patients with parkinsonism. A video-polysomnographic and neurophysiological study. 2016 , 26, 37-44	4
818	RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease. 2016 , 96, 312-322	11
817	Anatomical and functional correlates of persistent pain in Parkinson's disease. 2016 , 31, 1854-1864	46
816	Impulse control disorders in Parkinson's disease: Predominant role of psychological determinants. 2016 , 31, 1391-1414	8
815	LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews. 2016 , 42, 1-6	7
814	Deep brain stimulation and sleep-wake functions in Parkinson's disease: A systematic review. 2016 , 32, 12-19	16
813	Neuroleptic-induced Parkinsonism: Clinicopathological study. 2016 , 31, 360-5	38
812	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. 2016 , 31, 898-905	94

811	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. 2016 , 31, 924-32	36
810	Neuroproteomic profiling of human body fluids. 2016 , 10, 485-502	6
809	The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication. 2016 , 91, 163-172	27
808	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. 2016 , 42, 77-94	114
807	Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging. 2016 , 37, 4500-4510	54
806	The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls. 2016 , 25, 2571-2577	8
805	Is PIGD a legitimate motor subtype in Parkinson disease?. 2016 , 3, 473-7	32
804	Cerebral peduncle angle: Unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases. 2016 , 32, 31-35	4
803	Progression of small vessel disease correlates with cortical thinning in Parkinson's disease. 2016 , 31, 34-40	13
802	Current Issues in Randomized Clinical Trials of Neurodegenerative Disorders at Enrolment and Reporting: Diagnosis, Recruitment, Representativeness of Patients, Ethnicity, and Quality of Reporting. 2016 , 39, 24-36	3
801	Bone mass and vitamin D levels in Parkinson's disease: is there any difference between genders?. 2016 , 28, 2204-9	13
800	Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. 2016 , 7, 13548	144
799	Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease. 2016 , 369, 347-353	11
798	The Effect of Neurodegeneration on Visuomotor Behavior in Alzheimer's Disease and Parkinson's Disease. 2016 , 20, 1-20	13
797	Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. 2016 , 151, 713-720	39
796	Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease. 2016 , 11, 736-742	32
795	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. 2016 , 629, 160-164	19
794	Persistent sparing of action conceptual processing in spite of increasing disorders of action production: A case against motor embodiment of action concepts. 2016 , 33, 191-219	9

793	Neural correlates of anxiety symptoms in mild Parkinson's disease: A prospective longitudinal voxel-based morphometry study. 2016 , 371, 131-136	18
792	Activities of daily living questionnaire from patients' perspectives in Parkinson's disease: a cross-sectional study. 2016 , 16, 73	6
791	Genetics of Parkinson's disease. 2016 , 30, 386-396	198
790	Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson's disease. 2016 , 123, 1381-1386	39
789	Visual dysfunction and its correlation with retinal changes in patients with Parkinson's disease: an observational cross-sectional study. 2016 , 6, e009658	44
788	Compartmental modeling of F-DOPA PET images from Parkinson's patients. 2016 ,	
787	What Could Posturography Tell Us About Balance Problems in Parkinson's Disease?. 2016 , 37, e326-31	4
786	Analysis of white matter characteristics with tract-based spatial statistics according to diffusion tensor imaging in early Parkinson's disease. 2018 , 675, 127-132	25
785	Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism. 2018 , 52, 48-53	9
784	Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation. 2018 , 33, 31-35	8
783	. 2018 ,	6
782	Echogenic alteration in the raphe nuclei measured by transcranial sonography in patients with Parkinson disease and depression. 2018 , 97, e13524	3
781	An Evaluation of the Effect of Vision on Standing Stability in the Early Stage of Parkinson's Disease. 2018 , 80, 261-267	6
780	Asymmetric Dopaminergic Degeneration and Attentional Resources in Parkinson's Disease. 2018 , 12, 972	6
779	Gastrointestinal nervous system β -synuclein as a potential biomarker of Parkinson disease. 2018 , 97, e11337	31
778	Determination of Parkinson's disease utilizing Machine Learning Methods. 2018 ,	2
777	Increased Serum Cystatin C in Early Parkinson's Disease with Objective Sleep Disturbances. 2018 , 131, 907-911	5
776	PARKINSON'S DISEASE: CLINICAL PRESENTATION AND MANAGEMENT. 2018 , 9, 7-11	2

775	Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study. 2018 , 91, e2238-e2243	39
774	IDENTIFICATION OF POSSIBLE MOLECULAR TARGETS OF POTENTIAL ANTI-PARKINSON DRUGS BY PREDICTING THEIR BINDING AFFINITIES USING MOLECULAR DOCKING TECHNIQUE. 2018 , 11, 28	1
773	Objective Arm Swing Analysis in Early-Stage Parkinson's Disease Using an RGB-D Camera (Kinect [®]). 2018 , 8, 563-570	12
772	24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome. 2018 , 9, 756	17
771	Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients. 2018 , 13, 1-4	51
770	Cognitive and Affective Theory of Mind in Mild Cognitive Impairment and Parkinson's Disease: Preliminary Evidence from the Italian Version of the Yoni Task. 2018 , 43, 764-780	14
769	Other Neurocognitive Disorders in Tropical Health (Amyotrophic Lateral Sclerosis and Parkinson's Disease). 2018 , 167-183	2
768	Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. 2018 , 46, 243-252	9
767	Spatial disorientation and executive dysfunction in elderly nondemented patients with Parkinson's disease. 2018 , 14, 2531-2539	10
766	AB13 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. 2018 , 13, 53	41
765	Novelty Detection using Deep Normative Modeling for IMU-Based Abnormal Movement Monitoring in Parkinson's Disease and Autism Spectrum Disorders. 2018 , 18,	22
764	Quantitative study of F-(+)-DTBZ image: comparison of PET template-based and MRI based image analysis. <i>Scientific Reports</i> , 2018 , 8, 16027	4.9 7
763	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. <i>Scientific Reports</i> , 2018 , 8, 13276	4.9 59
762	The effect of resistance training on the anxiety symptoms and quality of life in elderly people with Parkinson's disease: a randomized controlled trial. 2018 , 76, 499-506	19
761	Whole body vibration and treadmill training in Parkinson's disease rehabilitation: effects on energy cost and recovery phases. 2018 , 39, 2159-2168	8
760	State estimation in dynamic MRI. 2018 ,	
759	Correlation Between Energy Pattern Factor and Weibull Shape Parameter of Wind Regimes. 2018 ,	
758	Correlation among olfactory function, motors' symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease. 2018 , 265, 1764-1771	40

757	A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in. 2018 , 2018, 6838965	24
756	Inflammation and fatigue in early, untreated Parkinson's Disease. 2018 , 138, 394-399	13
755	Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease. 2018 , 138, 508-514	16
754	Validity of shoe-type inertial measurement units for Parkinson's disease patients during treadmill walking. 2018 , 15, 38	21
753	Transdifferentiation: a new promise for neurodegenerative diseases. 2018 , 9, 830	23
752	Comparative Motor Pre-clinical Assessment in Parkinson's Disease Using Supervised Machine Learning Approaches. 2018 , 46, 2057-2068	41
751	Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. 2018 , 15, 205	98
750	A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease. 2018 , 54, 3-8	49
749	An 8-Week Low-Intensity Progressive Cycling Training Improves Motor Functions in Patients with Early-Stage Parkinson's Disease. 2018 , 14, 225-233	11
748	Are Hypometric Anticipatory Postural Adjustments Contributing to Freezing of Gait in Parkinson's Disease?. 2018 , 10, 36	38
747	Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. 2018 , 9, 156	75
746	The Length of Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson's Disease. 2018 , 9, 213	19
745	Gait Stability Has Phase-Dependent Dual-Task Costs in Parkinson's Disease. 2018 , 9, 373	16
744	Autophagy Disruptions Associated With Altered Optineurin Expression in Extranigral Regions in a Rotenone Model of Parkinson's Disease. 2018 , 12, 289	7
743	Salusin- β mediate neuroprotective effects for Parkinson's disease. 2018 , 503, 1428-1433	5
742	Jaw tremor: a manifestation of vascular parkinsonism? - a case report. 2018 , 18, 92	1
741	Measuring Gait Quality in Parkinson's Disease through Real-Time Gait Phase Recognition. 2018 , 18,	20
740	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. 2018 , 265, 2211-2220	22

739	A monocyte gene expression signature in the early clinical course of Parkinson's disease. <i>Scientific Reports</i> , 2018 , 8, 10757	4.9	27
738	Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. 2018 , 6, 82		13
737	Constraints, Facilitators, and Stages of Behavioral Change in Physical Activity for Individuals with Parkinson's Disease. 2018 , 49, 179-189		1
736	Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison. 2018 , 265, 1343-1352		9
735	Effects of Antiparkinson Medication on Cognition in Parkinson's Disease: A Systematic Review. 2018 , 45, 375-404		13
734	Validity and Clinical Utility of Different Clock Drawing Test Scoring Systems in Multiple Forms of Dementia. 2018 , 31, 114-122		6
733	Phosphorylated α -Synuclein in the retina is a biomarker of Parkinson's disease pathology severity. 2018 , 33, 1315-1324		69
732	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. 2018 , 53, 53-57		22
731	Safinamide: an add-on treatment for managing Parkinson's disease. 2018 , 10, 31-41		9
730	Plasma Metabolome Signature in Patients with Early-stage Parkinson Disease. 2018 , 6,		13
729	The effects of functional training and stationary cycling on respiratory function of elderly with Parkinson disease: a pilot study. 2018 , 31,		3
728	Importance of Balance-Gait Disorder as a Risk Factor for Cognitive Impairment, Dementia and Related Non-Motor Symptoms in Parkinson's Disease. 2018 , 8, 539-552		9
727	The natural history of idiopathic autonomic failure: The IAF-BO cohort study. 2018 , 91, e1245-e1254		16
726	Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events. 2018 , 117, 82-113		47
725	Cognitive Impairment and Mortality in a Population-Based Parkinson's Disease Cohort. 2018 , 8, 353-362		16
724	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. 2018 , 56, 33-40		14
723	Excess amounts of 3-iodo-L-tyrosine induce Parkinson-like features in experimental approaches of Parkinsonism. 2018 , 67, 178-189		5
722	Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome. 2018 , 56, 20-26		12

721	Long-term management of Parkinson's disease using levodopa combinations. 2018 , 19, 1003-1011	9
720	Effects of 99mTc-TRODAT-1 drug template on image quantitative analysis. 2018 , 13, e0194503	2
719	Awareness and current knowledge of Parkinson's disease: a neurodegenerative disorder. 2019 , 129, 55-93	30
718	Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease. 2019 , 29, 567-574	4
717	Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study. 2019 , 405, 116421	7
716	Immediate effects of rhythmic auditory stimulation on gait kinematics in Parkinson's disease ON/OFF medication. 2019 , 130, 1789-1797	11
715	Using gait analysis' parameters to classify Parkinsonism: A data mining approach. 2019 , 180, 105033	33
714	Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease. 2019 , 126, 1437-1445	12
713	Reliability of visual assessment by non-expert nuclear medicine physicians and appropriateness of indications of [¹⁸ F]FP-CIT SPECT imaging by neurologists in patients with early drug-naive Parkinson's disease. 2019 , 9, 63	4
712	Neuroimaging in Parkinson's disease dementia: connecting the dots. 2019 , 1, fcz006	26
711	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.. 2019 , 14 Pt B, 74-82	1
710	Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies. 2019 , 13, 263	42
709	. 2019 ,	2
708	Towards computerized diagnosis of neurological stance disorders: data mining and machine learning of posturography and sway. 2019 , 266, 108-117	10
707	Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis. 2019 , 1722, 146342	1
706	Resistance training reduces depressive symptoms in elderly people with Parkinson disease: A controlled randomized study. 2019 , 29, 1957-1967	15
705	Circulatory miR-223-3p Discriminates Between Parkinson's and Alzheimer's Patients. <i>Scientific Reports</i> , 2019 , 9, 9393	4-9 17
704	Blue Light Therapy Glasses in Parkinson's Disease: Patients' Experience. 2019 , 2019, 1906271	4

703	The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , 2019 , 26, 1327-1333	6	13
702	Parkinson's disease biomarkers based on β synuclein. 2019 , 150, 626-636		46
701	P. 2019 , 451-554		
700	L-Dopa Modulation of Brain Connectivity in Parkinson's Disease Patients: A Pilot EEG-fMRI Study. 2019 , 13, 611		14
699	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from β Synucleinopathies. 2019 , 293, 646-653		10
698	Population-scale hand tremor analysis via anonymized mouse cursor signals. 2019 , 2, 93		4
697	A Novel Approach for Investigating Parkinson's Disease Personality and Its Association With Clinical and Psychological Aspects. 2019 , 10, 2265		1
696	Identifying Correlations among Biomedical Data through Information Retrieval Techniques. 2019 ,		3
695	Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study. 2019 , 99, 203-216		44
694	Influences of elbow, shoulder, trunk motion and temporospatial parameters on arm swing asymmetry of Parkinson's disease during walking. 2019 , 68, 102527		6
693	A Power Spectral Density-Based Method to Detect Tremor and Tremor Intermittency in Movement Disorders. 2019 , 19,		3
692	Track density imaging: A reliable method to assess white matter changes in Progressive Supranuclear Palsy with predominant parkinsonism. 2019 , 69, 23-29		4
691	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. <i>Scientific Reports</i> , 2019 , 9, 15417	4.9	5
690	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. 2019 , 34, 1851-1863		18
689	Motion analysis of Parkinson diseased patients using a video game approach. 2019 ,		4
688	Herpes simplex virus-1 (HSV-1) infection induces a potent but ineffective IFN- γ production in immune cells of AD and PD patients. 2019 , 17, 286		7
687	Parkinson's disease and Levodopa effects on muscle synergies in postural perturbation. 2019 ,		2
686	Paraquat and Parkinson's disease: a systematic review and meta-analysis of observational studies. 2019 , 22, 172-202		18

685	Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease. 2019 , 14, e0222002	9
684	Overall and Disease Related Mortality in Parkinson's Disease - a Longitudinal Cohort Study. 2019 , 9, 767-774	6
683	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. 2019 , 11, 82	26
682	Intriguing Mixed Pathologic Features in a Case of Dementia With Lewy Bodies. 2019 , 119, 632-636	0
681	Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors. 2019 , 183, 111703	28
680	Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade. 2019 , 13, 399	24
679	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. 2019 , 67, 105-112	13
678	A Comprehensive Analysis of Population Differences in Variant Distribution in Parkinson's Disease. 2019 , 11, 13	30
677	Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease. 2019 , 10, 1791-1800	14
676	Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson's disease. 2019 , 90, 681-687	13
675	Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson's disease. 2019 , 34, 722-729	12
674	Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial. 2019 , 99, 591-600	17
673	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. 2019 , 76, 1035-1048	237
672	The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects. 2019 , 129, 104495	12
671	GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients. 2019 , 13, 697	13
670	Parkinsonism in essential tremor cases: A clinicopathological study. 2019 , 34, 1031-1040	9
669	Rotenone and Parkinson's Disease: Reduced Sensitivity in Females. 2019 , 170, 562-563	2
668	New Sensor and Wearable Technologies to Aid in the Diagnosis and Treatment Monitoring of Parkinson's Disease. 2019 , 21, 111-143	35

667	The effect of postural deformities on back function and pain in patients with Parkinson's disease. 2019 , 44, 419-424	6
666	Antibodies against alpha-synuclein: tools and therapies. 2019 , 150, 612-625	27
665	Dual Role of Autophagy in Diseases of the Central Nervous System. 2019 , 13, 196	40
664	Freezing of gait and dementia in parkinsonism: A retrospective case-control study. 2019 , 9, e01247	6
663	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. 2019 , 94, 892-905	53
662	Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinson's Disease Patients: A Questionnaire-Based Study. 2019 , 2019, 7832487	1
661	Deficits in tapping accuracy and variability in tremor patients. 2019 , 16, 54	5
660	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. <i>Scientific Reports</i> , 2019 , 9, 6079	4-9 8
659	Optimizing the Diagnosis of Parkinsonian Syndromes With I-Ioflupane Brain SPECT. 2019 , 213, 243-253	5
658	Low-volume resistance training improves the functional capacity of older individuals with Parkinson's disease. 2019 , 19, 635-640	12
657	Depression in neurodegenerative diseases: Common mechanisms and current treatment options. 2019 , 102, 56-84	79
656	Evaluation of tremor interference with control of voluntary reaching movements in patients with Parkinson's disease. 2019 , 16, 38	3
655	Upper limb motor pre-clinical assessment in Parkinson's disease using machine learning. 2019 , 63, 111-116	31
654	Microstructural changes of normal-appearing white matter in Vascular Parkinsonism. 2019 , 63, 60-65	8
653	Handwritten pattern recognition for early Parkinson's disease diagnosis. 2019 , 125, 78-84	21
652	The impact of evoked cutaneous afferents on voluntary reaching movement in patients with Parkinson's disease. 2019 , 16, 036029	4
651	Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson's Disease. 2019 , 9, 389-400	15
650	Feasible Classified Models for Parkinson Disease from Tc-TRODAT-1 SPECT Imaging. 2019 , 19,	9

649	Electrocortical networks in Parkinson’s disease patients with Mild Cognitive Impairment. The PaCoS study. 2019 , 64, 156-162	10
648	Concordance for Parkinson’s disease in twins: A 20-year update. 2019 , 85, 600-605	35
647	Neurobehavioral performance of patients diagnosed with manganese and idiopathic Parkinson disease. 2019 , 92, 383-394	7
646	Imaging counterpart of postural instability and vertical ocular dysfunction in patients with PSP: A multimodal MRI study. 2019 , 63, 124-130	16
645	DAPHNE: A Novel e-Health System for the Diagnosis and the Treatment of Parkinson’s Disease. 2019 , 271-288	
644	Genetic variants in nicotinic receptors and smoking cessation in Parkinson’s disease. 2019 , 62, 57-61	3
643	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson’s Disease. 2019 , 9, 229-239	4
642	Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson’s Disease Patients. 2019 , 13, 58	38
641	A Fuzzy Rule-Based Diagnosis of Parkinson’s Disease. 2019 , 1229-1238	
640	The influence of postural deformities on neck function and pain in patients with Parkinson’s disease. 2019 , 44, 79-84	3
639	Refining initial diagnosis of Parkinson’s disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study. 2019 , 34, 487-495	16
638	A Fully-Integrated Kinetic Energy Harvesting Circuit with a Transposed Hybrid Series-Parallel SC DC-DC. 2019 ,	
637	The Evaluation of Operational Efficiency in International Disaster Public Welfare Organizations. 2019 ,	
636	Rain attenuation of Ka-band signal over a Tropical station. 2019 ,	2
635	Eye Blink Controlled Low Cost Smart Wheel Chair Aiding Disabled People. 2019 ,	0
634	Spin Blockade and Magnetoresistance in Double Quantum Well Diode with Inverted Electric Field. 2019 ,	
633	Surface-enhanced Raman Spectroscopy in Microfluidic Chips for Directed Evolution of Enzymes and Environmental Monitoring. 2019 ,	
632	Securing the Space Data Link Communication Protocol of Earth Observation Satellites. 2019 ,	

631	Enhanced RF Fingerprinting for IoT Devices with Recurrent Neural Networks. 2019,	4
630	. 2019,	4
629	Conceptualizing the cyber incident & event statistics reporting standards. 2019,	
628	Table of contents. 2019,	
627	Event-driven frequency and voltage stability predictive assessment and unified load shedding. 2019 , 13, 4410-4420	10
626	Program Area Chairs. 2019,	
625	Masthead. 2019, 17, 3-3	
624	Toward a Dynamic QoS Management over LTE/EPC Network using ANFIS. 2019,	
623	. 2019,	194
622	Multimodal Image-Free Ultrasound Technique for Evaluation of Arterial Viscoelastic Properties: A Feasibility Study. 2019, 2019, 5034-5037	1
621	Implantation Process of Enterprise IT Application in a Medium-Sized Enterprise. 2019,	
620	Hybrid Force/Motion Control and Implementation of an Aerial Manipulator towards Sustained Contact Operations. 2019,	2
619	An Ultra-thin Triple-band Smartwatch Antenna with Support of Several Wireless Application Bands. 2019,	1
618	Double-Barrier Resonant Tunneling in Nano-Optics and Quantum Mechanics: Wavelength-Scale Analysis by the Method of Single Expression. 2019,	1
617	[Blank page]. 2019, 37, C4-C4	
616	ICSPCS 2019 List Reviewers. 2019,	
615	. 2019,	
614	Maturity Assessment: A Case Study toward Sustainable Smart Manufacturing Implementation. 2019 ,	

613 . 2019,

612 . 2019,

611 Fabrication and Characterization of Back-Gate Controlled Silicon Nanowire based Field-effect pH Sensor. 2019, 0

610 e-Vent : Support System for Event Registration. 2019,

609 A 3-Dimensional Matching Method for Resource Allocation in D2D-Assisted Indoor Wireless Communications. 2019,

608 A Novel Ensemble Approach to Multi-label Classification for Electric Power Fault Diagnosis. 2019, 0

607 Mos2 transistor gated by PMMA-based electrolyte for sub-1 V operation. 2019,

606 Finite-Time Surrounding Control of Multi-Agent Systems with Multiple Targets. 2019, 0

605 Strategies for Congestion Control in Wireless Sensor Networks : A Survey. 2019, 1

604 Accurate and Robust RGB-D Dense Mapping with Inertial Fusion and Deformation-Graph Optimization. 2019,

603 Structural Test and Functional Test for Digital Acoustofluidic Biochips. 2019, 1

602 Simultaneous Electric Powertrain Hardware and Energy Management Optimization of a Hybrid Electric Vehicle Using Deep Reinforcement Learning and Bayesian Optimization. 2019, 2

601 Proposal for Identification Scheme of Driver and Impostor based on Acceleration Data. 2019, 0

600 Free Registration Based Shape Prior for Active Contours. 2019,

599 A Fast and Accurate Fully Convolutional Network for End-to-End Handwritten Chinese Text Segmentation and Recognition. 2019, 12

598 Increased Activation of Default Mode Network in Early Parkinson's With Excessive Daytime Sleepiness. 2019, 13, 1334 2

597 Effect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population. 2019, 10, 1231 1

596 'Atypical' Parkinson's disease - sporadic. 2019, 149, 195-206

595	Short-term effects of postural control by standing on a tilting board in patients with Parkinson's disease. 2021 , 37, 1306-1312		1
594	Self-reported and experimentally induced self-disgust is heightened in Parkinson's disease: Contribution of behavioural symptoms. 2019 , 14, e0223663		4
593	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. 2019 , 9, e01448		6
592	Gait classification for Parkinson's Disease using Stacked 2D and 1D Convolutional Neural Network. 2019 ,		4
591	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. 2019 , 73, 9-20		19
590	The impact of cognitive interventions on cognitive symptoms in idiopathic Parkinson's disease: a systematic review. 2019 , 26, 637-659		7
589	Non-motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life. <i>European Journal of Neurology</i> , 2019 , 26, 400-406	6	38
588	Early ophthalmologic features of Parkinson's disease: a review of preceding clinical and diagnostic markers. 2019 , 266, 2103-2111		16
587	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. 2019 , 76, 9-17		13
586	Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. 2019 , 49, 2342-2353		22
585	Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. 2019 , 61, 111-117		12
584	Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease. 2019 , 126, 377-396		10
583	Sardinian Folk Dance for Individuals with Parkinson's Disease: A Randomized Controlled Pilot Trial. 2019 , 25, 305-316		25
582	Classification of gait patterns between patients with Parkinson's disease and healthy controls using phase space reconstruction (PSR), empirical mode decomposition (EMD) and neural networks. 2019 , 111, 64-76		25
581	Radiotracers for imaging of Parkinson's disease. 2019 , 166, 75-89		15
580	Cognitive profile of non-demented Parkinson's disease: Meta-analysis of domain and sex-specific deficits. 2019 , 60, 32-42		15
579	Episodic recognition memory and the hippocampus in Parkinson's disease: A review. 2019 , 113, 191-209		32
578	A recurrence plot-based approach for Parkinson's disease identification. 2019 , 94, 282-292		51

577	Track density imaging in progressive supranuclear palsy: A pilot study. 2019 , 40, 1729-1737		7
576	Complexity of electrocortical activity as potential biomarker in untreated Parkinson's disease. 2019 , 126, 167-172		2
575	Artificial Intelligence Integration for Neurodegenerative Disorders. 2019 , 77-89		3
574	Dynamic Atlas-Based Segmentation and Quantification of Neuromelanin-Rich Brainstem Structures in Parkinson Disease. 2019 , 38, 813-823		19
573	Everyday task knowledge and everyday function in dementia. 2019 , 13, 96-120		10
572	Voice Tremor Outcomes of Subthalamic Nucleus and Zona Incerta Deep Brain Stimulation in Patients With Parkinson Disease. 2019 , 33, 545-549		2
571	Automated detection of Parkinson's disease using minimum average maximum tree and singular value decomposition method with vowels. 2020 , 40, 211-220		32
570	Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. 2020 , 41, 483-498		12
569	Sex-related differences in olfactory function and evaluation of possible confounding factors among patients with Parkinson's disease. 2020 , 267, 57-63		23
568	Head-to-head comparison of tau positron emission tomography tracers [¹⁸ F]flortaucipir and [¹⁸ F]RO948. 2020 , 47, 342-354		33
567	Understanding the links between cardiovascular disease and Parkinson's disease. 2020 , 35, 55-74		28
566	Influence of Striatal Dopamine, Cerebral Small Vessel Disease, and Other Risk Factors on Age-Related Parkinsonian Motor Signs. 2020 , 75, 696-701		7
565	The value of cerebrospinal fluid β -synuclein and the tau/ β -synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. <i>European Journal of Neurology</i> , 2020 , 27, 43-50	6	5
564	Current Concepts in Ophthalmology. 2020 ,		
563	Are genetic and idiopathic forms of Parkinson's disease the same disease?. 2020 , 152, 515-522		8
562	Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. 2020 , 40, 30-39		21
561	Comparison of virtual reality rehabilitation and conventional rehabilitation in Parkinson's disease: a randomised controlled trial. 2020 , 106, 36-42		30
560	Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease. 2020 , 74, 76-77		5

559	Changes of brain structural network connection in Parkinson's disease patients with mild cognitive dysfunction: a study based on diffusion tensor imaging. 2020 , 267, 933-943	15
558	Evolving concepts on bradykinesia. 2020 , 143, 727-750	50
557	The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias. 2020 , 26, 210-225	7
556	Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease. 2020 , 20, 180-188	6
555	Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis. 2020 , 7, 45-51	1
554	α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients. 2020 , 35, 268-278	43
553	Chronic waterborne exposure to benzo[a]pyrene induces locomotor dysfunction and development of neurodegenerative phenotypes in zebrafish. 2020 , 716, 134646	13
552	Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. 2020 , 127, 323-330	6
551	Characterization of the intestinal microbiota during infection in a mouse model of infection-triggered Parkinson's disease. 2020 , 12, 1-11	5
550	The white matter hyperintensities within the cholinergic pathways and cognitive performance in patients with Parkinson's disease after bilateral STN DBS. 2020 , 418, 117121	1
549	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). 2020 , 10, 1561-1569	3
548	Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease. 2020 , 5, 20	15
547	Microorganisms that are related with increased risk for Parkinson's disease. 2020 ,	1
546	Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice. 2020 , 13, 164	6
545	Frontal lobe syndrome and dementias. 2020 , 617-632	0
544	Parkinson's Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish. 2020 , 54, 392-397	1
543	Echogenicity Changes in Brainstem Raphe Detected by Transcranial Parenchymal Sonography and Clinical Characteristics in Parkinson's Disease. 2020 , 11, 821	0
542	An elderly man with normal pressure hydrocephalus presenting with asymmetric parkinsonism in the upper and lower extremities. 2020 , 20, 791-792	1

541	Association of MAPT subhaplotypes with clinical and demographic features in Parkinson's disease. 2020 , 7, 1557-1563	2
540	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. 2020 , 57, 4667-4691	14
539	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. 2020 , 10, 1611-1620	7
538	Progress in α -Synuclein-Associated Parkinson's Disease Animal Models. 2020 , 14, 674	10
537	. 2020 ,	6
536	Impact of Trunk Resistance and Stretching Exercise on Fall-Related Factors in Patients with Parkinson's Disease: A Randomized Controlled Pilot Study. 2020 , 20,	5
535	A Study of the Relationship Between Uric Acid and Substantia Nigra Brain Connectivity in Patients With REM Sleep Behavior Disorder and Parkinson's Disease. 2020 , 11, 815	8
534	Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson's Disease. 2020 ,	9
533	Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy. 2020 , 143, 3352-3373	16
532	The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism. 2020 , 10, e01808	7
531	Effectiveness analysis of bio-electronic stimulation therapy to Parkinson's diseases via joint singular spectrum analysis and discrete fourier transform approach. 2020 , 62, 102131	6
530	Resting-state electroencephalographic delta rhythms may reflect global cortical arousal in healthy old seniors and patients with Alzheimer's disease dementia. 2020 , 158, 259-270	4
529	Deep learning-assisted comparative analysis of animal trajectories with DeepHL. 2020 , 11, 5316	17
528	Eye movements in anorexia nervosa: State or trait markers?. 2020 , 53, 1678-1684	6
527	Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease. 2020 , 88, 893-906	18
526	Striatal asymmetry index and its correlation with the Hoehn & Yahr stage in Parkinson's disease. 2020 , 1-6	2
525	Automatic Gait Phases Detection in Parkinson Disease: A Comparative Study. 2020 , 2020, 798-802	4
524	Blinded RT-QuIC Analysis of α -Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients. 2020 , 35, 2230-2239	37

523	A Discrete Fractional-Order Prion Model Motivated by Parkinson's Disease. 2020 , 2020, 1-12	1
522	Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease: A protocol for systematic review and meta-analysis. 2020 , 99, e21458	2
521	Investigation of anti-Parkinson activity of dicyclomine. 2020 , 1-14	4
520	Genetic risk scores and hallucinations in patients with Parkinson disease. 2020 , 6, e492	4
519	Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease. 2020 , 127, 1369-1376	0
518	[Copyright notice]. 2020 ,	
517	The Cognitive Profile of Mild Cognitive Impairment Due to Dementia With Lewy Bodies-An Updated Review. 2020 , 12, 597579	2
516	Association Between REM Sleep Behavior Disorder and Cognitive Dysfunctions in Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studies. 2020 , 11, 577874	2
515	The efficacy of cognitive-cycling dual-task training in patients with early-stage Parkinson's disease: A pilot study. 2020 , 47, 415-426	1
514	An Optimized Brain-Based Algorithm for Classifying Parkinson's Disease. 2020 , 10, 1827	17
513	Automatic Striatal ROI Delineation for Semi-quantitative Analysis of 99mTc-TRODAT-1 Brain SPECT Imaging. 2020 , 40, 428-439	
512	Fibrillar form of α -synuclein-specific scFv antibody inhibits α -synuclein seeds induced aggregation and toxicity. <i>Scientific Reports</i> , 2020 , 10, 8137	4.9 4
511	Postural control learning dynamics in Parkinson's disease: early improvement with plateau in stability, and continuous progression in flexibility and mobility. 2020 , 19, 29	3
510	CSF total and oligomeric α -synuclein along with TNF- α s risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. 2020 , 9, 15	11
509	Diagnosis of Parkinson's Disease by A Metabolomics-Based Laboratory-Developed Test (LDT). 2020 , 10,	6
508	Plasma Levels of α -Synuclein, A β -40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease. 2020 , 12, 112	10
507	Serum microRNA expression levels in Turkish patients with Parkinson's disease. 2021 , 131, 1181-1189	9
506	Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. 2020 , 15, 33	16

505	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. 2020 , 139, 1001-1024	27
504	Distinct cortical activity patterns in Parkinson's disease and essential tremor during a bimanual tapping task. 2020 , 17, 45	4
503	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. 2020 , 91, 88-111	13
502	A neuropalliative care focus on Parkinson's disease and related disorders. 2020 , 9, S1-S2	
501	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. 2020 , 139, 104831	18
500	Multi-User V-Band Uplink Using a Massive MIMO Antenna and a Fiber-Wireless IFOF Fronthaul for 5G mmWave Small-Cells. 2020 , 38, 5368-5374	13
499	Electromyography Biomarkers for Quantifying the Intraoperative Efficacy of Deep Brain Stimulation in Parkinson's Patients With Resting Tremor. 2020 , 11, 142	2
498	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between Synucleinopathies. 2020 , 267, 3444-3456	10
497	Reprogramming and transdifferentiation - two key processes for regenerative medicine. 2020 , 882, 173202	4
496	Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study. 2020 , 35, 1765-1773	8
495	A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. 2020 , 10, 1195-1207	3
494	The neuropathological basis of anxiety in Parkinson's disease. 2020 , 144, 110048	1
493	High fluorescence quenching probe-based reverse fluorescence enhancement LFTS coupling with IS-primer amplification reaction for the rapid and sensitive Parkinson Disease-associated MicroRNA detection. 2020 , 165, 112278	7
492	Dizziness in patients with early stages of Parkinson's disease: Prevalence, clinical characteristics and implications. 2020 , 20, 443-447	1
491	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. 2020 , 26, 379-386	292
490	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. 2020 , 20, 421-441	19
489	Symptomatic Characteristics of Parkinson's Disease Induced by Neuroleptic Drugs, Based on a Functional Neuroimaging Diagnosis. 2020 , 59, 485-490	5
488	Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine. 2020 , 12, 4	31

487	. 2020 , 1-10	1
486	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. 2020 , 35, 976-983	20
485	Exploring \$Bona~Fide\$ Optimal Noise for Bayesian Parameter Estimation. 2020 , 8, 18822-18831	2
484	A Method for the Prediction of Clinical Outcome Using Diffusion Magnetic Resonance Imaging: Application on Parkinson's Disease. 2020 , 9,	3
483	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. 2020 , 12, 19	11
482	WITHDRAWN: Genetics of Parkinson's disease. 2020 , 101471	
481	Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease. 2019 , 10, 1388	35
480	Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease. 2020 , 127, 265-272	2
479	Role of Alcohol Drinking in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. 2020 , 21,	23
478	Effect of Olfactory and Gustatory Dysfunction and Motor Symptoms on Body Weight in Patients with Parkinson's Disease. 2020 , 10,	8
477	The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population. 2020 , 41, 2531-2537	3
476	Long Noncoding RNA POU3F3 and β Synuclein in Plasma L1CAM Exosomes Combined with α -Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease. 2020 , 17, 1104-1119	15
475	NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease. 2020 , 83, 106441	23
474	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. 2020 , 11, 1683	133
473	A Quantity Evaluation and Reconfiguration Mechanism for Signal- and Power-Interconnections in 3D-Stacking System. 2020 ,	
472	Gait Characteristics under Imposed Challenge Speed Conditions in Patients with Parkinson's Disease During Overground Walking. 2020 , 20,	6
471	Framework for Automated Earthquake Event Detection Based on Denoising by Adaptive Filter. 2020 , 67, 3070-3083	2
470	Perturbative Generalized Magneto-optical Ellipsometry. 2020 , 69, 8432-8440	

469	Evolution of Initial Pharmacologic Treatment of Newly Diagnosed Parkinson's Disease Patients over a Decade in Singapore. 2020 , 2020, 6293124	1
468	Common gene expression signatures in Parkinson's disease are driven by changes in cell composition. 2020 , 8, 55	16
467	Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial. 2020 , 94, e1764-e1773	33
466	Alterations of Brain Signal Oscillations in Older Individuals with HIV Infection and Parkinson's Disease. 2021 , 16, 289-305	2
465	Phytochemical analyses with LC-MS/MS and in vitro enzyme inhibitory activities of an endemic species <i>Allium stylosum</i> O. Schwarz (Amaryllidaceae). 2021 , 136, 70-75	5
464	Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. 2021 , 128, 273-277	9
463	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. 2021 , 36, 681-689	11
462	Serum BDNF discriminates Parkinson's disease patients with depression from without depression and reflect motor severity and gender differences. 2021 , 268, 1411-1418	7
461	Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial Direct Current Stimulation in Neurological and Psychiatric Disorders. 2021 , 24, 256-313	73
460	Non-motor symptoms are associated with REM sleep behavior disorder in Parkinson's disease: a systematic review and meta-analysis. 2021 , 42, 47-60	4
459	Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism. 2021 , 36, 1-10	23
458	Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand?. 2021 , 94, 760-797	8
457	Health-Related Quality of Life May Predict Disease Staging in 10 Years in Parkinson Disease With Hoehn-Yahr Stage III. 2021 , 11, e261-e266	
456	Proteomic Complexity in Parkinson's Disease: A Redox Signaling Perspective of the Pathophysiology and Progression. 2021 , 453, 287-300	3
455	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. 2021 , 132, 232-245	14
454	Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. 2021 , 11, 71-92	7
453	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. 2021 , 3, fcab180	5
452	Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. 2021 , 3, fcab191	2

451	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. 2021 , 291-310		
450	Freezing of Gait in Parkinson's Disease: Risk Factors, Their Interactions, and Associated Nonmotor Symptoms. 2021 , 2021, 8857204		7
449	Putative second hit rare genetic variants in families with seemingly GBA-associated Parkinson's disease. 2021 , 6, 2		1
448	On the use of histograms of oriented gradients for tremor detection from sinusoidal and spiral handwritten drawings of people with Parkinson's disease. 2021 , 59, 195-214		3
447	Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. 2021 , 182, 211-222		0
446	Increased Risk of Autopsy-Proven Pneumonia with Sex, Season and Neurodegenerative Disease. 2021 ,		3
445	Machine learning for healthcare using wearable sensors. 2021 , 137-149		1
444	Interaction between Parkin and -Synuclein in -Mediated Parkinson's Disease. 2021 , 10,		8
443	Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. 2021 , 11,		10
442	Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis. 2021 , 13, 4007-4023		3
441	A synthetic kinematic index of trunk displacement conveying the overall motor condition in Parkinson's disease. <i>Scientific Reports</i> , 2021 , 11, 2736	4-9	2
440	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. 2021 , 13, 38		4
439	Visualizing correlations among Parkinson biomedical data through information retrieval and machine learning techniques. 1		
438	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. 2021 , 9, 25		7
437	Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease. 2021 ,		25
436	Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease. 2021 , 83, 22-30		2
435	Numerical Activities of Daily Living - Financial: a short version. 2021 , 42, 4183-4191		4
434	Mild Cognitive Impairment in Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. 2021 , 12, 546476		1

433	Depression and Nigral Neuron Density in Lewy Body Spectrum Diseases. 2021 , 89, 1046-1050	2
432	Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA.	1
431	Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease. 2021 , 14, 64-69	2
430	Altered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson's disease.	0
429	Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinson's and Huntington's diseases. 2021 , 42, 4997-5006	0
428	Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. 2021 , 12, 1592	27
427	Hunting for Familial Parkinson's Disease Mutations in the Post Genome Era. 2021 , 12,	1
426	Acute Brain Ischemia, Infarction and Hemorrhage in Subjects Dying with or Without Autopsy-Proven Acute Pneumonia. 2021 ,	3
425	Association of fall risk factors and non-motor symptoms in patients with early Parkinson's disease. <i>Scientific Reports</i> , 2021 , 11, 5171	4-9 2
424	Machine Learning Approaches for Detection and Diagnosis of Parkinson's Disease - A Review. 2021 ,	0
423	Screen Fast, Screen Faster: A Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast Screen in Parkinson's Disease With Mild Cognitive Impairment. 2021 , 12, 640137	3
422	Gender may be related to the side of the motor syndrome and cognition in idiopathic Parkinson's disease. 2021 ,	0
421	Impact of motor subtype on non-motor symptoms and fall-related features in patients with early Parkinson's disease. 2021 , 21, 416-420	3
420	The Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. 2021 , 11, 455-474	16
419	Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson's disease. 2021 , 3, fcab109	3
418	Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort. 2021 , 11, 811-819	1
417	Safety and Tolerability of Burst-Cycling Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease. 2021 , 15, 651168	1
416	Effect of the combination of automated peripheral mechanical stimulation and physical exercise on aerobic functional capacity and cardiac autonomic control in patients with Parkinson's disease: a randomized clinical trial protocol. 2021 , 22, 250	

415	Sex and onset-age-related features of excessive daytime sleepiness and night-time sleep in patients with Parkinson's disease. 2021 , 21, 165	0
414	Activation-Induced Rigidity in Neurologically and Cognitively Healthy Individuals Aged 18-90 Years: A Cross-Sectional Study. 2021 , 11, 847-856	
413	Molecular Imaging of Neurodegenerative Parkinsonism. 2021 , 16, 261-272	
412	High-resolution ultrasound changes of the vagus nerve in idiopathic Parkinson's disease (IPD): a possible additional index of disease. 2021 , 42, 5205-5211	5
411	An efficient dimensionality reduction method using filter-based feature selection and variational autoencoders on Parkinson's disease classification. 2021 , 66, 102452	20
410	Parkinson's disease case ascertainment in a large prospective cohort. 2021 , 16, e0251852	
409	Neuropsychological correlates of prospective memory: A comparison between tremor-dominant Parkinson's disease and cervical dystonia. 2021 , 87, 156-161	0
408	Molecular Imaging of Extrapyrarnidal Movement Disorders With Dementia: The 4R Tauopathies. 2021 , 51, 275-285	2
407	Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. 2021 , 16, 31	5
406	Current directions in biomarkers and endophenotypes for anorexia nervosa: A scoping review. 2021 , 137, 303-310	6
405	Levodopa responsiveness in Parkinson's disease patients and white matter alterations in diffusion tensor imaging: a cross-sectional tract-based spatial statistics study. 2021 , 32, 636-642	1
404	The effect of levodopa on bilateral coordination and gait asymmetry in Parkinson's disease using inertial sensor. 2021 , 7, 42	0
403	The splenic angle: a novel radiological index for idiopathic normal pressure hydrocephalus. 2021 , 31, 9086-9097	1
402	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease. 2021 , 10,	2
401	Sleep problems affect quality of life in Parkinson's disease along disease progression. 2021 , 81, 307-311	5
400	Dopaminergic and Serotonergic Degeneration and Cortical [F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. 2021 , 36, 2293-2302	3
399	Functional variant rs17525453 within RAB35 gene promoter is possibly associated with increased risk of Parkinson's disease in Taiwanese population. 2021 , 107, 189-196	
398	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. 2021 , 144, 2826-2836	12

397	Neuronal autophagy and mitophagy in Parkinson's disease. 2021 , 82, 100972	5
396	Wearable Technology to Detect Motor Fluctuations in Parkinson's Disease Patients: Current State and Challenges. 2021 , 21,	6
395	Premotor antidepressants use differs according to Parkinson's disease subtype: A cohort study. 2021 , 87, 137-141	
394	Frequency and Determinants of Olfactory Hallucinations in Parkinson's Disease Patients. 2021 , 11,	11
393	P2X7 receptor/NLRP3 inflammasome complex and β -synuclein in peripheral blood mononuclear cells: a prospective study in neo-diagnosed, treatment-naïve Parkinson's disease. <i>European Journal of Neurology</i> , 2021 , 28, 2648-2656	6 2
392	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. 2021 , 312, 111273	2
391	Asymmetry at Disease Onset Is Not a Predictor of Parkinson's Disease Progression. 2021 , 11, 1689-1694	0
390	Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review). 2021 , 22, 1010	0
389	Diagnostic performance of T2* gradient echo, susceptibility-weighted imaging, and quantitative susceptibility mapping for patients with multiple system atrophy-parkinsonian type: a systematic review and meta-analysis. 2022 , 32, 308-318	2
388	Effect of aerobic exercise on functional capacity and quality of life in individuals with Parkinson's disease: A systematic review of randomized controlled trials. 2021 , 95, 104422	4
387	CSF and Circulating NFL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes: Meta-analysis.. 2021 , 11, e867-e875	
386	Anxiety in Parkinson's Disease: A Systematic Review of Neuroimaging Studies. 2021 , 33, 280-294	2
385	Objective Measurement of Walking Activity Using Wearable Technologies in People with Parkinson Disease: A Systematic Review Protocol. 2021 , 6, 64-68	0
384	Bisphenol A exposure induces neurobehavioral deficits and neurodegeneration through induction of oxidative stress and activated caspase-3 expression in zebrafish brain. 2021 , 35, e22873	4
383	Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. 2021 , 58, 5517-5532	1
382	Shared Genetic Background between Parkinson's Disease and Schizophrenia: A Two-Sample Mendelian Randomization Study. 2021 , 11,	2
381	Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach. 2021 , 36, 2264-2272	3
380	A biomarker and endophenotype for anorexia nervosa?. 2021 , 48674211047189	3

379	Utility of quantitative susceptibility mapping and diffusion kurtosis imaging in the diagnosis of early Parkinson's disease. 2021 , 32, 102831		2
378	Bodies in the Novel. 2021 , 12, 539555		
377	Stability of MDS-UPDRS Motor Subtypes Over Three Years in Early Parkinson's Disease. 2021 , 12, 704906		0
376	The Four Square Step Test for Assessing Cognitively Demanding Dynamic Balance in Parkinson's Disease Patients. <i>Journal of Movement Disorders</i> , 2021 , 14, 208-213	2.9	1
375	Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. 2021 , 15, 665820		3
374	The functions of Thioredoxin 1 in neurodegeneration. 2021 ,		1
373	Bilateral Subthalamic Nucleus Deep Brain Stimulation Improves Gastric Emptying Time in Parkinson Disease. 2021 , 154, e683-e688		
372	Effect of Resistance Exercise on Body Structure and Function, Activity, and Participation in Individuals With Parkinson Disease: A Systematic Review. 2021 , 102, 1998-2011		3
371	Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease. <i>Scientific Reports</i> , 2021 , 11, 19582	4.9	0
370	The Nature of Finger Enslaving: New Results and Their Implications. 2021 , 25, 680-703		3
369	Early balance impairment in Parkinson's Disease: Evidence from Robot-assisted axial rotations. 2021 , 132, 2422-2430		1
368	Identifying Parkinson's disease with mild cognitive impairment by using combined MR imaging and electroencephalogram. 2021 , 31, 7386-7394		3
367	Parkinsonism. 2021 , 82-120.e21		
366	Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants. 2021 , 4, 100094		8
365	Olfactory impairment as an early marker of Parkinson's disease in REM sleep behaviour disorder: a systematic review and meta-analysis. 2021 , 92, 271-281		4
364	Analysis of Gait for Disease Stage in Patients with Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
363	Parkinson's Disease. 194-223		9
362	Kognitive Störungen: Koma, Delir, Demenz. 2006 , 221-295		6

361	Gene- and cell-based approaches for neurodegenerative disease. 2010 , 671, 117-30	7
360	Hybrid Model for Parkinson's Disease Prediction. 2020 , 621-634	2
359	The Role of Astrocytes in Parkinson's Disease. 2014 , 127-144	3
358	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. 2018 , 265, 2211	1
357	Parkinson's Disease: Symptoms and Age Dependency. 2001 , 675-688	4
356	Neuropathology of Movement Disorders. 2011 , 871-898	2
355	Parkinson-Syndrom. 2013 , 207-233	0
354	Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. 2017 , 8, 131-138	57
353	Pesticide use and incident Parkinson's disease in a cohort of farmers and their spouses. 2020 , 191, 110186	14
352	Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. 2017 , 42, 28-33	22
351	Utility of quantitative EEG in early Lewy body disease. 2020 , 75, 70-75	11
350	Bipolar Spectrum disorders in Parkinson's disease: a systematic evaluation. 2020 , 1-7	3
349	Quantitative und qualitative Analysen von verbalen Flüssigkeitsaufgaben bei Parkinsonpatienten. 2001 , 12, 188-199	4
348	Face Memory in Idiopathic Parkinson's Disease Moderated by Sex and Encoding Duration. 2015 , 26, 109-120	1
347	Optogenetic investigation of neural circuits underlying brain disease in animal models.	1
346	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. 2002 , 125, 789-800	18
345	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.	1
344	Common gene expression signatures in Parkinson's disease are driven by changes in cell composition.	2

343	Genome-wide dysregulation of histone acetylation in the Parkinson's disease brain.	2
342	Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog). 2013 , 28, 121-5	5
341	The coefficient of friction in Parkinson's disease gait. 2017 , 32, 17-22	3
340	Parkinson's disease misdiagnosed as stroke. 2009 , 2009,	5
339	Diseases of movement and system degenerations. 2008 , 889-1030	5
338	Parkinson Disease. 2019 , 25, 896-918	14
337	Comparison of Quantitative Electroencephalogram During Sleep in Depressed and Non-Depressed Patients with Parkinson's Disease. 2019 , 25, 1046-1052	2
336	The role of dance therapy in the rehabilitation of Parkinson disease patients. 2019 , 10, 300-304	1
335	KSNR Clinical Consensus Statements: Rehabilitation of Patients with Parkinson's Disease. 2020 , 13,	1
334	Characteristics of Writing in Parkinson's Disease: Focused on Pen Pressure, Letter Size, and Writing Speed. 2020 , 25, 63-74	3
333	Haptic perception of object curvature in Parkinson's disease. 2008 , 3, e2625	33
332	Visuo-motor coordination deficits and motor impairments in Parkinson's disease. 2008 , 3, e3663	28
331	Metabolomic profiling in LRRK2-related Parkinson's disease. 2009 , 4, e7551	112
330	Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. 2011 , 6, e17338	105
329	On the origin of tremor in Parkinson's disease. 2012 , 7, e41598	51
328	Unbiased and mobile gait analysis detects motor impairment in Parkinson's disease. 2013 , 8, e56956	135
327	Genetic variants of LRRK2 in Taiwanese Parkinson's disease. 2013 , 8, e82001	21
326	Influence of perturbation velocity on balance control in Parkinson's disease. 2014 , 9, e86650	16

325	Observations on sleep-disordered breathing in idiopathic Parkinson's disease. 2014 , 9, e100828	30
324	Differences in muscle strength in parkinsonian patients affected on the right and left side. 2015 , 10, e0121251	17
323	Motor Performance Assessment in Parkinson's Disease: Association between Objective In-Clinic, Objective In-Home, and Subjective/Semi-Objective Measures. 2015 , 10, e0124763	63
322	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. 2015 , 10, e0135458	66
321	Resistance versus Balance Training to Improve Postural Control in Parkinson's Disease: A Randomized Rater Blinded Controlled Study. 2015 , 10, e0140584	35
320	The Roles of Dopamine and Hypocretin in Reward: A Electroencephalographic Study. 2015 , 10, e0142432	8
319	Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson's Disease: Drug Effects of Withania somnifera (Dunal) Administration. 2016 , 11, e0146140	15
318	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. 2016 , 11, e0157755	29
317	Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms. 2017 , 12, e0172145	16
316	Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. 2017 , 12, e0173503	15
315	Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease. 2017 , 12, e0189161	74
314	Serum Uric Acid, Serum Uric Acid to Serum Creatinine Ratio and Serum Bilirubin in Patients With Parkinson's Disease: A Case-Control Study. 2020 , 12, 172-179	5
313	Risk Factors for Falls in Patients with de novo Parkinson's Disease: A Focus on Motor and Non-Motor Symptoms. <i>Journal of Movement Disorders</i> , 2020 , 13, 142-145	2.9 3
312	Chronic neurological diseases and COVID-19: Associations and considerations. 2020 , 11, 294-301	6
311	Is the timed up and go (TUG) sensitive to differentiating patients with mild to moderate PD compared to age matched controls: a descriptive pilot study. 2018 , 3,	1
310	Parkinson's disease and wearable devices, new perspectives for a public health issue: an integrative literature review. 2019 , 65, 1413-1420	6
309	Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. 2005 , 6, 22-7	14
308	Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson's disease: a Complete Review. 2017 , 1, 001-026	6

307	Uncoupling protein 4 () gene variability in neurodegenerative disorders: further evidence of association in Frontotemporal dementia. 2018 , 10, 3283-3293	9
306	Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease. 2020 , 12, 1488-1495	7
305	Asymmetrical nigral iron accumulation in Parkinson's disease with motor asymmetry: an explorative, longitudinal and test-retest study. 2020 , 12, 18622-18634	3
304	Rep1 microsatellite length influences non-motor symptoms in early Parkinson's disease. 2020 , 12, 20880-20887	7
303	Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. 2016 , 7, 54215-54227	23
302	Conceptualization of depression in Parkinson's disease. 2005 , 1, 135-43	1
301	Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease. 2019 , 26, 3719-3753	23
300	Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study. 2019 , 16, 633-649	1
299	Recent progress of imaging agents for Parkinson's disease. 2014 , 12, 551-63	10
298	Usefulness of 5 Minutes 123I-mIBG Scan in Parkinson's Disease and Heart Failure. 2020 , 13, 120-129	1
297	Functional Magnetic Resonance Imaging Biomarkers Predicting Cognitive Progression in Parkinson Disease: Protocol for a Prospective Longitudinal Cohort Study. 2019 , 8, e12870	2
296	Detecting Motor Impairment in Early Parkinson's Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting. 2018 , 20, e89	21
295	Effects of Korean Medicine on Patients with Idiopathic Parkinson's Disease: A Retrospective Study. 2016 , 37, 653-660	6
294	Strength training improves the respiratory muscle strength and quality of life of elderly with Parkinson disease. 2019 , 59, 1756-1762	11
293	Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson's disease. 2017 , XII,	3
292	Epidemiology. 2013 , 24-39	3
291	Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. 2004 , 6, 259-80	226
290	Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms. 2020 , 9,	21

289	Backward Gait is Associated with Motor Symptoms and Fear of Falling in Patients with Parkinson's Disease. 2019 , 15, 473-479	3
288	Bone mineral density and serum vitamin D status in Parkinson's disease: Are the stage and clinical features of the disease important?. 2020 , 68, 394-400	5
287	Transcranial Sonographic Alterations of Substantia Nigra and Third Ventricle in Parkinson's Disease with or without Dementia. 2017 , 130, 2291-2295	3
286	The Causes of Dizziness in Parkinson's Disease. 2014 , 05, 667-673	3
285	Effects of <i>Nigella sativa</i> Seed Extract on Perphenazine-Induced Muscle Rigidity in Male Mice. 2014 , 04, 313-318	5
284	Tear Osmolarity, Break-up Time and Schirmer's Scores in Parkinson's Disease. 2015 , 45, 142-145	10
283	HDTV System for Parkinson's Disease Diagnosis. 2013 , 13, 91-96	2
282	Transcranial sonography in movement disorders. 2008 , 152, 251-8	9
281	Freezing of gait is associated with cortical thinning in mesial frontal cortex. 2017 , 161, 389-396	9
280	State transitions in the substantia nigra reticulata predict the onset of motor deficits in models of progressive dopamine depletion in mice. 2019 , 8,	24
279	Gait characteristics in individuals with Parkinson's disease during 1-minute treadmill walking. 2020 , 8, e9463	4
278	The role of specialist nurses in managing Parkinson's disease. 2006 , 16, 20-22	2
277	Association of Decreased Serum BDNF With Restless Legs Syndrome in Parkinson's Disease Patients. 2021 , 12, 734570	0
276	The potential neuroprotective effect of diosmin in rotenone-induced model of Parkinson's disease in rats. 2021 , 174573	3
275	Epidemiologie, etiologie, physiopathologie, diagnostic et troubles cognitifs de la maladie de Parkinson. 2001 , 9, 1-10	
274	Familial Variants of Parkinson's Disease. 2002 , 281-284	
273	Parkinson's Disease: Current Scientific Understanding and John's Story. 2002 , 40, 30-37	
272	Genetics. 2003 , 344-357	

- 271 Movement Disorders. **2004**, 131-161
- 270 Morbus Parkinson –Pathophysiologie, Diagnose und medikamentöse Therapie. **2004**, 206-228
- 269 Classifying the State of Parkinsonism by Using Electronic Force Platform Measures of Balance. **2004**, 477-483
- 268 Parkinsonism, Autosomal Dominant. **2004**, 970-975
- 267 Presymptomatic and Symptomatic Stages of Intracerebral Inclusion Body Pathology in Idiopathic Parkinson’s Disease. **2005**, 475-502
- 266 Patient Selection and Indications for Surgery. **2005**, 27-43
- 265 Non-motor somatic symptoms. **2005**, 65-78
- 264 Parkinson’s Disease. **2007**, 591-600
- 263 LRRK2-Associated Parkinsonism. **2007**, 45-59
- 262 Genetics. **2007**, 287-296
- 261 Relationship Between the Striatal and Cerebellar Glucose Metabolism and the Response to Levodopa Treatment in Patients With Multiple System Atrophy. *Journal of Movement Disorders*, **2008**, 1, 26-32 2.9
- 260 The Characteristics of Cognitive Impairment in Parkinson’s Disease and Recognition of Cognitive Symptom by Questionnaire. *Journal of Movement Disorders*, **2008**, 1, 38-46 2.9
- 259 The Correlation of ON and OFF Status With Clinical Characteristics in Patients With Parkinson’s Disease. *Journal of Movement Disorders*, **2008**, 1, 65-70 2.9
- 258 Reliability of Serum Anti-thyroid Antibody Screening in the Diagnosis of Parkinson’s Disease and Multiple System Atrophy. *Journal of Movement Disorders*, **2008**, 1, 75-81 2.9
- 257 PET and SPECT in the Evaluation of Patients with Central Motor Disorders. **2009**, 67-92
- 256 Patient Selection for Surgery for Parkinson’s Disease. **2009**, 1529-1538 1
- 255 Chapitre 17. Prise en charge des troubles cognitifs chez le patient avec maladie de Parkinson et d’emblée. **2009**, 215-223
- 254 7 Effecten van fysiotherapie en het gebruik van externe ritmische cues bij patiënten met de ziekte van Parkinson. **2010**, 106-123

253 Chapter 17Neurological Disorders. **2010**,

252 Posturographic Evaluation of Dizziness Complaining Patients under Suspicion to Develop Parkinson's Disease. **2011**, 02, 28-33

251 Combination Lesion Models of MSA. **2011**, 37-54

250 Clinical Overview of Movement Disorders. **2011**, 899-913

249 Neuropathology of Dementia in Parkinson's Disease. 153-162

248 Parkinson's disease. **2012**, 81-94

247 Sleep Disorders in Parkinson's Disease and Parkinsonian Syndromes. **2012**, 330-344

246 The interaction between the dopaminergic and the serotonergic systems in the 6-OHDA rat model of Parkinson's disease. **2012**, 04, 1218-1224

245 Genetics. **2013**, 317-340

244 Differential diagnosis. **2013**, 40-60

1

243 Epidemiology. **2013**, 24-39

242 Parkinson's Disease. 471-513

1

241 Deep Brain Stimulation in Parkinson's Disease: Subthalamic Nucleus. 26-36

240 The Pael-R gene does not mediate the changes in rotenone-induced Parkinson's disease model cells. **2014**, 9, 402-6

1

239 Neuromelanin and Parkinson's Disease. **2014**, 913-932

1

238 Role of the Innate and Adaptive Immune System in the Pathogenesis of PD. **2014**, 75-103

1

237 Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years. **2014**, 04, 443-449

236 Role of Mitochondria and Oxidative Stress in Parkinson's Disease. **2014**, 521-548

- 235 Recent Medical and Surgical Treatments for Parkinson's Disease. **1999**, 4, 9-12
- 234 Characteristics of Dysarthria and Cognitive Functions in Patients with Parkinson's Disease and Parkinson-plus Syndrome. **2014**, 19, 551-557 3
- 233 Parkinson-Syndrom. **2015**, 77-102 2
- 232 Parkin and <i>LRRK2</i>/Dardarin Mutations in Early Onset Parkinson's Disease in the Basque Country (Spain). **2015**, 05, 101-108
- 231 Effect of Immature Citrus sunki Peel Extract on Neuronal Cell Death. **2015**, 23, 144-149 1
- 230 Encyclopedia of Geropsychology. **2016**, 1-8 0
- 229 Motor Patterns Recognition in Parkinson's Disease. **2016**, 1-16
- 228 19. Neurological Disorders. **2016**,
- 227 Encyclopedia of Geropsychology. **2017**, 1758-1766 0
- 226 Prevalence and Predisposing Factors of Parkinson Disease: A Community-Based Study In Barangay Mangilag Sur, Candelaria, Quezon: A Research Protocol. **2017**, 1, 109-119 0
- 225 Motor Patterns Recognition in Parkinson's Disease. **2018**, 1237-1252
- 224 Biomechanical analysis of Sit-To-Walk movement in Parkinson's patients. 036-042
- 223 Berberis vulgaris alleviates Levodopa-induced dyskinesia in male mice. **2018**, 64, 44-49 0
- 222 Parkinson's Disease. **2019**, 252-273
- 221 [Clinical, neuropsychological and epidemiological aspects of the 'transitional' form of Parkinson's disease in the Yaroslavl region]. **2019**, 119, 66-71 0
- 220 The genetic architecture of Parkinson disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight. 1
- 219 Is insulin resistance associated with fatigue, the severity of the disease and motor disability in idiopathic Parkinson's disease?.
- 218 Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease.

217	Neuroimaging biomarkers differentiate Parkinson disease with and without cognitive impairment and dementia.		
216	Effects of Lax Vox Voice Therapy on Respiration and Phonation in Patients with Parkinsonâs Disease. 2019 , 24, 785-799		6
215	Clinical Updates and Recent Developments in Neuro-Ophthalmology. 2020 , 201-249		
214	Impulse Control Disorders in Parkinsonâs disease.		
213	The Role of Dysphonia and Voice Recordings in Diagnosis of Parkinsonâs Disease. 21-26		0
212	Molecular docking investigation of the amantadine binding to the enzymes upregulated or downregulated in Parkinson's disease.. 2020 , 8, 149-175		0
211	Clinical Characteristics of Pain in Patients with Parkinsonâs Disease Who Have Visited a Korean Medical Hospital : A Retrospective Chart Review. 2020 , 41, 23-33		1
210	1-Indanone and 1,3-indandione Derivatives as Ligands for Misfolded α Synuclein Aggregates. 2021 , 17, e202100611		1
209	Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson's Disease. 2020 , 11,		1
208	Social Symptoms of Parkinson's Disease. 2020 , 2020, 8846544		11
207	Parkinsonâs Disease Detection Using Multiple Speech Signals. 2020 ,		1
206	Association between Cardiac Autonomic Control and Postural Control in Patients with Parkinson's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	1
205	A Real-World Study of Cerebral 99mTc-TRODAT-1 Single-Photon Emission Computed Tomography (SPECT) Imaging of the Dopamine Transporter in Patients with Parkinson Disease from a Tertiary Hospital in Brazil. 2020 , 26, e925130		
204	A Consensus Proteomic Analysis of Alzheimerâs Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation.		1
203	Muscle thickness and functional performance of patients with Parkinsonâs disease. 22,		
202	Acoustic Characteristics of VOT in Plosive Consonants Produced by Parkinsonâs Patients. 2020 , 303-311		1
201	DIAGNOSIS OF AUTONOMIC DISORDERS IN PARKINSONâS DISEASE. 2020 , 73, 809-813		1
200	Introduction and Basic Concepts in Stem Cell Research and Therapy: The Facts and the Hype. 2020 , 1-36		

- 199 [Epidemiological and clinical aspects of chronic neuroborreliosis with parkinsonism in the Yaroslavl region]. **2020**, 120, 53-59
- 198 Parkinson's disease-related motor and non-motor symptoms are not more prevalent in the Lancaster Amish.
- 197 Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study. **2021**, 93, 12-18 3
- 196 Effectiveness Analysis of Bio-electronic Stimulation Therapy to Parkinson's Disease via Discrete Fourier Transform Approach. **2020**,
- 195 A synthetic kinematic index of trunk displacement conveying the overall motor condition in Parkinson's disease. 1
- 194 Thalamic and Cortical Changes in Parkinsonian Disorders. **2005**, 415-424
- 193 Movement Disorders. **2006**, 161-178
- 192 Optimization of Discharge Patterns in Parkinson Condition in External Globus Pallidus Model of Basal Ganglia Using Particle Swarm Optimization Algorithm. **2021**, 281-291
- 191 Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor. **2021**, 46, 95-102 5
- 190 Approach to diagnosis of Parkinson disease. **2006**, 52, 862-8 13
- 189 Cognitive impairment and dementia in patients with Parkinson disease. **2009**, 9, 903-12 47
- 188 Osteoporosis and Parkinson's disease. **2011**, 8, 16-8 10
- 187 Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. **2012**, 1, 160-7 21
- 186 Essential Tremor Prevalence is Low in the Druze Population in Northern Israel. **2012**, 2, 3
- 185 Validation of hospital register-based diagnosis of Parkinson's disease. **2012**, 59, A4391 40
- 184 Transcranial sonography on Parkinson's disease and essential tremor. **2013**, 18, S28-31 5
- 183 Association between serum biochemical levels, related to bone metabolism and Parkinson's disease. **2013**, 18, S39-42 7
- 182 The Effects of Below Knee Compression Garments on Functional Performance in Individuals with Parkinson Disease. **2016**, 10, 373-80 1

181	Association between changes in visual evoked magnetic fields and non-motor features in Parkinson's disease. 2017 , 79, 147-155	0
180	ELECTRONIC PLATFORM MEASURES OF BALANCE IMPAIRMENT IN PARKINSONIANS AND FIRST DEGREE RELATIVES. 2004 , 13, 259-272	1
179	Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. 2007 , 28, 309-13	64
178	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study. 2021 , 11, e414-e421	
177	PINK1: Multiple mechanisms of neuroprotection. 2021 , 193-219	
176	Neurodegenerative diseases. 2022 , 1-67	
175	Segmental Alterations of the Corpus Callosum in Progressive Supranuclear Palsy: A Multiparametric Magnetic Resonance Imaging Study. 2021 , 13, 720634	1
174	Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease. 2021 , 11, e414-e421	3
173	Parkinson's Disease Predictor via Voice Analysis. 2021 ,	
172	Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders.. 2022 , 112, 122-128	0
171	Longitudinal Study of SNCA Rep1 Polymorphism on Executive Function in Early Parkinson's Disease.. 2022 ,	
170	Quantifying regional β synuclein, amyloid β and tau accumulation in lewy body dementia.. 2022 ,	2
169	Lewy body disease or diseases with Lewy bodies?. 2022 , 8, 3	2
168	Strong Predictive Algorithm of Pathogenesis-Based Biomarkers Improves Parkinson's Disease Diagnosis.. 2022 , 59, 1476	0
167	Determinants of impaired bed mobility in Parkinson's disease: Impact of hip muscle strength and motor symptoms.. 2022 ,	0
166	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.. 2022 ,	1
165	Fluid markers of synapse degeneration in synucleinopathies.. 2022 , 129, 187	0
164	Fading of brain network fingerprint in Parkinson's disease predicts motor clinical impairment.	0

163	Plasma Metabolite Markers of Parkinson's Disease and Atypical Parkinsonism.. 2021 , 11,	0
162	Parkinson's Disease Diagnosis Through Electroencephalographic Signal Processing and Sub-optimal Feature Extraction. 2022 , 118-127	2
161	Curcumin-Loaded Human Serum Albumin Nanoparticles Prevent Parkinson's Disease-like Symptoms in .. 2022 , 12,	1
160	Differentiating Parkinson's Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis.. 2022 ,	0
159	-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases.. 2022 , 11,	3
158	Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD.. 2022 , 14, 407-418	0
157	A Study on Lower Limb Asymmetries in Parkinson's Disease during Gait Assessed through Kinematic-Derived Parameters.. 2022 , 9,	0
156	Lower activity linkage between caregivers and persons with neurodegenerative diseases is associated with greater caregiver anxiety.. 2022 , e14040	
155	Undetected ophthalmological disorders in Parkinson's disease.. 2022 , 1	1
154	Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease.. 2022 ,	0
153	Multichannel Transcranial Direct Current Stimulation Combined With Treadmill Gait Training in Patients With Parkinson's Disease: A Pilot Study.. 2022 , 13, 804206	
152	Assessing Mild Cognitive Impairment in Parkinson's Disease by Magnetic Resonance Quantitative Susceptibility Mapping Combined Voxel-Wise and Radiomic Analysis.. 2022 , 1-11	2
151	DRD2 Taq1A Polymorphism-Related Brain Volume Changes in Parkinson's Disease: Voxel-Based Morphometry.. 2022 , 2022, 8649195	0
150	Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA.. 2022 , 1-16	0
149	Interventions to improve gait in Parkinson's disease: a systematic review of randomized controlled trials and network meta-analysis.. 2022 , 1	1
148	Longitudinal Healthcare Utilization and Costs in Parkinson's Disease: Pre-Diagnosis to 9 Years After.. 2021 ,	0
147	Better Outcomes with Intranigral versus Intrastratial Cell Transplantation: Relevance for Parkinson's Disease.. 2022 , 11,	2
146	White Matter β -Amyloid Precursor Protein Immunoreactivity in Autopsied Subjects With and Without COVID-19.	1

- 145 The Occurrence of Alzheimer’s Disease and Parkinson’s Disease in Individuals With Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Screening Database in Korea.. **2021**, 13, 786337 2
- 144 Deafferentation of Olfactory Bulb in Subjects Dying with COVID-19.
- 143 Parkinson’s Disease and Parkinson’s Disease Dementia. **2022**, 231-243
- 142 Multimodality Anatomic and Molecular Imaging of Parkinson Disease and Atypical Parkinson Syndromes with MRI, Iodine 123 N-Fluoropropyl-2-(4-Iodophenyl) Nortropine SPECT (Dopamine Transporter SPECT), Iodine 123 Metaiodobenzylguanidine Cardiac Scintigraphy, and [18F] FDG-PET. **2021**, 11, 259-274
- 141 Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson’s Disease.. **2022**, 2
- 140 Multiarea Brain Activation and Gait Deterioration During a Cognitive and Motor Dual Task in Individuals With Parkinson Disease.. **2022**,
- 139 Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson’s disease: are we on the right track?. **2022**, 1-7 0
- 138 Parkinson’s disease and the spectrum of Lewy body disease. 10-26
- 137 Clinical aspects of movement disorders. 29-50
- 136 Data_Sheet_1.DOCX. **2018**,
- 135 data_sheet_1.DOC. **2018**,
- 134 image_1.JPEG. **2018**,
- 133 Data_Sheet_1.docx. **2020**,
- 132 Data_Sheet_1.pdf. **2019**,
- 131 Data_Sheet_2.pdf. **2019**,
- 130 Table_1.DOCX. **2019**,
- 129 Table_2.DOCX. **2019**,
- 128 Table_3.DOCX. **2019**,

127 Data_Sheet_1.doc. **2019**,

126 Data_Sheet_1.PDF. **2018**,

125 Data_Sheet_2.PDF. **2018**,

124 Data_Sheet_3.PDF. **2018**,

123 Data_Sheet_4.PDF. **2018**,

122 Data_Sheet_5.PDF. **2018**,

121 Data_Sheet_6.PDF. **2018**,

120 Table_1.DOCX. **2019**,

119 Data_Sheet_1.pdf. **2020**,

118 Image_1.tiff. **2020**,

117 Image_2.tif. **2020**,

116 Image_3.tif. **2020**,

115 Image_4.tif. **2020**,

114 Table_1.DOCX. **2020**,

113 Table_1.DOCX. **2019**,

112 Table_2.DOCX. **2019**,

111 Identification of the Raman Salivary Fingerprint of Parkinson's Disease Through the Spectroscopic-Computational Combinatory Approach. **2021**, 15, 704963 3

110 Sensitivity to gait improvement after levodopa intake in Parkinson's disease: A comparison study among synthetic kinematic indices.. **2022**, 17, e0268392 0

109	Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. 2022,		0
108	The Indirect Impact of COVID-19 on Major Clinical Outcomes of People With Parkinson's Disease or Parkinsonism: A Cohort Study. 2022, 13,		0
107	Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson's disease through a randomized controlled trial.. <i>Scientific Reports,</i> 2022, 12, 8024	4.9	0
106	Microorganisms associated with increased risk of Parkinson's disease. 2022,		
105	Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. 2022, 8,		0
104	Review of Active Extracorporeal Medical Devices to Counteract Freezing of Gait in Patients with Parkinson Disease. 2022, 10, 976		1
103	PERFORMANCE OF SYNUCLEIN RT-QUIC IN RELATION TO NEUROPATHOLOGICAL STAGING OF LEWY BODY DISEASE.		
102	Comparative Analysis of Machine Learning Algorithms for Parkinson's Disease Prediction. 2022,		0
101	Interplay between gait and neuropsychiatric symptoms in Parkinson's Disease.		2
100	Prosodic features in Finnish-speaking adults with Parkinson's disease. 1-16		
99	Objective Measurement of Walking Activity Using Wearable Technologies in People with Parkinson Disease: A Systematic Review. 2022, 22, 4551		0
98	Performance of Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. 2022, 10,		2
97	Does visual cueing improve gait initiation in people with Parkinson's disease?. 2022, 84, 102970		0
96	Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration. 10.1212/WNL.0000000000200860		0
95	Nicotine Has a Therapeutic Window of Effectiveness in a Drosophila melanogaster Model of Parkinson's Disease. 2022, 2022, 1-11		
94	Risk of SARS-CoV -2 infection, hospitalization and death for COVID -19 in people with Parkinson's disease or parkinsonism over a 15-month period: a cohort study. <i>European Journal of Neurology,</i>	6	1
93	Effects of therapeutic intervention on spatiotemporal gait parameters in adults with neurological disorder: systematic review and meta-analysis. 2022,		
92	The Role of Monoaminergic Tones and Brain Metabolism in Cognition in ' de ' novo Parkinson's Disease. 2022, 1-11		

91	SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19.	3
90	A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson's Disease. 2022 , 1-21	0
89	Burden of neurological disease. 2023 , 1047-1064	
88	Rare variant screening and burden analysis of PLXNA1 in Parkinson's Disease. <i>European Journal of Neurology</i> ,	6
87	Semiautomated Algorithm for the Diagnosis of Multiple System Atrophy With Predominant Parkinsonism. <i>Journal of Movement Disorders</i> ,	2.9
86	New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19, 8799	4.6 0
85	Associations of cognitive dysfunction with motor and non-motor symptoms in patients with de novo Parkinson's disease. <i>Scientific Reports</i> , 2022 , 12,	4.9 1
84	CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice. <i>Biomedicines</i> , 2022 , 10, 1776	4.8 0
83	Spectrum and Burden of Movement Disorder Conditions in a Tertiary Movement Disorders Centre's 10-Year Trend. 2014 , 43, 203-208	2
82	Complications, Readmissions, Revisions and Patient-Reported Outcomes in Patients with Parkinson's Disease Undergoing Elective Spine Surgery- a Propensity Matched Analysis. Publish Ahead of Print,	
81	Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. 2022 , 8,	5
80	Connectivity Alterations in Vascular Parkinsonism: A Structural Covariance Study. 2022 , 12, 7240	
79	Plasma biomarkers inclusive of Synuclein/amyloid-beta40 ratio strongly correlate with Mini-Mental State Examination score in Parkinson's disease and predict cognitive impairment.	0
78	Genome-wide analysis of Structural Variants in Parkinson's Disease using Short-Read Sequencing data.	0
77	A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease. 2022 , 8, e200008	1
76	Emerging role of mesenchymal stromal cells (MSCs)-derived exosome in neurodegeneration-associated conditions: a groundbreaking cell-free approach. 2022 , 13,	3
75	Clinical differences between early-onset and mid-and-late-onset Parkinson's disease: Data analysis of the Hellenic Biobank of Parkinson's disease. 2022 , 442, 120405	1
74	MindBody Exercises for Non-motor Symptoms of Patients With Parkinson's Disease: A Systematic Review and Meta-Analysis. 13,	0

73	Deep Learning-based model for the detection of Parkinson’s disease using voice data. 2022,	1
72	Pervasive and diffuse muscle activity during REM sleep and non-REM sleep characterises multiple system atrophy in comparison with Parkinson’s disease.	0
71	Functional connectivity of the cortico-subcortical sensorimotor loop is modulated by the severity of nigrostriatal dopaminergic denervation in Parkinson’s Disease. 2022, 8,	0
70	Toward More Accessible Fully Automated 3D Volumetric MRI Decision Trees for the Differential Diagnosis of Multiple System Atrophy, Related Disorders, and Age-Matched Healthy Subjects.	0
69	Association Between Gait and Dysautonomia in Patients With De Novo Parkinson’s Disease: Forward Gait Versus Backward Gait.	0
68	Global Alterations of Whole Brain Structural Connectome in Parkinson’s Disease: A Meta-analysis.	1
67	Use of Laughter for the Detection of Parkinson’s Disease: Feasibility Study for Clinical Decision Support Systems, Based on Speech Recognition and Automatic Classification Techniques. 2022, 19, 10884	0
66	Integrating virtual reality and exergaming in cognitive rehabilitation of patients with Parkinson disease: a systematic review of randomized controlled trials.	1
65	Effects of Multimodal Rehabilitation on the Activities of Daily Living, Quality of Life, and Burden of Care for Patients with Parkinson’s Disease: A Randomized Control Study. 2022, 10, 1888	0
64	Mild cognitive impairment in patients with Parkinson’s disease: An updated mini-review and future outlook. 14,	0
63	Young-Onset Dementia and Neurodegenerative Disorders of the Young With an Emphasis on Clinical Manifestations. 2022,	0
62	Exploring the feasibility of technological visuo-cognitive training in Parkinson’s: Study protocol for a pilot randomised controlled trial. 2022, 17, e0275738	1
61	Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder.	0
60	Soluble LRP-1 in Parkinson’s disease: clues for paradoxical effects. 1-12	0
59	Quantifying Motor Skills in Early-Stage Parkinson’s Disease Using Human Controller Modeling. 2022 , 55, 96-101	0
58	Identifying Behavioural Changes due to Parkinson’s Disease Progression in Motor Performance Data. 2022, 55, 102-107	0
57	Extracting Knowledge from Images of Meanders and Spirals in the Diagnosis of Patients with Parkinson’s Disease. 2022, 32, 658-664	0
56	Diagnosis and Medical Management of Parkinson Disease. 2022, 28, 1281-1300	0

- 55 Detecting Parkinson's Disease through Gait Measures Using Machine Learning. **2022**, 12, 2404 ○
- 54 Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome. **2022**, 23, 12004 ○
- 53 Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease. **2022**, 13, 1937 2
- 52 Effect of Lower Limb vs. Abdominal Compression on Mobility in Orthostatic Hypotension: A Single-Blinded, Randomized, Controlled, Cross-Over Pilot Study in Parkinson's Disease. **2022**, 1-11 ○
- 51 Other Important Dementias. **2003**, 312-329 ○
- 50 Metabotropic glutamate receptors and cognition: From underlying plasticity and neuroprotection to cognitive disorders and therapeutic targets. **2022**, ○
- 49 Molecular imaging in prodromal Parkinson's disease. **2023**, 251-272 ○
- 48 Is EQ-5D a Valid Quality of Life Instrument in Patients With Parkinson's Disease? A Study in Singapore. **2009**, 38, 521-528 4
- 47 In vivo 18F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D Synuclein mutation. ○
- 46 Parkinson's Disease Wearable Gait Analysis: Kinematic and Dynamic Markers for Diagnosis. **2022**, 22, 8773 ○
- 45 Inhibition of Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated Synuclein Fibrils. ○
- 44 Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. **2022**, 21, 1099-1109²
- 43 Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. **2022**, ○
- 42 Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California. **2023**, 864, 160851 ○
- 41 VGG11 Parkinson's Disease Detection Based on Voice Attributes. **2022**, 58-70 ○
- 40 Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease. 0271678X2211411 ○
- 39 Effectiveness of Acupuncture in Parkinson's Disease Symptoms: A Systematic Review. **2022**, 10, 2334 1
- 38 Fading of brain network fingerprint in Parkinson's disease predicts motor clinical impairment. ○

- 37 Benefits of dance for Parkinson's: The music, the moves, and the company. **2022**, 17, e0265921 ○
- 36 A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease. **2022**, 8, ○
- 35 The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study. ○
- 34 Impaired migratory phenotype of CD4+ T cells in Parkinson's disease. **2022**, 8, 1
- 33 Exercise-Boosted Mitochondrial Remodeling in Parkinson's Disease. **2022**, 10, 3228 ○
- 32 Gut-brain axis: Review on the association between Parkinson's disease and plant lectins. **2022**, 9, 177-183 ○
- 31 Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. **2022**, 17, ○
- 30 Novel insights regarding the measurement properties of the SCOPA-AUT. **2022**, 22, ○
- 29 The genetic regulation of protein expression in cerebrospinal fluid. ○
- 28 Comparing Backward Walking Performance in Parkinson's Disease with and without Freezing of Gait: A Systematic Review. **2023**, 20, 953 ○
- 27 Gold Nanoclusters Enhance the Efficacy of the Polymer-Based Chaperone in Restoring and Maintaining the Native Conformation of Human Islet Amyloid Polypeptide. **2023**, 15, 3409-3419 ○
- 26 Human mini-brains for reconstituting central nervous system disorders. ○
- 25 Effect of aquatic exercise programs according to the International Classification of Functionality, Disability and Health domains in individuals with Parkinson's disease: a systematic review and meta-analysis with GRADE quality assessment. 1-14 ○
- 24 A Supervised Machine Learning Approach to Classify Parkinson's Disease. **2022**, ○
- 23 Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. **2023**, 24, 690 ○
- 22 Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China. **2022**, Publish Ahead of Print, ○
- 21 Efficacy of Specific Trunk Exercises in the Balance Dysfunction of Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. **2023**, 23, 1817 ○
- 20 Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition. **2023**, 92, 573-580 ○

- 19 Right posterior hypometabolism in Pisa syndrome of Parkinson's disease: A key to explain body schema perception deficit?. **2023**, 110, 105371 ○
- 18 Machine learning- and statistical-based voice analysis of Parkinson's disease patients: A survey. **2023**, 219, 119651 1
- 17 Neuromelanin and Parkinson's Disease. **2022**, 1593-1612 ○
- 16 Genome-Wide Analysis of Structural Variants in Parkinson Disease. 1
- 15 Loss of RAB39B does not alter MPTP-induced Parkinson's disease-like phenotypes in mice. 15, ○
- 14 Patients with Alzheimer's disease dementia show partially preserved parietal hubs modeled from resting-state alpha electroencephalographic rhythms. 15, ○
- 13 Smelling the Disease: Diagnostic Potential of Breath Analysis. 1
- 12 Microstructure of Brain Nuclei in Early Parkinson's Disease: Longitudinal Diffusion Kurtosis Imaging. **2023**, 13, 233-242 ○
- 11 Identification of a Gait Pattern for Detecting Mild Cognitive Impairment in Parkinson's Disease. **2023**, 23, 1985 ○
- 10 Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition. **2023**, 43, 2615-2629 ○
- 9 Local white matter abnormalities in Parkinson's disease with mild cognitive impairment: Assessed with neurite orientation dispersion and density imaging. ○
- 8 Burning mouth disorder and Parkinson's disease: A scoping review of the literature. ○
- 7 Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid: A Systematic Review and Meta-Analysis. ○
- 6 Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson's disease. **2023**, 18, e0282203 ○
- 5 Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology. 17, ○
- 4 mTORC1-Dependent Protein and Parkinson's Disease: A Mendelian Randomization Study. **2023**, 13, 536 ○
- 3 Genetic Evidence for Endolysosomal Dysfunction in Parkinson's Disease: A Critical Overview. **2023**, 24, 6338 ○
- 2 Quantifiable Analysis of 18f-(+) DTBZ Picture: Comparison of PET Template & MRI Centred Image Investigation. **2023**, ○

- 1 Risk estimation for idiopathic normal-pressure hydrocephalus: development and validation of a brain morphometry-based nomogram.

o